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Abstract of the Dissertation
Computational Analysis of Non-CpG DNA Methylation in the Mammalian Nervous System
by
Dennis Yawen Wu
Doctor of Philosophy in Biology and Biomedical Sciences
Computational and Systems Biology
Washington University in St. Louis, 2020
Professor John Edwards, Chair

Noncanonical forms of DNA methylation, especially non-CpG DNA methylation, play
essential roles in the neuronal epigenome, and have only recently begun to be characterized.
While most DNA methylation within mammals is found in a CG context and maintained by
DNMT1, neurons contain uniquely high levels of non-CpG methylation, such that the total
amounts of methylation in non-CpG contexts equals or surpasses the total amounts of
methylation in CG contexts. Non-CpG methylation, unlike CpG methylation, cannot be
maintained by DNMT1, and must be established by the de novo methyltransferase DNMT3A.
One unique characteristic of non-CpG methylation compared to canonical CpG
methylation is the extremely wide range of biological signal it exhibits across large regions of
the genome. This may enable MeCP2, a critical methyl-binding protein whose disruption causes

viii

multiple neurodevelopmental diseases, to repress regulatory elements across entire domains of
the genome. How these patterns of varied methylation are established throughout the genome
and what factors direct methylation to one location versus another, however, are unknown. In
addition, the mechanisms by which these methyl binding proteins function and the
transcriptomic effects when non-CpG methylation is lost are not well understood. As such, my
dissertation work centers around the patterning, function, and consequences of this unique neural
regulatory mark.
Firstly, by applying multiscale analysis of bisulfite-sequencing and high-throughput
chromatin conformation capture data in the cerebral cortex of mice we find that megabase-scale
regions of high non-CG methylation can correspond with topologically-associating domains of
chromatin folding, identifying a new mechanism influencing mCA deposition across the
neuronal genome. We find that MeCP2 represses enhancers found in these domains when they
are enriched for non-CG and CG methylation, with the strongest repression occurring for
enhancers located within MeCP2-repressed genes. These alterations in enhancer activity provide
a mechanism for how MeCP2 disruption in neurodevelopmental disorders can lead to widespread
changes in gene expression.
In light of our findings that enhancer-based repression by MeCP2 and mCA is disrupted
in models of MeCP2 disorders, we investigated whether this pathway is affected in a new model
of NDD caused by DNMT3A disruption.We find that multiple transcriptomic and epigenomic
changes are shared between a knockout of MeCP2, and a heterozygous knockout of DNMT3A,
the enzyme that establishes neuronal non-CpG methylation.

ix

Together these findings demonstrate a previously unrecognized role for non-CpG DNA
methylation in the regulation of enhancer activity in neurons, and a role for enhancer
dysregulation, stemming from disruption of non-CpG DNA methylation, in multiple disorders.
This highlights non-CpG methylation as a possible convergence point between multiple
neurodevelopmental disorders.

x

Chapter 1: Introduction
The mammalian nervous system requires extremely precise control of gene expression
and regulatory networks in order to develop properly, and these requirements change over each
stage of development. A critical mechanism that contributes to gene regulation is DNA
methylation (Bird & Wolffe, 1999; P. A. Jones & Takai, 2001), the addition of a methyl group to
the 5’ position of a cytosine. DNA methylation is primarily associated with gene repression (Bird
& Wolffe, 1999; Greenberg & Bourc’his, 2019), as it is enriched within silenced promoters and
highly repetitive regions of the genome. There are several known mechanisms by which DNA
methylation can lead to gene repression, including blocking the binding of activating
transcription factors (Tate & Bird, 1993) and recruiting methyl-binding proteins that can have
repressive effects on transcription (P. L. Jones et al., 1998). This relationship, however, is not
absolute; some transcription factors can bind to both methylated and unmethylated DNA, and
methylation changes can occur downstream of activation or repression (Feldmann et al., 2013).
There are developmental consequences if DNA methylation is disrupted, as zygotic ablation of
DNA methylation through knockout of DNA methyltransferases results in embryonic lethality
(Li et al., 1992; Okano et al., 1999), and mutations in these methyltransferases and disruption of
methylation are widely associated with cancer (Das & Singal, 2004; Robertson, 2001).

DNA methylation appears to be especially important within the mammalian brain, as
neuronal DNA is enriched for noncanonical forms of methylation, and disruption of DNA
methyltransferase 3a (DNMT3A) within the brain leads to neurological defects in mice. Altering
1

methylation specifically within the mouse brain through a conditional knockout of DNMT3A
leads to broad behavioral and neuromuscular defects (Nguyen et al., 2007). Within humans,
mutations in a major neuronal reader of methylation, Methyl-CpG Binding Protein 2 (MeCP2)
cause Rett syndrome, another severe neurological disorder (Amir et al., 1999). Recently, more
links between human disease and neuronal methylation have been found, as new exome
sequencing studies have identified heterozygous mutations in DNMT3A in autism spectrum
disorders (Feliciano et al., 2019; Sanders et al., 2015; Satterstrom et al., 2020) and
Tatton-Brown-Rahman syndrome (TBRS), a neurodevelopmental disorder typified by
overgrowth and intellectual disability (Tatton-Brown et al., 2014, 2018). Given the clear links to
disease and the growing amount of evidence that methylation has a particularly important role in
neuronal function, there is a pressing need to understand more about the unique forms of
neuronal methylation, how they are established, the functions of their readers, and the diseases
that result when neuronal methylation is disrupted.

1.1 The unique neuronal methylome
While DNA methylation within mammals is typically characterized by the addition of a
methyl group to a cytosine followed by a guanine (mCG), that methyl group can become
oxidized and converted into a hydroxymethyl group by Tet Methylcytosine Dioxygenase 1
(TET1) (Tahiliani et al., 2009; Wu & Zhang, 2014). This form of methylation,
hydroxymethylation (hmCG), is commonly thought of as an intermediary in removing
methylation, through both passive and active mechanisms (He et al., 2011). While hmCG is
present within most cell types, it is enriched 10-fold within neurons (Globisch et al., 2010;
2

Kriaucionis & Heintz, 2009) and is a stable mark that builds up within gene bodies
proportionally to those genes’ expression levels (Guo et al., 2014; Mellén et al., 2012). hmCG
provides another possible dimension to the neuronal epigenome, as it has been suggested to
functionally demethylate highly expressed genes, rendering them less repressible by methyl
binding proteins such as MeCP2 (Chen et al., 2015; Gabel et al., 2015; Mellén et al., 2017).

While hmCG function is largely defined by its ability to actively, passively, and
functionally demethylate regions (a sort of epigenetic “negative space”), another unique form of
methylation in mammalian neurons may be able to recruit regulators in a way that traditional
mCG is unable to. This unique noncanonical methylation differs by context, rather than type of
modification. In most cells, the vast majority of DNA methylation is in a CG context, but
neurons contain uniquely high levels of non-CpG DNA methylation (mCH, where H = A, T, or
C), the majority of which is in a CA context (mCA) (Lister et al., 2013; Schultz et al., 2015).
While the methylation rate (mC/C) of any given CA dinucleotide is low (the majority between
2-5% in neurons, compared to .01% or lower for most other cell types) compared to methylation
at CG sites (70-90%), there are many more CA sites in mammalian genomes than CG sites (in
mice, ~380 million CA sites vs ~43 million CG sites), due to the susceptibility of methylated
cytosines to be deaminated and converted into a thymine over evolutionary time (Sved & Bird,
1990). Because of this, the total number of methylated sites in a CA context rivals the total
number of mCG sites within adult neurons. The high quantities of mCA in neurons compared to
other cell types, and its prevalence equaling that of mCG in these cells suggests that this newly
discovered form of methylation may be an important epigenetic mechanism for nervous system
3

function (Clemens & Gabel, 2020; Lister et al., 2013). In addition, neuronal mCA can vary
contiguously in regions of the genome 100kb long or larger, such that a given 100kb region of
the genome can have up to three times the amount of mCA within it compared to another
neighboring region. This variation may provide a wide range of biological signal for binding and
repression.

Initially discovered within embryonic stem cells (Ramsahoye et al., 2000), non-CpG
methylation is also enriched within heart cells and glia (Schultz et al., 2015). However, neurons
contain up to ten times as much mCA as these cells, and certain neuronal subtypes contain even
more mCA (Mo et al., 2015). The exact mechanisms by which neurons accumulate these
exceptionally high levels of mCA are unknown, but several contributing factors have started to
emerge. One such likely reason for neurons to accumulate high amounts of mCA is due to their
postmitotic nature, and how mCA and mCG differ between their establishment and maintenance
through cell division: mCG can be maintained by DNA methyltransferase 1 (DNMT1) through
cell division, as DNMT1 binds to hemimethylated CG sites and rapidly methylates the opposing
strand (Bestor, 2000; Leonhardt et al., 1992; Li et al., 1992). However, mCA is rapidly lost
through cell division, as DNMT1 has no such mechanism for maintaining it. Instead, mCA must
be established by the de-novo methyltransferases DNMT3A and DNMT3B (Bestor, 2000; Gabel
et al., 2015; Ramsahoye et al., 2000), which, unlike DNMT1, do not depend on hemimethylation
in order to efficiently deposit a mC. Thus, mCA likely has a greater ability to build up over time
within neurons and other postmitotic cells, such as cardiac cells. Mammalian neurons also
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experience a surge of expression of DNMT3A in early postnatal development (Feng et al., 2005),
contributing to their high levels of mCA.

1.2 DNA methyltransferase 3A establishes neuronal mCA
Additional analysis of DNMT3A and mCA patterns in neurons has established that
DNMT3A is the primary enzyme responsible for deposition of mCA within neurons. A
neuronal-specific knockout of DNMT3A leads to the complete ablation of mCA with
comparatively minor effects on mCG (Gabel et al., 2015), and analysis of DNMT3A binding at
different timepoints finds that early postnatal binding of DNMT3A is highly correlated with
adult mCA levels (Stroud et al., 2017). Characterizing DNMT3A and the factors that influence
its binding at this time period is thus essential in determining how mCA is distributed across the
neuronal genome. Few existing studies describing DNMT3A have examined its regulation in the
nervous system, where DNMT3A is exceptionally highly expressed, and there are yet to be any
studies that examine how the timing of DNMT3A expression and the factors that promote
DNMT3A binding impact mCA.

Outside of the nervous system, peptide assays characterizing the ADD protein-interacting
domain of DNMT3A have found that it binds to the N-terminal tail of Histone H3. Notably, this
binding disrupted in the presence of methylated Histone H3 lysine 4 (H3K4me1/2/3)(Zhang et
al., 2010), which mark active and poised transcription start sites. It is thought that this inhibition
of binding contributes to a strong depletion of both mCA and mCG within these active
regulatory regions. Another domain of DNMT3A, the PWWP domain, has been shown to bind to
5

Histone H3 lysine 36 trimethylation (H3K36me3) (Dhayalan et al., 2010), a histone mark
enriched within highly transcribed gene bodies (Kolasinska-Zwierz et al., 2009). However,
seemingly at odds with this finding, mCA is depleted within expressed genes in neurons, rather
than enriched. More recent work in non-neural cells has suggested while DNMT3A does bind to
H3K36me3, it preferentially binds to H3K36me2 with greater efficiency, while DNMT3B
preferentially binds to H3K36me3 (Weinberg et al., 2019; Xu et al., 2020). These observations
may have implications for mCA in the nervous system, where mCA levels are low at expressed
gene bodies, where H3K36me3 is abundant, but high within broad euchromatic regions.
H3K36me2 profiles are broadly euchromatic in non-neural cells, suggesting that similar patterns
could be recruiting DNMT3A and driving broad mCA deposition, but to date the profiles of
H3K36me2 have not been assessed in neurons. In addition, other factors such as RNA
Polymerase II may also have an effect on DNMT3A binding (Stroud et al., 2017). While these
factors that interact with DNMT3A may impact mCA deposition, no studies have been
performed on if, how, and when they do. DNMT3A is expressed at extremely high levels in the
brain (Feng et al., 2005), and its surge and subsequent decline of expression during early
postnatal development suggests a potential role for mCA and DNMT3A in an important period
of synaptic pruning and refinement. Exactly what this role is, and how the temporal dynamics of
DNMT3A help accomplish its regulatory role, however, must be elucidated.

1.3 mCA forms the basis of a critical neural-specific epigenetic mechanism
DNMT3A mutations in humans lead to Tatton-Brown-Rahman syndrome (Tatton-Brown
et al. 2014), and have been linked to autism spectrum disorders. Recent work characterizing the
6

function of DNMT3A and mCA through epigenomic and transcriptomic studies reveals a
possible link to Rett syndrome and other neurodevelopmental diseases. Studying the gene
expression changes of the aforementioned neuronal-specific knockout of DNMT3A identifies
hundreds if not thousands of subtly changed genes (Gabel et al., 2015). The genes most changed
upon loss of Dnmt3a have high amounts of mCA throughout their gene bodies (Gabel et al.,
2015), a characteristic shared with genes changed in a mouse model of Rett syndrome,
suggesting potentially overlapping mechanisms and pathology though a prominent neuronal
reader of methylation, MeCP2.

MeCP2, similarly to DNMT3A and mCA, is highly enriched within neurons, where its
expression reaches near-histone levels (Skene et al., 2010). While it was first identified through
its strong affinity to mCG, further research has shown it also binds tightly to mCA (Buchmuller
et al., 2020; Gabel et al., 2015; Guo et al., 2014; Lagger et al., 2017). Disruptions of MeCP2 in
humans cause Rett syndrome, a severe neurological disorder that is characterized by a period of
normal development from birth to 6-18 months, then a gradual loss of speech followed by
microcephaly, ataxia, seizures, and autism-like symptoms (Amir et al., 1999). This onset of
symptoms takes place concurrently with the rise of expression in MeCP2 as well as mCA
deposition, suggesting that the loss of MeCP2 interferes with proper postnatal neurological
function. However, it has been difficult to determine how MeCP2 alters transcription, and what
its targets are. Along with its histone-like expression levels within neurons, it exhibits extremely
broad, histone-like binding patterns, with slight enrichments within highly methylated regions,
but no sharp peaks to identify discrete binding sites with (Buchmuller et al., 2020; Lagger et al.,
7

2017; Skene et al., 2010). In MeCP2 mutants in mice, hundreds or thousands of genes experience
subtle (<2-fold) changes in expression, both up and down (Chahrour et al., 2008; Gabel et al.,
2015).

Although few trends have been found that explain the genes downregulated in the
knockout (MeCP2-activated genes), several striking trends have been detected in the genes
upregulated in the MeCP2 knockout (MeCP2-repressed genes) that link the transcriptomic
changes to the unique neuronal methylome. Firstly, although these MeCP2-repressed genes do
not display an enrichment of mCA or mCG at their promoters, the canonical site of action for
repression and activation of gene expression, they are enriched for mCA within their gene
bodies. Secondly, MeCP2-repressed genes have long transcribed gene lengths, many of them
spanning over 100kb in size (Gabel et al., 2015; Kinde et al., 2016). Thus, long, highly
methylated genes that are particularly susceptible to repression by MeCP2 may require the
specific patterns of neuronal mCA, which can vary greatly over large genomic regions, unlike
mCG. In addition, recent work studying mice carrying an engineered MeCP2 protein that can
bind mCG but not mCA has demonstrated the critical importance of mCA to MeCP2 function.
These mice recapitulate many of the same phenotypes seen in a complete MeCP2 KO, indicating
that MeCP2 requires mCA in order to properly guide neuronal function (Tillotson et al., 2020).
While these findings demonstrate the importance of mCA to regulation by MeCP2, many
questions remain unanswered. How do large regions of the genome maintain and establish varied
methylation levels, such that genes over 100kb long can have consistent levels of high mCA? Do
the high mCA levels within these genes impact MeCP2 binding and regulation? And if MeCP2
8

does rely on high mCA levels at the gene body to bind to, how does MeCP2 then affect the
expression levels of that gene?

1.4 Disruptions in multiple mCA-related proteins result in disease
The critical importance of mCA to neuronal function is illustrated clearly from the
overlapping neurological deficits resulting from disrupting its deposition through DNMT3A or
from disrupting its readout by MeCP2. However, it is unknown what role methylation changes
play in TBRS, and how mCA and MeCP2 interact to regulate genes. The recent discovery of
links between neuronal mCA and disease emphasizes the need to learn more about the origins
and factors influencing this novel form of methylation. Mutations in Nuclear receptor SET
Domain-containing protein 1 (NSD1), which establishes H3K26me2, are known to cause Sotos
syndrome, a disease with features of overgrowth and intellectual disability similar to TBRS
(Kurotaki et al., 2002). Given that H3K36me2 has recently been proposed to recruit DNMT3A
outside of neurons, it is possible that the overlapping features between Sotos syndrome and
TBRS are partially due to changes in neuronal mCA. Lending further support for this hypothesis
is the finding that patients with Sotos syndrome experience numerous methylation changes at CG
sites within blood (Choufani et al., 2015), showing that NSD1 mutations can cause methylation
changes, and may potentially affect mCA within the brain. The commonalities between Sotos
syndrome, TBRS, and Rett suggest that the unique neuronal factor that these three disorders
share, mCA, is critical for normal neuronal function, and that disruptions at multiple steps in this
neuronal-specific regulatory mechanism can result in disease. Exactly how mCA regulates
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neuronal expression, and how disruptions in mCA depositors and readers impact the nervous
system, however, is yet to be known.

To provide insight on these questions, I present my research on insights into how
genomic topology influences mCA patterns to remain at a consistent level across long stretches
of the genome. I subsequently show that these insights shed light on the mechanism by which
MeCP2 represses long genes with high methylation, revealing that this process occurs through
repression of highly-methylated intragenic enhancers. In my third chapter, I will present work on
the transcriptomic and epigenetic changes in a new mouse model of TBRS. Therein, I will
present evidence that there is a global loss of mCA upon heterozygous disruption of DNMT3A,
and that transcriptomic changes overlap between mouse models of Rett syndrome and TBRS.
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Chapter 2: MeCP2 represses enhancers through chromosome
topology-associated DNA methylation

This chapter is adapted from a manuscript published in Molecular Cell:

Clemens AW, Wu DY, Moore JR, Christian DL, Zhao G, Gabel HW. MeCP2 Represses
Enhancers through Chromosome Topology-Associated DNA Methylation. Mol Cell.
2020;77(2):279-293.e8. doi:10.1016/j.molcel.2019.10.033

A.W.C. carried out all of the experiments in collaboration with J.R.M. and D.L.C. and performed
ChIP-seq analysis; D.Y.W. performed RNA-seq, Bisulfite-seq, and TAD analysis, and
contributed to analysis of ChIP-seq studies; G.Z. and D.Y.W. performed the Hi-C analysis;
A.W.C, D.Y.W, and H.W.G. designed the experiments and analysis, and wrote the manuscript.

2.1

Abstract
The genomes of mammalian neurons contain uniquely high levels of non-CG DNA

methylation that can be bound by the Rett syndrome protein, MeCP2, to regulate gene
expression. How patterns of non-CG methylation are established in neurons and the mechanism
by which this methylation works with MeCP2 to control gene expression is unclear. Here we
find that genes repressed by MeCP2 are often located within megabase-scale regions of high
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non-CG methylation that correspond with topologically-associating domains of chromatin
folding. MeCP2 represses enhancers found in these domains that are enriched for non-CG and
CG methylation, with the strongest repression occurring for enhancers located within
MeCP2-repressed genes. These alterations in enhancer activity provide a mechanism for how
MeCP2 disruption in disease can lead to widespread changes in gene expression. Hence, we find
that DNA topology can shape non-CG DNA methylation across the genome to dictate
MeCP2-mediated enhancer regulation in the brain.

2.2

Introduction
The development and function of the mammalian brain requires precise control of gene

expression (Cholewa-Waclaw et al., 2016). While DNA methylation at CG dinucleotides is used
to control genes in all cells, neurons also utilize a unique form of non-CG DNA methylation for
gene regulation (Lister et al., 2013; Xie et al., 2012). Non-CG DNA methylation is deposited by
DNA methyltransferase 3A (DNMT3A), accumulating specifically in neurons postnatally until
methylated cytosine (mC) at non-CG sites is nearly equal to mC at CG sites (mCG) (Lister et al.,
2013). DNMT3A disruption in the mouse brain results in ablation of mC at non-CG sites and
neurological phenotypes (Nguyen et al., 2007), supporting the importance of this methyl-mark.
Studies indicate that Methyl-CpG binding Protein 2 (MeCP2) has high affinity for mC in
CA dinucleotides (mCA) similar to its classical substrate, mCG (Chen et al., 2015; Gabel et al.,
2015; Guo et al., 2014). MeCP2 is expressed at near-histone levels in neurons and binds widely
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across the genome, with some enrichment at regions high in mCG and mCA sites (Chen et al.,
2015; Gabel et al., 2015; Skene et al., 2010). The protein interacts with the NCoR-HDAC3
corepressor complex and can block reporter expression in vitro, suggesting an important function
of MeCP2 is gene repression (Lyst and Bird, 2015). Loss of MeCP2 causes the neurological
disorder Rett syndrome, and duplication of MeCP2 leads to autism spectrum disorder (Amir et
al., 1999; Van Esch et al., 2005). Transcriptomic studies of brains from Rett syndrome patients
and MeCP2 knockout (MeCP2 KO) or overexpression (MeCP2 OE) mice detect only subtle
changes across many genes however, making it difficult to differentiate direct targets of MeCP2
regulation from secondary gene expression effects (Chahrour et al., 2008; Tudor et al., 2002).
Defining how MeCP2 mediates its broad, subtle expression effects is thus recognized as an
important challenge to address (Ip et al., 2018; Lyst and Bird, 2015).
Recent analysis has revealed that MeCP2 represses genes marked by high mCA levels
(Chen et al., 2015; Gabel et al., 2015; Lagger et al., 2017). Notably, these genes are not
substantially enriched for mCA at promoters, a canonical site of action for methylation, but show
high mCA in their transcribed regions (“gene bodies”) and flanking sequences. In addition,
MeCP2 KO causes a relative upregulation of genes genome-wide that is correlated with both the
length and mC level of the gene body (Gabel et al., 2015; Sugino et al., 2014). These
observations have led to the proposal that MeCP2 regulates expression by binding to mC in gene
bodies to repress transcription (Kinde et al., 2016).
While these findings provide insight into mCA and MeCP2 in the brain, it is not known
how high mCA levels are established at MeCP2-repressed genes. In addition, while MeCP2
represses the mRNA of long, high-mCA genes, it has not been demonstrated that this occurs
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through direct repression of transcription, and alternative post-transcriptional mechanisms have
been proposed (Johnson et al., 2017). Finally, the mechanism by which binding of MeCP2 to mC
outside of promoters can drive subtle, but critical, gene repression is unknown.
Here we examined how high mCA levels are established at MeCP2-repressed genes and
explored how MeCP2 functions with mCA to control transcription. We find that mCA patterning
in neurons is associated with chromatin folding, and that genes most strongly repressed by
MeCP2 often land in mCA-enriched topologically-associating domains (TADs). We uncover
evidence that MeCP2 binds to mCA and mCG within mCA-enriched TADs to repress activity of
enhancer elements and cause downregulation of promoter activity for target genes. These
findings provide insight into how disruption of MeCP2 drives neurological dysfunction in Rett
syndrome and related disorders.

2.3

Results
To explore how high levels of mCA are established at MeCP2-repressed genes and to

determine how MeCP2 reads out mC to control gene expression, we analyzed the cerebral
cortex, a brain region where MeCP2 mutations disrupt gene expression and physiology (Pacheco
et al., 2017; Shepherd and Katz, 2011). We integrated our data with epigenomic datasets for this
brain region (Dixon et al., 2012; Sloan et al., 2016; Stroud et al., 2017) to search for features that
can explain patterns of high mCA at genes repressed by MeCP2. We focused on mCA, the most
prevalent, highest affinity non-CG site for MeCP2 (Gabel et al., 2015), but obtained similar
results for minor non-CG methylation sites (mCT, mCC) in our studies.
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Combined RNA-seq analysis of cortex from MeCP2 KO and MeCP2 OE mice (see
methods) identified 884 “MeCP2-repressed genes” significantly upregulated in MeCP2 KO and
downregulated in MeCP2 OE and 843 “MeCP2-activated genes” affected in the opposite manner
in these mutants (Figure 2.1A). These genes overlap with genes identified by meta-analysis of
non-cortical brain regions in MeCP2 mutants (Gabel et al., 2015), indicating many
MeCP2-regulated genes are shared across brain regions (Figure 2.8A,B). As in other studies
(Gabel et al., 2015; Renthal et al., 2018; Sugino et al., 2014), cortical MeCP2-repressed genes
are longer than the genome average (Figure 2.8D) and are enriched for mCA (mCA/CA, or
“mCA level”) in and around the gene, with little mCA enrichment at their transcription start site
(TSS) (Figure 2.1B,C; 2.8C). We also detected global length- and mCA-associated upregulation
of genes in MeCP2 KO and downregulation in MeCP2 OE (Figure 2.8E,F), with dysregulation
most correlated with gene body mCA levels compared to gene-flanking regions (Figure 2.8G,H).
These results confirm that MeCP2 represses long, high-mCA genes and provide a
high-confidence set of MeCP2-regulated cortical genes for our analyses.

Large-scale non-CG DNA methylation profiles are linked to chromatin topology.
We next explored how high mCA levels are established at MeCP2-repressed genes. We
observed that mCA enrichment can extend for megabases around these genes (Figure 2.1B,C)
(Kinde et al., 2016), suggesting that regional mCA varies on a megabase scale. High-throughput
chromatin conformation capture (Hi-C) analysis of the mouse cortex (Dixon et al., 2012, 2016)
has detected TADs on a similar megabase scale. TADs are regions of cis-interactions, where
enhancers interact with promoters in the same TAD more often than with promoters outside of
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the TAD (Spielmann et al., 2018). We noted instances where high mCA surrounding
MeCP2-repressed genes dropped off at transition points in Hi-C interactions similar to those
delineating TADs (Figure 2.1D). A correlation between mCA patterns and TADs could have
important implications for regulation of gene expression within each TAD. We therefore
investigated if TADs in the cerebral cortex (Dixon et al., 2012; Weinreb and Raphael, 2016, see
methods) delineate regions of high mCA at MeCP2-repressed genes.
We find that TADs containing MeCP2-repressed genes are significantly enriched for
mCA compared to TADs genome-wide (Figure 2.1E). Further, we observe a drop-off of mCA
levels at boundaries of TADs containing MeCP2-repressed genes that is not detected in control
TADs generated by shuffling genomic locations (Figure 2.1F; 2.9B,C). While the shift in mCA
across all boundaries returns toward the genome average (Figure 2.1F), a dramatic drop-off in
mCA at boundaries is detected when high-mCA TADs containing MeCP2-repressed genes are
adjacent to lower mCA regions (Figure 2.1G). Such strong mCA enrichments and drop-offs at
boundaries are not observed for shuffled TADs (Figure 2.1F,G; 2.9B, see methods) or for
potential sources of sequencing bias (Figure 2.9B), indicating that these mCA patterns are not
due to technical artifacts. Cross-correlation analysis (Rao et al., 2014, see methods) shows that
mCA levels are more highly correlated for regions in the same TAD than for regions in
neighboring TADs (Figure 2.1H). This relationship is detected for all TADs but is most
prominent for TADs containing MeCP2-repressed genes. Control TADs shuffled across the
genome do not show similar correlations (Figure 2.1H, see methods). These findings suggest that
TADs are units of organization for mCA levels in the genome and that MeCP2-repressed genes
often occupy high-mCA TADs.
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In contrast to MeCP2-repressed genes, TADs containing MeCP2-activated genes display
lower mCA levels (Figure 2.1E; 2.9A). Genomic mCG levels do not show prominent
megabase-scale variation, but some mCG depletion occurs in TADs containing MeCP2-activated
genes (Figure 2.1D; 2.9A,B). Increased correlation of mCG within TADs is observed (Figure
2.9D), suggesting TADs do organize modest regional mCG fluctuations.
As an added test of the association between topology and regional mCA, we analyzed
Hi-C data from the embryonic cortex (Bonev et al., 2017), prior to the deposition of mCA.
Topology at this time point is similarly associated with adult mCA (Figure 2.9E-H), indicating
that chromatin folding early in development is predictive of adult mCA patterns. We further
generalized our findings using an independent cortical mC dataset (Lister et al., 2013), as well as
Hi-C and mC data from the cerebellum (Mellén et al., 2017; Yamada et al., 2019). This analysis
indicated that the association between genome topology and mCA levels is robustly detected in
independent datasets and brain regions (Figure 2.9I-K).
We next explored how mCA is established in TADs during development. DNMT3A
deposits mCA in mouse cortex from birth to six weeks of age (Lister et al., 2013), and DNMT3A
binding in kilobase-scale regions at two weeks predicts mCA levels at eight weeks (Figure
2.10A; Stroud et al., 2017). We therefore asked if megabase-scale DNMT3A binding at two
weeks supports a role for TADs in influencing large-scale mCA patterning. We find that
DNMT3A ChIP-seq signal at two-weeks shows higher cross-correlations within TADs than
across TAD boundaries (Figure 2.2A) and predicts TAD mCA in the adult cortex (Figure 2.2B).
DNMT3A ChIP also drops off at boundaries of TADs containing MeCP2-repressed genes
(Figure 2.2C), while input controls do not (Figure 2.10B). Analysis of topology from embryonic
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neurons and DNMT3A at a later timepoint yielded similar results (Figure 2.10C-F, see methods).
These findings indicate that DNMT3A binding during postnatal development is shaped by TAD
structures, defining a long-term mCA “set-point” for each TAD into adulthood.
To examine how TAD mCA affects MeCP2 binding, we quantified MeCP2 ChIP-seq
signal (Kinde et al., 2016) in the adult cortex. MeCP2 ChIP signal is extremely broad, showing
only very modest fluctuations across the genome (Chen et al., 2015; Gabel et al., 2015). In the
context of these small effects however, we find that MeCP2 levels in TADs associate with TAD
mCA set-points (Figure 2.2D) and that MeCP2 cross-correlation is higher within TADs than
across TAD boundaries (Figure 2.10G). Analysis of MeCP2 binding when mCA is blocked by
deletion of DNMT3A (Figure 2.10H) (Kinde et al., 2016) revealed relative reductions in MeCP2
TAD binding that correlate with the wild-type mCA levels of each TAD (Figure 2.10I). Thus,
high TAD mCA levels are associated with some enrichment of MeCP2 binding, and when mCA
is lost, large-scale MeCP2 profiles are measurably altered.
We then considered how TAD-associated mCA levels could impact gene regulation.
Methylation levels for regulatory elements and genes are thought to be determined by local
sequence features and activity level at these sites (Schübeler, 2015). However, the TAD mCA
set-point could act on top of these local determinants to drive consistently higher or lower mCA
across all elements within each TAD. Indeed, we detect robust correlations between the TAD
set-point mCA level and mCA levels of gene bodies and enhancers inside each TAD (Figure
2.2E). This correlation occurs only for elements found within the TAD, breaking down
immediately outside of the TAD (Figure 2.10J). Correlations in mCA levels between elements in
the same TAD are also stronger than for elements on different sides of a TAD boundary (Figure
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2.10K). In contrast, mCA levels in TSS regions have limited correlation with TAD mCA levels,
suggesting that these elements escape the TAD mCA set-point. Control analysis randomizing
TAD or genomic element locations (see methods) confirmed that TAD boundaries delineate
transitions in mCA set-points for enhancers and genes (Figure 2.10J,K) and showed that only
true TSS regions escape TAD mCA levels (Figure 2.10L,M). mCG levels at these elements did
not show strong TAD-associated signals (Figure 2.10L,M). These findings indicate that mCA
levels at enhancers and genes in each TAD are linked to the mCA set-point for the TAD. By
influencing mCA at genes and enhancers, TAD-associated mCA levels can directly impact
regulation of genes within each TAD by MeCP2.

Loss of MeCP2 leads to promoter activation at MeCP2-repressed genes.
We next investigated how MeCP2 reads out mCA in TADs to affect transcription.
Consistent with analysis above (Figure 2.2E), the high TAD mCA set-point for
MeCP2-repressed genes is associated with high mCA in and around these genes but little mCA
enrichment at the TSS (Figure 2.1B; 2.8C). This suggests that MeCP2 binds to mCA outside of
the promoter to repress these genes. Based on the long length of MeCP2-repressed genes and the
correlation between repression and gene body mCA (Figure 2.8D,G,H), we considered several
possible regulatory mechanisms for MeCP2. For example, MeCP2 binding to gene body mCA
might block transcribing RNA polymerase, resulting in premature termination and reduced
mRNA. Alternatively, binding of MeCP2 to mCA at regulatory elements could act at a distance
to block promoter activation. To test these and other possible mechanisms, we carried out
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genomic analysis of RNA intermediates and histone marks associated with transcription in
MeCP2 mutant mice.
We first performed RNA-seq on nuclear RNA from MeCP2 KO and wild-type cortex to
enrich for pre-mRNA (Figure 2.3A) and analyzed intronic reads to assess changes in
transcription (Boswell et al., 2017). We reasoned that if MeCP2 normally reduces the
processivity of RNA polymerase II to cause premature termination of repressed genes, increased
transcript completion in the MeCP2 KO would result in more intronic reads at the 3’ end of
genes but no change in reads at the 5’ end. Alternatively, if MeCP2 represses promoter
activation, loss of MeCP2 would cause a consistent increase in intronic reads along the entire
gene. Finally, if post-transcriptional mechanisms affect these genes, no intronic changes would
be seen. Differential expression analysis of introns detected highly concordant effects with
mRNA from whole cells, with introns also showing upregulation of long and high-mCA genes
relative to shorter and lower-mCA genes (Figure 2.3B; Figure 2.11A-F). Analysis of intronic
RNA changes across the length of significantly upregulated genes detected a consistent increase
of intronic reads across the pre-mRNA (Figure 2.3C; 2.11G,H). These results suggest that subtle
changes in mRNA for MeCP2-repressed genes result from concomitant subtle changes in
pre-mRNA transcription and that loss of MeCP2 leads to promoter activation, rather than
changes in polymerase processivity.
As an independent measure of transcriptional effects, we performed ChIP-seq of histone
modifications that report on transcriptional activity. Analysis of gene body Histone 3 lysine 36
trimethylation (H3K36me3), a mark associated with transcription levels (Guenther et al., 2007),
revealed a subtle but significant increase in signal for MeCP2-repressed genes in the MeCP2 KO
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(Figure 2.3A,D). Analysis of Histone 3 lysine 27 acetylation (H3K27ac) and Histone 3 lysine 4
trimethylation (H3K4me3), marks associated with promoter activation (Heintzman et al., 2007;
Santos-Rosa et al., 2002), showed promoter upregulation for MeCP2-repressed genes (Figure
2.3A,D). While subtle, these effects are consistent with the magnitude of mRNA increases for
these genes. Together with our intronic RNA analysis, these findings support a model in which
MeCP2 acts at a distance to repress promoter activity.
Given the small magnitude of these effects, we sought to independently test if MeCP2
controls promoter activation. Based on the opposite effects on mRNA in the MeCP2 OE
compared to the MeCP2 KO, we predicted intronic RNA and histone marks should be
reciprocally affected in the MeCP2 OE. Indeed, integrated RNA-seq and ChIP-seq analyses in
the MeCP2 OE revealed opposite effects of those in the MeCP2 KO (Figure 2.3E-G; 2.11I).
These findings provide further support that MeCP2 represses long, high-mCA genes through
promoter downregulation.

MeCP2 represses enhancers that are enriched for mCA and mCG binding sites.
We next considered how binding of MeCP2 to high levels of mC found outside of the
TSS could lead to promoter downregulation. One way MeCP2 could achieve this is through
enhancers. Since our analysis shows that high-mCA set-points of TADs containing
MeCP2-repressed genes would lead to high mCA at enhancers in the TAD (Figure 2.1E; 2.2E),
we considered that repression of these enhancers by MeCP2 could underlie regulation of
MeCP2-repressed genes. To date however, effects of MeCP2 on enhancer activity have not been
examined. Enhancer activation is associated with H3K27ac signal at these sites (Creyghton et al.,
26

2010), and visualization of our H3K27ac ChIP signal at enhancers near MeCP2-repressed genes
suggests subtly increased acetylation in the MeCP2 KO (Figure 2.4A). Combined differential
analysis of H3K27ac signal in MeCP2 KO and OE cortex genome-wide (see methods) identified
significantly altered enhancers (Figure 2.4B; 2.12A). Quantification of mCA and mCG at
dysregulated enhancers detected enriched and depleted mCA levels at MeCP2-repressed and
MeCP2-activated enhancers respectively, while mCG levels showed limited variation at these
regions (Figure 2.4C; 2.12B).
Given the high affinity of MeCP2 for mCG (Meehan et al., 1989), but limited mCG/CG
signal at MeCP2-regulated enhancers, we further considered if the number of mCG sites rather
than the level of mCG contributes to enhancer repression by MeCP2. The number of mC binding
sites for MeCP2 at enhancers is determined both by per-base methylation at CA and CG sites
(e.g. mCG/CG) and dinucleotide frequencies at each enhancer (e.g. CG/kb). This is particularly
relevant for CG dinucleotides, which are depleted from the genome and non-uniformly
distributed (Bird, 1980). We therefore quantified mC “density” (mC/kb) at dysregulated
enhancers and detected a robust signal for mCG density, which is driven by the presence or
absence of CG dinucleotides (Figure 2.4C; 2.12B). These findings suggest that both mCA and
mCG do contribute to MeCP2 enhancer regulation, but mCA enrichment is driven by per-base
methylation, while mCG enrichment is driven by CG frequencies.
To further explore the link between high-affinity sites for MeCP2 and enhancer
regulation, we examined enhancer effects at higher stringency. While mCA is the highest affinity
non-CG dinucleotide for MeCP2 (Gabel et al., 2015), the third nucleotide also affects MeCP2
binding, with mCAC showing highest affinity for MeCP2 (Lagger et al., 2017). We find that
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mCAC is most significantly associated with MeCP2-regulated enhancers compared to lower
affinity sites (Figure 2.4D; 2.12C). Consistent with the presence of high-affinity MeCP2 sites at
dysregulated enhancers, MeCP2 ChIP signal is enriched at MeCP2-repressed enhancers (Figure
2.4E). Analysis of high-stringency MeCP2-repressed enhancers, selected based on enriched
MeCP2 binding, yields similar changes in H3K27ac and mC enrichment (Figure 2.12A,B). This
supports a direct role for MeCP2 in enhancer regulation.
While significantly dysregulated enhancers display robust signal for mCA and mCG,
methylation at enhancers occurs in a continuous distribution genome-wide (Figure 2.12D). Thus,
every enhancer may be regulated by MeCP2 to some degree, with the number of mC sites
determining the repression level. Indeed, when we compared mC density and H3K27ac changes
at all enhancers in the genome, we detected a positive correlation between mCA and mCG
density and H3K27ac changes in the MeCP2 KO and a negative correlation in the MeCP2 OE
(Figure 2.4F,G). While mC density is enriched in and around MeCP2-repressed enhancers
(Figure 2.4C), we find that enhancer H3K27ac dysregulation in MeCP2 mutants best correlates
with mC density at enhancer centers (Figure 2.4H,I). Thus, mC specifically within the enhancer
is most important for regulation by MeCP2. Together, these findings support a model in which
repression of enhancers by MeCP2 genome-wide is proportional to the mC density at each
enhancer.
We also noted minor increases of H3K27ac at sites outside of stringently defined
enhancer regions in the MeCP2 KO (Figure 2.12E). Examination of a set of possible regulatory
elements (ATAC-seq peaks), defined across 13 mouse tissues (Cusanovich et al., 2018), showed
that these regions overlap with enhancers as well as sites of H3K27ac enrichment not formally
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called as enhancers (Figure 2.12E,F, see methods). Analysis of these regions genome-wide
revealed noisier, but detectable correlations between H3K27ac changes and mC density at these
putative regulatory sites (Figure 2.12F,G,H). Thus, while a larger absolute change in H3K27ac is
observed at called enhancers in MeCP2 mutants (Figure 2.12F), altered H3K27ac outside of
enhancer regions may also contribute to effects observed in these mice.
We next tested the role of mCA and mCG in enhancer repression by selectively
disrupting mCA in neurons. Conditional Dnmt3a deletion in the brain ablates mCA while
preserving mCG, and leads to overlapping, but smaller effects on MeCP2-repressed genes
compared to MeCP2 mutants (Gabel et al., 2015). We speculated that these partial expression
effects arise due to loss of enhancer repression by mCA, but preserved repression by mCG. To
test this, we deleted Dnmt3a from post-mitotic neurons in a DNMT3A Baf53b-cKO mouse (see
methods) and measured effects on mC, RNA, and H3K27ac. Bisulfite-seq revealed ablation of
mCA, but retention of mCG, at enhancers and other genomic elements (Figure 2.5A, 2.13A-C),
and RNA-seq showed significant, but partial, dysregulation of MeCP2-regulated genes (Figure
2.5B).

H3K27ac ChIP-seq

similarly detected

robust,

but partial,

dysregulation of

MeCP2-regulated enhancers (Figure 2.5B). Significantly up- and downregulated enhancers
defined in the DNMT3A Baf53b-cKO (see methods) displayed enrichment or depletion of mCA,
but equivalent mCG (Figure 2.5C, 2.13D,E). Unthresholded analysis showed that, like MeCP2
mutants, H3K27ac changes correlate with wild-type mCA density at enhancers genome-wide
(Figure 2.5D). In contrast, no association was detected for mCG (Figure 2.5D). Together, the
robust but smaller effects on MeCP2-regulated enhancers and lack of mCG-associated changes
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in the DNMT3A mutant demonstrate the role of mCA in enhancer repression by MeCP2 and also
support a function for mCG in this regulation.

Enhancer repression by MeCP2 is associated with MeCP2-mediated gene regulation.
We next investigated if enhancer dysregulation is linked to altered gene expression in
MeCP2 mutants. As predicted by our analysis above (Figure 2.2E), enhancers in high-mCA
TADs containing MeCP2-repressed genes are enriched for mCA (Figure 2.6A), suggesting
possible repression by MeCP2. Analysis of gene-enhancer links by several methods (TAD
overlap, GREAT analysis (McLean et al., 2010), and Hi-C) revealed that MeCP2-repressed
enhancers are significantly associated with MeCP2-repressed genes (Figure 2.6B). In light of the
genome-wide association between mC density and repression of H3K27ac at enhancers (Figure
2.4F,G), we considered that many high-mCA enhancers in TADs with MeCP2-repressed genes
might undergo upregulation in the MeCP2 KO that are below the statistical significance cutoff.
Supporting

this

idea, H3K27ac changes for

enhancers

in TADs with prominent

MeCP2-repressed genes displayed trends toward upregulation (Figure 2.6C). Indeed, the
population of enhancers found in TADs containing MeCP2-repressed genes showed significant
upregulation as a group in the MeCP2 KO and downregulation in the MeCP2 OE (Figure 2.6D).
While this analysis linked MeCP2 enhancer repression to gene regulation, we sought to
understand our previous finding that MeCP2 mutant mRNA changes are better correlated with
mC levels in long genes than with mC levels in gene-flanking regions (Figure 2.8F-H; 2.11E,F)
(Kinde et al., 2016). We speculated this signal might reflect preferential repression of intragenic
enhancers by MeCP2. Indeed, H3K27ac changes at prominent MeCP2-repressed genes in the
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MeCP2 KO showed stronger increases at intragenic enhancers than at extragenic enhancers
(Figure 2.6C). Analysis of all MeCP2-repressed enhancers showed they tend to be intragenic
(Figure 2.6E), and significantly overlap with MeCP2-repressed genes (Figure 2.6B). As a
population, enhancers in MeCP2-repressed genes are more robustly upregulated in the MeCP2
KO and downregulated in the MeCP2 OE than all enhancers in the same TAD (Figure 2.6D).
Furthermore, while H3K27ac repression by MeCP2 is correlated with mC density for both
intragenic and extragenic enhancers, for a given mC density, intragenic enhancers are more
repressed (Figure 2.6F).
Given the susceptibility of intragenic enhancers to MeCP2 repression, we investigated
their interactions with promoters of target genes. Hi-C data revealed that intragenic sequences
interact more with promoters than extragenic sequences do (Figure 2.6G), and intragenic
enhancers contact promoters of their cognate gene more than equidistant extragenic enhancers do
(Figure 2.6H). Quantitative 3C analysis of the MeCP2 KO detected no evidence of altered
interaction strength between enhancers and promoters of MeCP2-repressed genes (Figure 2.12I).
This suggests that intragenic enhancers are privileged over extragenic enhancers to control their
cognate genes, but that MeCP2 does not regulate looping between enhancers and promoters.
Rather, MeCP2 may affect the degree of gene activation driven by enhancers once they interact
with their target promoter.
If the repression of genes containing high gene body mCA is largely due to repression of
enhancers in these genes, we reasoned that gene body mCA and gene upregulation in the MeCP2
KO should only be tightly linked for genes that contain enhancers and not be linked for genes
that do not contain enhancers. Because long genes contain more enhancers than shorter genes
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(Figure 2.12J), MeCP2 intragenic enhancer repression could also explain the dysregulation of
longer genes observed in MeCP2 mutants (Figure 2.8F-H) (Gabel et al., 2015; Sugino et al.,
2014). We therefore examined gene expression effects in MeCP2 mutants for genes that do or do
not contain intragenic enhancers. We detect little correlation between gene dysregulation and
gene body mCA density for genes that do not contain enhancers but a robust correlation for
genes containing intragenic enhancers (Figure 2.6I, 2.12L). Importantly, we observe these effects
when controlling for gene length (Figure 2.12K). Consistent with the idea that enhancers
specifically contribute to this effect, we find that H3K27ac changes in intragenic enhancers are
more predictive of the gene expression changes in MeCP2 mutants than H3K27ac changes in
non-peak sequences (Figure 2.12M). These results suggest that dysregulation of intragenic
enhancers contributes to the dysregulation of long, highly-methylated genes that we previously
observed in MeCP2 mutants.

2.4

Discussion
Our findings suggest a model in which TADs shape DNMT3A activity across the

neuronal genome during early postnatal development, establishing mCA set-points for genes and
enhancers within each TAD (Figure 2.7A). In mature neurons, MeCP2 reads-out mC to repress
enhancer elements and control gene expression. Because MeCP2 most potently represses
highly-methylated, intragenic enhancers, it has the largest impact on genes in high mCA TADs
that contain multiple enhancers (Figure 2.7B).
The enriched DNMT3A binding and resulting high-mCA set-point we detect in TADs
with MeCP2-repressed genes provides insight into the origin of high mCA previously noted at
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these genes (Kinde et al., 2016; Lagger et al., 2017). The large fluctuations in mCA observed
between TADs can occur because of the dynamic distribution of mCA across the genome. This
contrasts with consistently high mCG across large regions. While sequence and activity states of
genes and enhancers are known to affect their methylation status (Schübeler, 2015), we show
here that TAD mCA set-points also influence mCA levels at genes and enhancers. Enhancers in
high-mCA TADs are enriched for mCA and are more repressed by MeCP2 compared to
enhancers in low-mCA TADs. In this way, TAD mCA patterns set the stage for
MeCP2-mediated gene regulation in the brain.
Previously, we and others have proposed that binding of MeCP2 in genes might block
RNA polymerase processivity to downregulate expression (Cholewa-Waclaw et al., 2019; Kinde
et al., 2016). Surprisingly, we did not detect disrupted processivity in the MeCP2 mutants, but
instead observed changes in promoter activity. Consistent with this finding, a parallel study used
multiple methodologies to identify regulation of transcription initiation by MeCP2 (Boxer et al.,
co-submitted). Our identification of intragenic enhancers that are dysregulated in MeCP2
mutants and analysis linking them to genes (Figure 2.6I, 2.12J-M) supports the model in which
MeCP2 preferentially represses long, highly-methylated genes but points to enhancer repression
as a mediator of this regulation.
MeCP2 binds nearly ubiquitously across the genome and its relevant sites of action have
not been clear. Through genome-wide H3K27ac analysis, we uncovered a role for MeCP2 in
enhancer repression that is driven in part by TAD-scale fluctuations in levels of mCA. While
identification of enhancers significantly changed in MeCP2 mutants revealed critical
determinants for MeCP2 regulation (e.g. mCA and mCG density), our unthresholded analysis
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suggests that these enhancers represent only extreme examples along a continuum, in which
graded repression by MeCP2 that is proportional to mC density occurs at enhancers genome
wide. Alterations in pervasive tuning of enhancers may explain why disruption of MeCP2 leads
to profound nervous system deficits, despite the small magnitude of effects observed for
individual genes.
Consistent with some role for mC sites in recruiting MeCP2 to the genome, MeCP2
ChIP-seq shows a measurable association with mCA and mCG sites (Figure 2.2D, 2.10I).
However, the binding of the protein is very broad, and signal is also present at demethylated
sites. Thus, mC sites may modulate MeCP2 repression of enhancers when it is bound, rather than
being a strict determinant of binding. Future analyses will be necessary to dissect the role of mC
sites in MeCP2 recruitment versus modulation of its repressive activity.
(Ebert et al., 2013; Kokura et al., 2001; Lyst et al., 2013) Our findings suggest a model in
which MeCP2 at enhancers can induce histone deacetylation to block their activating effects on
target promoters. This could occur through the interaction between MeCP2 and the NCoR
histone deacetylase complex that is critical for MeCP2-mediated gene repression (Kokura et al.,
2001; Lyst et al., 2013; Nott et al., 2016). Alternatively, MeCP2 could modulate NCoR functions
on non-histone proteins to affect enhancer activity.
A striking finding from our study is that MeCP2 represses intragenic enhancers more
than extragenic enhancers, and intragenic enhancer dysregulation is closely linked to gene
changes in MeCP2 mutants. We observed that intragenic enhancers more readily contact their
cognate promoters than extragenic enhancers, suggesting intragenic enhancer effects in MeCP2
mutants are particularly impactful for gene expression. Notably, intragenic enhancer regulation
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by MeCP2 provides an explanation for the gene length and gene body mC signature that we
previously observed for MeCP2-repressed genes (Kinde et al., 2016). These findings also
suggest that the presence of an enhancer within a gene can fundamentally alter the nature of its
regulation. Future studies can dissect how MeCP2 preferentially represses intragenic enhancers,
providing insight into the unique regulatory environment of these elements.
Our study focused on mCA at MeCP2-repressed genes, but enhancer repression by
MeCP2 may also explain MeCP2-activated genes. The MeCP2-activated enhancers we identify
here are depleted of mC sites (Figure 2.4C; 2.12B-D). If MeCP2 primarily represses enhancers
through mC, then H3K27ac changes at “activated” enhancers could reflect a relative lack of
de-repression in the MeCP2 KO and escape from repression in the MeCP2 OE. MeCP2-activated
enhancers are associated with MeCP2-activated genes (Figure 2.6B), suggesting the relative
changes in gene expression may stem from enhancer effects. Future studies can test if a single
model of enhancer repression by MeCP2 applies, or if MeCP2 directly activates genes by other
mechanisms.
While robust changes occur at enhancers in MeCP2 mutants, the protein binds broadly
across the genome and disruption of MeCP2 has effects on acetylation outside of stringently
defined enhancer sequences (Figure 2.12E) (Boxer et al., co-submitted). While some of this
signal appears to originate at subthreshold enhancers (Figure 2.12E), MeCP2 is likely to have
repressive effects on chromatin outside of enhancers that can contribute to gene regulation.
Multiple datasets support a role for MeCP2 in repressing long, high-mCA genes (Gabel et
al., 2015; Rube et al., 2016; Sugino et al., 2014), but a recent study proposed that long gene
upregulation in MeCP2 mutants results from post-transcriptional rather than transcriptional
35

effects (Johnson et al., 2017). Another study suggested long-gene dysregulation in individual
MeCP2 datasets does not reach statistical significance (Raman et al., 2018). Here, independent
RNA-seq and ChIP-seq analyses further show that MeCP2 preferentially affects long, high-mCA
genes. Notably, a parallel study using multiple methodologies and large-replicate datasets has
also verified these effects (Boxer et al., co-submitted). Our additional insights into enhancer
regulation not only support these effects but also provide a mechanism for how they can occur.
Our findings have important implications for Rett syndrome and MeCP2 duplication
disorder. Mutation of MeCP2 in these disorders is likely to disrupt enhancer activity in
high-mCA TADs, driving altered gene expression, and contributing to disease pathology. In this
way, our study suggests that Rett syndrome and MeCP2 duplication syndrome are disorders that
stem in part from disruption of enhancer control.

2.5

Methods

Mice
MeCP2 knockout mice (B6.129P2(C)-MeCP2tm1.Bird/J) were obtained from The Jackson
Laboratory. Female heterozygous mice (MeCP2-/+) were crossed with C57BL/6J male mice to
generate hemizygous male knockout mice (MeCP2-/y
 ) and wild-type male litter mates
+/y
(MeCP2 ). MeCP2 overexpression mice (FVB-Tg(MECP2)3Hzo/J) were cryo-recovered from
The Jackson Laboratory. Female heterozygous mice (MeCP2Tg3/+
 ) were crossed with FVB/NJ
male mice to generate hemizygous male transgenic mice (MeCP2Tg3/y) and wild-type male litter
mates (MeCP2+/y). Female Dnmt3afl/fl
 were provided by M. Goodell and crossed to male
B6.Cg-Tg(Nes-cre)1Kln/J (Nestin- Cre+/-) to generate Dnmt3afl/+; Nestin-Cre+/-
 . Male Dnmt3afl/+;
Nestin-Cre+/ were then crossed to female Dnmt3afl/fl to generate Dnmt3afl/fl Tg(Nes-cre)1Kln/J
conditional knockout mice (DNMT3A Nestin-cKO) (Gabel et al., 2015). To generate Dnmt3afl/fl
 ;
fl/fl
Tg(Actl6b-cre)4092Jiwu/J conditional knockout mice (DNMT3A Baf53b-cKO), Dnmt3a were
crossed to Tg(Actl6b-cre)4092Jiwu/J (Baf53b-Cre+/+) to generate Dnmt3afl/+; Baf53b-Cre+/-
 .
fl/ +
+/- 
fl/fl
Dnmt3a ; Baf53b-Cre were then crossed to Dnmt3a producing experimental and control
animals for analysis.
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Topologically associated domain analysis
Topologically associating domains were called using the TADtree algorithm (Weinreb and
Raphael, 2016) on interaction matrices (Dixon et al., 2012), with the following parameters:
gamma (sensitivity vs specificity tradeoff) = 200, M (number of hierarchical layers) = 1, p and q
(minimum scale of interaction shift) = 3 and 12 respectively, and N (maximum number of TADs
detected) = 500. To allow for manual model selection, TADtree also computes TADs for the
range of 1:500, in this case. We leveraged this to apply an additional filter for consistency,
wherein we selected for TADs that are called in at least 30% of all runs. When we applied this
filter, we found that the effects of changing gamma were moderated, and the program performed
consistently at many ranges of sensitivity vs specificity. TADs defined in the cerebral cortex by
this method are ~400kb on average and range in size from ~160kb to ~2mb, a scale that is
similar to regions that we observed with enriched mCA levels. We defined TAD-related “contact
domains” of interaction across the genome using the Arrowhead algorithm as previously
described (Rao et al., 2014) at 5kb resolution from embryonic neocortex. These contact domains
had a similar length distribution to TADs, with a median length of half that of TADs. These
domains are established and detected before DNMT3A increases in expression and establishes
mCA, and the close correlation between early TAD structure, early DNMT3A binding, and mCA
patterns suggests (Figure 2.10C,D) that the activity of DNMT3A in a TAD during early postnatal
development defines a long-term “set-point” for mCA across this region into adulthood. In
addition, the fact that DNMT3A expression is low at 8-weeks and that 8-week DNMT3A
binding, concurrent with adult TAD structure, is less correlated with mCA compared to 2-week
DNMT3A binding (Figure 2.10E,F), lends more support to a stable “set-point” of mCA, rather
than levels that fluctuate through adulthood.
8-week cortex Hi-C data was obtained as pre-processed observed/expected contact
matrices, from http://chromosome.sdsc.edu/mouse/hi-c/download.html (Dixon et al., 2012). For
analysis of neocortex Hi-C data from Bonev and colleagues (Bonev et al., 2017), raw FASTQ
files were downloaded from GEO. HiC-Pro (Servant et al., 2015) was used to generate contact
matrices using the mm10 mouse genome as reference. Juicer (Durand et al., 2016) was then run
on the contact matrices to generate Hi-C contact matrices at 1.5kb, 5kb, and 40kb resolutions
using KR normalization. Arrowhead domains were then called on the data within Juicer. For
cerebellum analysis, contact domains called from 10kb-resolution Hi-C data were used (Yamada
et al., 2019).
Total and nuclear RNA isolation
Cerebral cortex was dissected on ice in phosphate buffered saline from 1) MeCP2 KO and
wild-type male litter mates at 7-8 weeks old, 2) MeCP2 OE and wild-type male litter mates at
7-10 weeks old, and 3) DNMT3A Baf53b-cKO and control mice at 7-8 weeks old. Total RNA
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was extracted from 1/16th of a whole cortex using RLT buffer following RNeasy Micro Kit
(Qiagen). Nuclear RNA was isolated following a modified version of the protocol described (Mo
et al., 2015). Briefly, half of a cortex was homogenized in 0.25M sucrose, 25mM KCl, 5mM
MgCl2, 20mM Tricine-KOH using a glass dounce homogenizer. Nuclei were isolated via
centrifugation at 10,000g for 18 minutes at 4°C (Sorvall HB-4) by pelleting through a 30%
iodixanol density gradient (Sigma D1556). RNA was isolated from nuclei by resuspending pellet
in RLT buffer following the RNeasy Micro Kit (Qiagen).
RNA sequencing
RNA libraries were generated from 250ng total and nuclear RNA with NEBNext Ultra
Directional RNA Library Prep Kit for Illumina (NEB) using a modified amplification protocol
(37°C, 15 minutes; 98°C, 30 seconds; (98°C, 10 seconds; 65°C, 30 seconds; 72°C, 30
seconds)x13; 72°C, 5 minutes; 4°C hold. RNA libraries were pooled at a final concentration of
8-10nM and sequenced using Illumina HiSeq 2500 or 3000 with the Genome Technology Access
Center (GTAC) at Washington University in St. Louis, typically yielding 20-30 million
single-end reads per sample.
RNA sequencing analysis
Raw FASTQ files were trimmed with Trim Galore, using a quality filter of 20, then rRNA
sequences were filtered out using Bowtie, using rRNA sequences from Mus Musculus obtained
from the NCBI sequence database. The unaligned reads from this step were then aligned to mm9
using STAR (Dobin et al., 2013) with the default parameters. Reads mapping to multiple regions
in the genome were then filtered out, and uniquely mapping reads were converted to BED files.
Intronic and exonic reads were then separated. To do this, splice-site reads were first filtered out
of the BED read files, then reads that mapped entirely within exons were added to the splice-site
reads to make the exonic read file. All remaining reads that overlapped introns were considered
intronic reads. Finally, reads were assigned to genes using bedtools coverage -counts.
For gene annotation we defined a "flattened" list of longest transcript forms for each gene,
generated on Ensgene annotations, obtained from the UCSC table browser. For each gene,
Ensembl IDs were matched to MGI gene names. Then, for each unique MGI gene name, the
most upstream Ensgene TSS and the most downstream TES were taken as that gene's start and
stop. Based on these Ensembl gene models, we defined TSS regions and gene bodies.
Chromatin immunoprecipitation protocol
Cerebral cortex was dissected on ice in phosphate buffered saline from 1) MeCP2 KO and
wild-type male litter mates at 7-8 weeks old, 2) MeCP2 OE and wild-type male litter mates at
7-10 weeks old, 3) DNMT3A Baf53b-cKO and control mice at 7-8 weeks old. The tissue was
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flash-frozen in liquid nitrogen and stored at -80°C. ChIP experiments were performed on half a
cortex as previously described (Cohen et al., 2011), using an alternative chromatin fragmentation
method. Chromatin were fragmented with Covaris E220 sonicator (5% Duty Factory, 140 Peak
Incidence Power, 200 cycles per burst, milliTUBE 1mL AFA Fiber). ChIP was performed with
H3K27ac (0.025-0.1µg; Abcam ab4729), H3K4me3 (2µg; Abcam ab1012), and H3K36me3
(0.2µg; Active Motif 61101). ChIP libraries for H3K27ac, H3K4me3, and H3K36me3 were
generated using Ovation Ultralow Library System V2 (NuGEN). Libraries were pooled to a final
concentration of 8-10nM and sequenced using Illumina HiSeq 3000 with GTAC, yielding 15-30
million single-end reads per sample.
Chromatin immunoprecipitation analysis
Sequenced reads were mapped to the mm9 genome using bowtie2 alignment, and reads were
extended based on library sizes and deduplicated to consolidate PCR duplicate reads.
Deduplicated reads were used to quantify read density normalized by the number of reads per
sample and by read length in basepairs. Bedtools coverage –counts was used to quantify ChIP
signal at the transcriptional start site (TSS), gene body (GB), and transcriptional end site (TES).
For consistency with methylation analysis, the TSS was defined as a 1kb region surrounding the
TSS (+/-500bp), the GB was defined as 3kb downstream of the TSS to the end of the transcript,
and the TES was defined as 2kb upstream through 3kb downstream of the end of the transcript,
based on our Ensembl gene models. edgeR was then used to determine differential ChIP-signal
across genotypes.
Whole-genome bisulfite sequencing
Cerebral cortex was dissected from DNMT3A Nestin-cKO or DNMT3A Baf53b-cKO and
controls at 7-8 weeks, flash-frozen in liquid nitrogen, and stored at -80°C. DNA extraction and
bisulfite conversion were performed as before (Gabel et al., 2015). Briefly, genomic DNA was
extracted and bisulfite libraries were generated using the Ovation Ultralow Methyl-Seq Library
System (NuGEN). Libraries were pooled and sequenced using Illumina MiSeq 2x150 with the
Spike-In Cooperative at Washington University in St. Louis.
Chromatin conformation capture
3C assays were adapted from previously described procedures (Kim and Dekker, 2018;
Lieberman-Aiden et al., 2009; Yamada et al., 2019). Half of a cerebral cortex was dounced 10x
with a loose pestle in cross-linking buffer (50mM Hepes-KOH, pH 7.9; 100mM NaCl; 1mM
EDTA; 0.5mM EGTA) with 1% formaldehyde at room temperature for 15 minutes.
Formaldehyde was quenched with 125mM glycine and incubated for 5 minutes at room
temperature. The suspension was pelleted at 1150xg for 5 minutes at 4°C and the pellet was
subsequently washed with PBS and frozen at -80°C. The frozen pellet was thawed and lysed
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(10mM Tris-HCl, pH 8; 10mM NaCl, 0.2% IGEPAL-630, Protease Inhibitor (Complete Protease
Inhibitor Cocktail, Roche)) for 15 minutes followed by douncing 25x with a loose pestle on ice.
The lysed cells were strained through a 70um cell strainer (Falcon) and pelleted at 200xg for 5
minutes at 4°C. Nuclei were resuspended in 1mL of 0.5% SDS and incubated at 62°C for 10
minutes to permeabilize the nuclei. 25ul (approx. 90-100k nuclei) were used for the 3C library
construction, and SDS was quenched with Triton X-100 (1% Triton, 1x NEB 3.1 Buffer). Nuclei
were digested overnight at 37°C with 200U of BglII. The digested nuclei were incubated at 65°C
for 15 minutes to inactivate the enzyme. Samples were then ligated for 6 hours at 16°C with
4000U of T4 DNA ligase (NEB Ligase Buffer, 0.1mg/ml BSA, Triton X-100, NEB T4 ligase).
Digested and ligated 3C samples were pelleted at 3500rpm for 5 minutes at 4°C and resuspended
in 200ul NEB 3.1 Buffer and brought to 1% SDS and 250mM NaCl. 3C libraries were
de-crosslinked overnight at 65°C. They were then incubated with 40ug RNase A at 37°C for 1
hour, followed by 80ug of Proteinase K at 55°C for 1 hour. The samples were purified with
Phenol/Chloroform/Isoamyl Alcohol (25:24:1) and subsequently ethanol precipitated (100mM
Sodium Acetate) overnight at -20°C. Control libraries were generated from Bacterial Artificial
Chromosomes (BACs) as previously published (Kim and Dekker, 2018). BACs (see STAR
methods) were isolated using PureLink HiPure Plasmid Maxiprep Kit (Invitrogen), following the
modified protocol for BAC isolation.
Quantification and Statistical Analysis
Whole-genome bisulfite analysis
Bisulfite-sequencing cannot distinguish between hydroxymethylation and methylation at
cytosines, detecting both only as modified sites during sequencing. Thus, measures of
methylation included in this study represent the aggregate of both forms of methylation at sites
across the genome. Bisulfite data for the DNMT3A Nestin-cKO and DNMT3A Baf53b-cKO,
and data obtained from GEO as FASTQ files, were adapter-trimmed, mapped to mm9, then
deduplicated and called for methylation using BS-seeker2 (with bowtie2). Nonconversion rate
was set to be (--XS=.3,2), and default settings were used otherwise. The methylation levels for
genes and regions were assessed by summing the number of reads mapping to Cs that supported
mC and dividing that by the number of reads mapping to Cs that supported non-mC, using
bedtools map -o sum. This allows sites with more read information to contribute more in
determining the methylation level of the surrounding region. In order to avoid confounding
effects of promoter-associated depletion of methylation, genic methylation was assessed 3kb
downstream of promoters to the TES. In order to assess any potential for C site coverage bias
influencing TAD-associated Bisulfite-seq results, a bed file of every C/G in the genome was
generated, and bedtools coverage -counts was run on it. Bisulfite coverage bias was assessed on
informative sites for methylation with bedtools map -o mean on the number of reads mapping to
Cs in the region.
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RNA-sequencing quantification
MeCP2-repressed and activated genes were identified by quantitative analysis of exonic reads
from total RNA from the MeCP2 KO and OE. For this analysis we applied an approach similar
to previous studies of other brain regions that combined results of gene expression in these two
strains in order to identify the most-robustly MeCP2-regulated genes (Ben-Shachar et al., 2009;
Chahrour et al., 2008; Chen et al., 2015). DESeq2 was run using default parameters on exonic
reads from MeCP2 KO and their littermate control animals (n=6 per genotype). Separately, we
ran DESeq2 analysis on exonic reads from MeCP2 OE and their littermate control animals (n=5).
The nominal p-values output by DESeq2 for each gene in each mutant-control comparison were
then combined using the Fisher method (log-sum). The resulting combined p-values were then
Benjamini-Hochberg corrected, and genes with a q-value < .1 and a log2 fold-change > 0 in the
KO and a log2 fold-change < 0 in the OE were labeled as MeCP2-repressed, while genes with a
q-value < .1 and a log2 fold-change < 0 in the KO and a log2 fold-change > 0 in the OE were
labeled as MeCP2-activated. Notably, similar results for enrichment of mCA, and gene length
were observed when examining lists of genes called as significantly dysregulated in the MeCP2
KO and OE on their own. However, a smaller gene list was identified in each independent
analysis, likely due to the reduced statistical power. For comparison between changes in intronic
RNA and changes in exonic RNA (Figure 2.3; S1) a list of significantly changed genes in the
MeCP2 KO compared to littermate controls based on intronic fold-changes was generated by
applying the same DESeq2 analysis to intronic reads derived from total RNA-seq of nuclear
RNA.
RNA-seq aggregate plots examining changes in expression over lengths of genes (Figure
2.11G-I) were performed by binning genes into 1kb windows, then calculating nuclear intronic
coverage over each bin using bedtools coverage -hist. Each gene was then normalized by the
median amount of combined coverage from the MeCP2 KO and wild-type. Finally, genes were
aligned by their TSSs, and median expression levels were plotted for each bin. For any given
graph, the genes are filtered such that the lengths of genes plotted is equal to or greater than the
aggregate length being plotted (Boswell et al., 2017; Gray et al., 2014). Termination ratios
(adapted from (Boswell et al., 2017)) were calculated in a manner similar to the aggregate plots
of expression. Windows were made for every gene longer than 100kb, from the TSS to 25kb
downstream of the TSS (window A), and from the TES to 25kb upstream of the TES (window
B). Coverage over these windows was calculated with bedtools coverage -hist, then coverage of
window A was divided by the coverage of window B, within each sample. Then, wild
type/MeCP2 KO samples were divided against each other, and a normalized metric for each wild
type/MeCP2 KO replicate was generated. Finally, median metrics were plotted for each wild
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type/MeCP2 KO replicate. Simulated metrics were generated by progressively applying exonic
fold-changes to the wild-type expression throughout the gene. For example, a gene 50kb long,
with an observed exonic log2 fold-change (MeCP2 KO/wild type) of -1 would be divided into 50
1kb bins. A simulated KO expression pattern would then be generated by progressing down each
of the 50 bins, applying a fold-change of 1/50 * -1, 2/50 * -1, etc, to the expression of the
corresponding bin in the WT.
Controlled resampling
A resampling approach that controls for a desired variable was used throughout the paper. A
sample set (e.g. MeCP2-repressed genes) and a control set (e.g. all other genes) are assessed for a
certain characteristic (e.g. expression, length, etc). The control set is then sorted on this
characteristic, and each entry in the sample set is assessed for where it would be placed in the
sorted control set. Then, for each sample entry, a control entry is selected that is within 10 places
of the sample entry, generating a control set the same size and variable distribution as the sample
set.
TAD boundary analysis
For Figures 2.1F, 2.2C, 2.9B, and 2.9F, all TADs that intersected MeCP2-repressed,
MeCP2-activated, and unchanged genes were selected, boundaries phased, and values for mC/C,
coverage, GC percent, or ChIP/Input plotted in aggregate using R, python, and bedtools.
Shuffling analysis was performed in these cases by moving each TAD randomly around their
target genes (TADs containing MeCP2-repressed genes were shuffled around MeCP2-repressed
genes, etc.). This was done once to generate a single example (e.g. Figure 2.1F), or up to 20
times to generate a resampling ribbon (e.g. Figure 2.9B). Figures 2.1G and 2.9K were generated
by selecting boundaries through the following method: TADs were assigned a score, based on
the difference between its mCA level and the mCA level of the next downstream TAD. Then, the
33% top scoring TADs were taken and plotted in aggregate analysis. For shuffled TAD control
plots, TAD locations were randomized and the selection process for these shuffled TADs was
repeated. We note that because both true TADs and shuffled TADs in these plots were selected
based on high differences in average methylation between them, a reduction of signal going from
left to right is predicted. However, true TADs display two aspects of mCA/CA signal that are not
present in shuffled TADs, which demonstrate the organizing effects associated with TAD
boundaries: 1) True TADs are more highly enriched for mCA, showing that resampling TADs
eliminates an organized enrichment of mCA/CA in specific regions of the genome. 2) A steep
step-down in mCA/CA occurs at true TAD boundaries, while a more gradual fall off in signal
occurs at reshuffled boundaries. These two differences illustrate that ~30% shifts in mCA/CA
levels are common between adjacent TADs, and they demonstrate that TAD boundaries
delineate a sharp transition between mCA/CA levels at these regions. Plotted in all figures is the
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average of the upstream and downstream TAD boundaries, taking into account TAD orientation.
Upstream boundaries (where the TAD would be on the right, instead of the left), have their
orientation flipped horizontally along the boundary. The value plotted is the mean of the flipped
upstream boundaries and the unflipped downstream boundaries.
TAD methylation cross-correlation
Cross-correlation matrices (e.g. Figure 2.1H) were generated by dividing each domain into 10
equally-sized bins, then prepending and appending 10 identically sized bins up and down-stream
of the domain, making a number of domains x 30 matrix. Each column of this matrix was then
correlated against each other, making a 30 x 30 correlation matrix, which was plotted in heatmap
form. Shuffled TADs were generated as a negative control by randomly placing TAD-sized
regions around the genome, separated from each other by similar distances as actual TADs to
retain TAD structure.
In order to calculate heatmaps of correlations between mCA/CA levels of genomic
elements in and outside of TADs and mean TAD mCA/CA levels (Figure 2.10J), TADs were
again divided into 10 equally sized bins, with equal-sized regions placed upstream and
downstream the domain. Enhancers, genes, and TSSs in the genome were then intersected with
these regions, and Spearman correlations between TAD methylation (subtracting out the
methylation of the element if necessary) and element methylation within each region were
calculated.
To assess the similarity of mCA levels between individual elements inside and outside of
the same TAD (i.e. TSS regions, enhancers, gene bodies; Figure 2.10K), each element was
paired to each other element on the same chromosome. Each pair was then assessed if they
paired within or between TADs. Because mCA varies with genomic distance, each intra-TAD
pair was matched to the extra-TAD pair with the most similar distance between elements, and
Spearman correlations were calculated on the two distance-matched sets.
Identification of enhancers
Enhancers in this study were defined by stringent criteria requiring the presence of overlapping
H3K27ac and H3K4me1 peaks that occur outside of a known TSS region, or a peak of the
promoter-associated histone mark H3K4me3. As noted, this led to the exclusion of some
subthreshold regions of H3K27ac enrichment that may represent true regulatory elements, but
ensured that we analyzed robust regulatory elements in our studies. For this analysis, bed files of
H3K27ac and H3K4me3 ChIP-seq were pooled by replicate. Peaks of H3K27ac and H3K4me3
ChIP-seq were identified using the MACS2 peak calling algorithm on the pooled bed files using
the pooled ChIP Input as background signal (macs2 callpeak --nomodel -q 0.05). MeCP2 KO
and wild type peak files were then combined using bedtools unionbedg, and overlapping peaks
were merged into single peaks using bedtools merge. Bedtools intersect was used to identify
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H3K27ac peaks that did not overlap with gene promoter regions (1kb around annotated TSS) or
with H3K4me3 peaks from MACS2. These non-overlapping H3K27ac peaks were then further
filtered for landing within an H3K4me1 peak, as called in the ENCODE-generated broadpeak
file for H3K4me1 ChIP from 8-week old cortex. All H3K27ac peaks that remained after these
rounds of filtering were defined as enhancers.
To identify the enhancers most robustly regulated by MeCP2, we used combined analysis
of the MeCP2 KO and OE, similar to the approach used for determining gene-expression
changes. We ran differential ChIP-seq analysis on H3K27ac from the MeCP2 KO and their
littermate control animals (n=5), and from the MeCP2 OE and their littermate controls (n=3).
Reads were quantified in all merged acetyl peaks, and edgeR was used to calculate nominal
p-values and fold-changes for these peaks. These p-values were then combined using the Fisher
method (log-sum) and were Benjamini-Hochberg corrected. Acetyl peaks with a combined
q-value < 0.1, and a log2 fold-change > 0 in the KO and a log2 fold-change < 0 in the OE were
called as MeCP2-repressed peaks, while peaks with a combined q-value < 0.1, and a log2
fold-change < 0 in the KO and a log2 fold-change > 0 in the OE were called as MeCP2-activated
peaks.
Enhancers were also called as misregulated in the DNMT3A Baf53b-cKO, using edgeR.
H3K27ac ChIP-seq reads from the DNMT3A Baf53b-cKO and control (n=6) were quantified in
the merged acetyl peaks called from the MeCP2 KO/control. edgeR was then run on these
regions, and peaks with a q-value < 0.1 were called as misregulated in the DNMT3A
Baf53b-cKO.
ATAC peak analysis
To sensitively detect sub-peak-threshold histone acetylation signal that could correspond to
putative regulatory elements, a compendium of all ATAC peaks detected in the genome was
obtained
from
http://atlas.gs.washington.edu/mouse-atac/data/
(atac_matrix.binary.qc_filtered.peaks.txt) and acetylation was quantified in these regions. ATAC
peaks that landed within 1kb of a TSS were filtered out, and methylation and acetylation analysis
was performed on them as described for enhancers. Equal-sized control regions for enhancers
and ATAC peaks were generated through a structured resampling approach. Enhancers and
ATAC peaks, if located within a gene, are shuffled within that gene. If the peak is extragenic, it
is shuffled between the nearest upstream and downstream enhancer/gene/ATAC peak. In each
case, enhancers and ATAC peaks are restricted from landing within existing enhancers and
ATAC peaks. Normalized pseudocounts of acetylation for enhancers, ATAC peaks, and
resampled ATAC peaks were generated from edgeR common dispersions, running on each
dataset and mouse strain separately.
Associations between enhancers and genes using Hi-C and GREAT
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GREAT 3.0 (McLean et al., 2010) was used to determine potential enhancer-promoter
interactions. NCBI build 37 of Mus Musculus was used as the species assembly, and bed files of
enhancer regions were uploaded into the web tool. Enhancer-promoter interactions were
identified for MeCP2-repressed, MeCP2-activated, and all other enhancers. All identified genes
linked to these enhancers were used for further analysis. To link enhancers to promoters by Hi-C,
intrachromosomal Hi-C matrices (KR-normalized) were extracted at 1.5kb resolution using
Straw (Durand et al., 2016), and mean average interactions for all distances were calculated
per-chromosome. Each matrix was then filtered down to only interactions between promoters
and enhancers within 3mb of each other, and enhancers-promoter pairs with greater than 3
observed interactions and an observed/expected ratio over 1.5 were linked, making Hi-C-linked
enhancers. Enhancers that were linked to promoters of MeCP2-repressed or MeCP2-activated
genes were then used in analysis in Figure 2.6B.
For analysis of intragenic versus extragenic contact frequencies (Figure 2.6G), the same
normalized contact matrices were analyzed. Genes greater than 50kb were extended on either
side by their respective gene lengths, and contacts were mapped to them using bedtools intersect
-wao -F 1. Each region was then split into 60 equally-sized bins (20 upstream, 20 intragenic, 20
downstream), making 3600 possible regions of interactions. Average interaction frequencies
within these regions were calculated from the interaction matrix, and each gene’s intragenic and
extragenic interactions were aggregated by calculating the mean of each bin of interaction.
For Figure 2.6H, intragenic and extragenic enhancer-promoter interactions were distance
matched to control for the greater number and variability of extragenic interactions. To do this, a
similar resampling approach to Figure 2.10K was used: for each intragenic interaction, an
extragenic interaction with a similar distance was selected for comparison.
To assess the relationship between enhancer acetylation fold-change and gene
fold-change (Figure 2.12M), partial correlations between enhancer/control region acetyl
fold-change and gene fold-change were calculated by averaging the acetyl fold-changes of
elements within the gene and correlating this aggregate value to that gene’s fold-change.
Quantitative 3C analysis
Quantitative PCR was employed, as previously described (Joo et al., 2016; Schaukowitch et al.,
2014; Tolhuis et al., 2002), to determine enhancer-promoter interactions of enhancers using the
primers listed. Negative regions were selected from genomic restriction fragments that did not
contain detectable enhancer sequences and were located nearby to the enhancer being tested but
in closer proximity to the anchor TSS. Relative concentrations of enhancers and corresponding
negative regions were calculated from a standard curve of BAC 3C libraries containing the
targeted loci (see STAR methods). Enrichments of interactions were then calculated as the
relative concentration of targeted enhancers divided by the relative concentration of the nearby
negative region.
45

mC context enrichment analysis
Trinucleotide contexts and methylation status (a rational number determined through bisulfite
coverage - # of Cs mapping to site / # of Ts mapping to site) were determined for each cytosine
and guanine in the genome, and then sites were assigned to enhancers based on proximity (a site
was assigned to an enhancer if it was within 1 kb of the enhancer’s center). T-tests were then run
for each context, summing methyl-weighted or unweighted (for total mC per kb / C sites per kb
respectively), or averaging methylation statuses (for percent mC), comparing test sets
(up/downregulated enhancers, or enhancers within certain genes) to a set of resampled control
enhancers with similar acetylation levels 5 times the size of the test set.
mC vs acetylation change local correlation analysis at enhancers
For both enhancers and gene local correlation analysis, 1 kb-sized bins were assessed for average
methylation around and within enhancers/genes, making an N x M sized matrix of methylation,
where N = # of enhancers/genes, and M = # of bins. Each column of this matrix was then
correlated against the matching enhancer/gene’s fold-change in the MeCP2 KO/MeCP2 OE. For
enhancers, correlation analysis was centered on summits of wild-type acetylation and MeCP2
KO acetylation and analyzed separately through MACS2.
Running-average plots
Running-average plots of mCA/CA and genic fold-change as well as total mC sites and genic
fold-change were generated from means of 201 gene bins, with a 1 gene step, using the rollMean
command in the zoo package of R. Length-controlled resampling was performed by selecting a
gene within .75 – 1.25 times the length of each gene in the test set.
TAD/element methylation correlation
Enhancers, transcriptional start sites, and gene bodies were intersected with TADs and contact
domains, and each unique intersection was plotted (Figure 2.2E, 2.9L,M). Shuffling analysis was
generated by moving elements randomly within its containing TAD. To avoid spuriously
detecting a correlation due to the contribution of the elements themselves to the calculated
average methylation of the TAD, the mC signal from the elements within the TAD (e.g. gene)
were excluded from the calculation of the mC levels for that TAD.
Misregulated gene-enhancer linkage enrichment
To calculate the significance and magnitude of the linkage between misregulated genes and
enhancers (Figure 2.6B), misregulated enhancers were resampled based on acetylation, and a
fisher’s exact test was performed comparing the association of enhancers with misregulated
46

genes between the misregulated and control set. This process was repeated 1000 times, and the
median p-value and log2 fold-enrichment was plotted.
Data and Software Availability
All genomic data generated in this study have been uploaded to the NCBI GEO archive
GSE123373
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Figure 2.1. Non-CG methylation in cerebral cortex is associated with domains of chromatin
folding.
A. Exonic RNA changes for all genes dysregulated in MeCP2 KO and OE (FDR <0.1) (left),
and an example MeCP2-repressed gene, Sdk1 ( right). ***, B-H adjusted p<10^-8 Wald
test.
B. Aggregate mCA/CA levels for MeCP2-regulated genes. Mean mCA/CA for 1kb bins
shown at kilobase (left) and megabase (right) scale. “Metagene” is 50 equally-sized bins
within gene bodies.
C. Genome browser view of mC at Sdk1.
D. Hi-C interactions and mC for a genomic region including two MeCP2-repressed genes,
Sdk1 and Auts2 (red). TAD-like structures visible in Hi-C interactions (blue).
E. mCA/CA for TADs containing MeCP2-regulated genes (see methods). ***, p < 10^-8
Wilcoxon test.
F. Aggregate mCA/CA at boundaries of TADs containing MeCP2-repressed genes.
Analysis of true TADs (red) or TADs shuffled around MeCP2-repressed genes (pink, see
methods). mCA/CA drop-off at true boundaries is significantly different from shuffled
boundaries. p<10^-3 (see Figure S2C, methods).
G. Aggregate mCA/CA as in F, but for TADs containing MeCP2-repressed genes with the
top 33% most differential mCA/CA levels compared to the neighboring TAD (see
methods).
H. Cross-correlation of mCA/CA levels for regions in and around TADs (see methods)
containing MeCP2-repressed genes, all genes, and shuffled control TADs.
See also Figure 2.8, 2.9
Data from cerebral cortex of 7-10 week-old animals. n=6 each (MeCP2 KO, wild type)
and n=5 each (MeCP2 OE, wild type) for RNA-seq, n=2 wild type for DNA methylation
(Stroud et al., 2017). Hi-C data (Dixon et al., 2012).
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Figure 2.2. Domain-associated DNMT3A defines megabase- and kilobase-scale mCA levels.
A. Cross-correlations in and around TADs for DNMT3A ChIP at 2 weeks (see methods).
B. Comparison of DNMT3A ChIP/Input at 2 weeks and mCA/CA levels at 8 weeks for each
TAD. ***, p<10^-8.
C. Aggregate DNMT3A ChIP/Input at 2 weeks at boundaries of TADs containing
MeCP2-repressed genes. Black line and ribbon indicate the mean and standard deviation
of shuffled TAD boundaries (see methods).
D. MeCP2 ChIP/Input in TADs for quartiles of TAD mCA/CA. ***, p<10^-8.
E. Comparison of TAD mCA/CA levels and mCA/CA levels at kilobase-scale genomic
elements in each TAD at 8 weeks of age (see methods). ***, p<10^-8.
See also Figure 2.10.
Data from cerebral cortex of 2 or 8 week-old animals. Per time point: n=2-3 for
DNMT3A ChIP-seq, n=2 wild type for DNA methylation (Stroud et al., 2017).
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Figure 2.3. Disruption of MeCP2 leads to promoter-associated transcriptional
dysregulation.
A. Left, genome browser view of nuclear total RNA-seq and ChIP-seq from MeCP2 KO and
wild type at an MeCP2-repressed gene, Zmat4. Right, overlay of MeCP2 KO and wild
type signal illustrating subtle increases for blue highlights at left.
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B. Changes in RNA-seq signal in the MeCP2 KO for exons in whole cortex RNA (Exonic),
or introns in nuclear RNA (Intronic). Genesets defined in combined analysis of exonic
RNA (see Figure 1A). ***, p<10^-8 Wilcoxon test.
C. Profile (black, gray) and fold-change (orange) of intronic reads from RNA-seq for the
first 100kb of upregulated genes in MeCP2 KO versus wild type (Figure S4B).
Normalized median of 1kb bins is plotted for genes >100kb (see methods, and Figure
S4G,H).
D. Fold-changes in ChIP signal in MeCP2 KO at MeCP2-regulated genes identified in
intronic RNA analysis. Value for Zmat4 is indicated by a point on each plot. **, p<10^-3;
***, p<10^-8 Wilcoxon test.
E. Fold-changes in gene expression as in panel B, but for MeCP2 OE. ***, p<10^-8
Wilcoxon test.
F. Profile of intron expression and fold-change as in panel C, but for MeCP2 OE. (see also
Figure S4I).
G. Fold-changes in ChIP signal as in panel D but for MeCP2 OE. *, p<0.05; **, p<10^-3 ;
***, p<10^-8 Wilcoxon test.
See also Figure 2.11.
Data from cerebral cortex of 7-10 week-old animals. MeCP2 KO per genotype: n=6 for
RNA-seq, n=3 for H3K36me3, n=4 for H3K4me3, n=5 for H3K27ac. MeCP2 OE per genotype:
n=5 for RNA-seq, n=2 each for H3K36me3 and H3K4me3, n=3 for H3K27ac.
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Figure 2.4. MeCP2 represses enhancers enriched for mCA and mCG binding sites.
A. Left, overlaid wild type and MeCP2 KO H2K27ac ChIP-seq signal at two
MeCP2-repressed genes, Zmat4 and Efna5. Right, close-up view of enhancers indicated
in blue at left.
B. Fold-changes of H3K27ac ChIP in MeCP2 KO or MeCP2 OE for changed enhancers
identified in combined analysis of H3K27ac ChIP-seq from MeCP2 KO and OE
(FDR<0.1).
C. Aggregate mC at MeCP2-regulated enhancers, centered at the midpoint for each
enhancer. Mean values plotted for 100 bp bins.
D. Enrichment significance (see methods) for mCNN trinucleotide density at
MeCP2-repressed and MeCP2-activated enhancers.
E. MeCP2 ChIP/Input for MeCP2-regulated enhancers. ***, p<10^-8 Wilcoxon test.
F. Fold-changes of H3K27ac in MeCP2 KO across deciles of mCA/kb (left) and mCG/kb
(right) for all enhancers. Spearman rho shown for mC and change in H3K27ac at
enhancers. ***, p<10^-8.
G. Fold-changes of H3K27ac, as in panel F, but for MeCP2 OE. ***, p<10^-8.
60

H. Spearman correlations between H3K27ac fold-change at enhancers in the MeCP2 KO
and mC/kb for 500bp bins across these enhancers. Plots centered at the summit of
H3K27ac ChIP peaks (see methods).
I. Spearman correlations, as in panel H, but for H3K27ac fold-change in the MeCP2 OE.
See also Figure 2.12.
Data from cerebral cortex of 7-10 week-old animals. MeCP2 KO per genotype: n=5 for
H3K27ac. MeCP2 OE per genotype: n=3 for H3K27ac. n=2 wild type for DNA
methylation (Stroud et al., 2017) and MeCP2 ChIP-seq data (Kinde et al., 2016).
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Figure 2.5. mCA-associated enhancer de-repression in DNMT3A Baf53b-cKO.
A. mCG/CG and mCA/CA levels at all enhancers for wild type and DNMT3A Baf53b-cKO.
Data shown are mean +/- SEM. **, p<10^-3; ***, p<10^-8 two-tailed t-test.
B. Fold-changes for mRNA of MeCP2-regulated genes (left) and H3K27ac at
MeCP2-regulated enhancers (right) in MeCP2 KO and DNMT3A Baf53b-cKO. ***,
p<10^-8 Wilcoxon test.
C. Aggregate wild-type mC profiles for enhancers significantly dysregulated in the
DNMT3A Baf53b-cKO (see Figure S6D).
D. Fold-changes of H3K27ac across deciles of mCA/kb (left) and mCG/kb (right) for all
enhancers in the DNMT3A Baf53b-cKO. Spearman rho shown for mC and H3K27ac
change at enhancers. *, p<0.05; ***, p<10^-8.
See also Figure 2.13.
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Data from cerebral cortex of 7-10 week-old animals. Per genotype: n=6 for DNA
methylation, n=4 for RNA-seq, n=6 for H3K27ac ChIP-seq.
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Figure 2.6. MeCP2-repressed enhancers are linked to MeCP2-repressed genes.
64

A. mCA/kb of enhancers in TADs containing MeCP2-regulated genes. **, p<10^-3; ***,
p<10^-8 Wilcoxon test.
B. Associations between MeCP2-regulated enhancers and MeCP2-regulated genes.
Comparisons are: enhancers in the same TAD as dysregulated genes (“Same TAD”),
assigned to dysregulated genes by GREAT analysis (McLean et al., 2010) (“GREAT”),
enriched for enhancer-promoter contacts by Hi-C (“Hi-C-linked”), and found in
dysregulated genes (“Intragenic”). Median significance (color) and log2 enrichment
(number) are shown for true enhancers compared to resampled control enhancers (see
methods).
C. Log2 fold-changes of H3K27ac in MeCP2 KO for enhancers near two MeCP2-repressed
genes. Blue, TADs overlapping MeCP2-repressed genes; red, enhancers in
MeCP2-repressed gene; pink, other enhancers in the same TAD; gray and black,
extragenic and intragenic enhancers in other TADs. *, significantly changed enhancers.
D. Fold-changes in H3K27ac ChIP in MeCP2 KO (top) and MeCP2 OE (bottom) for
enhancers in TADs containing MeCP2-repressed, MeCP2-activated, or no dysregulated
genes (“Same TAD”), or for enhancers in these genes (“Intragenic”). ***, p<10^-8
Wilcoxon test.
E. Genic distributions of MeCP2-regulated enhancers. **, p<10^-3; ***, p<10^-8
chi-squared test (see methods).
F. Fold-changes of H3K27ac ChIP in MeCP2 KO (top) or MeCP2 OE (bottom) for
intragenic and extragenic enhancers across deciles of enhancer mCA/kb (left) and
mCG/kb (right). Spearman rho for correlation of enhancer mC and change in H3K27ac.
***, p<10^-8.
G. Aggregate observed/expected Hi-C interaction frequencies for regions inside and outside
of genes (see methods).
H. Observed/expected Hi-C interactions between enhancers and promoters for intragenic or
distance-matched extragenic enhancers (see methods). ***, p<10^-8 Wilcoxon test.
I. Running-average plot of intronic RNA fold-change in the MeCP2 KO (top) and MeCP2
OE (bottom) versus gene body mCA/kb for genes containing various numbers of
enhancers. Mean changes are plotted for genes sorted by gene body mCA/kb (bins of 201
genes with a 1-gene step).
See also Figure 2.12
Data from cerebral cortex of 7-10 week-old animals. MeCP2 KO per genotype: n=6 for
RNA-seq, n=5 for H3K27ac. MeCP2 OE per genotype: n=3 for H3K27ac, n= 5 for RNA-seq.
n=2 wild type for DNA methylation (Stroud et al., 2017). Hi-C data from E14.5 cortical neurons
(Bonev et al., 2017).
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Figure 2.7. A model of TAD-associated mCA and enhancer repression by MeCP2 in
neurons.
A. DNMT3A activity during early postnatal development establishes high or low mCA
set-points within TADs.
B. In mature neurons, MeCP2 reads-out this mCA and mCG, repressing enhancers. MeCP2
most strongly affects intragenic enhancers, resulting in repression of genes found within
high-mCA TADs that contain multiple enhancers.

66

Figure 2.8. Identification of MeCP2-regulated genes in the cerebral cortex by combined
RNA-seq analysis of MeCP2 KO and MeCP2 OE. Related to Figure 2.1.
A. Venn diagram of the overlap between genes identified as MeCP2-repressed and
MeCP2-activated in combined analysis of MeCP2 KO and OE versus wild type cerebral
cortex and genes previously identified as consistently dysregulated across multiple
datasets and brain regions (Gabel et al., 2015). ***, p < 10^-8 hypergeometric test.
Analysis was performed using coding genes found in annotation sets of both studies.
B. Boxplot of fold-changes in exonic RNA in the cortex of MeCP2 KO and wild type mice,
for genes previously identified as consistently dysregulated across multiple datasets and
brain regions (Gabel et al., 2015). ***, p < 10^-8 Wilcoxon rank-sum test.
C. Boxplots of mCA/CA and mCG/CG levels at the TSS (left) and gene bodies (right) of
MeCP2-repressed, MeCP2-activat- ed, and all other genes. Light colored boxplots are
plots generated for a control set of genes matched for the distribution of gene expression
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D.

E.

F.

G.

H.

for each dysregulated gene set (see methods). * p < 0.05 ; **, p <10^-3; ***, p < 10^-8
Medians of Wilcox- on rank-sum tests on 100 gene-set resamplings.
Boxplot of gene lengths for MeCP2-repressed, MeCP2-activated, and all other genes
identified in combined analysis of total RNA-seq from MeCP2 KO and OE cerebral
cortex. ***, p<10^-8 Wilcoxon rank-sum test.
Running average plots of exonic RNA fold-changes versus gene length, for MeCP2 KO
(left) and OE (right) versus wild type. Mean fold-changes are plotted for bins of 201
genes sorted by gene length with a 1-gene step (see methods).
Running average plots of exonic RNA fold-change vs gene body mCA/CA for the
MeCP2 KO (left) and OE (right) versus wild type. mCA/CA levels are calculated for the
gene body defined as +3kb from the TSS to the TES. Mean fold-changes are plotted for
bins of 201 genes sorted by mean mCA/CA per gene with a 1-gene step (see methods).
Plot of genome-wide correlations between methylation levels for 1kb regions in and
around genes and fold-changes in exonic RNA expression in the MeCP2 KO versus wild
type for each gene.
Plot of genome-wide correlations between methylation levels for 1kb regions in and
around genes and fold-changes in exonic RNA expression in the MeCP2 OE versus wild
type for each gene.

Data from cerebral cortex of 7-10 week old animals. n=6 per genotype for RNA-seq (MeCP2
KO, wild type), n=5 per genotype for RNA-seq (MeCP2 OE, wild type), n=2 wild type for DNA
methylation (Stroud et al., 2017). In G and H analysis was carried out for genes over 75kb to
visualize correlation signal within gene bodies.
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Figure 2.9. Chromatin topology is associated with non-CG DNA methylation in the
cerebral cortex. Related to Figure 2.1.
A. Boxplots of mCA/CA and mCG/CG within TADs that contain MeCP2-repressed genes,
MeCP2-activated genes, or no dysregulated genes. ***, p < 10^-8 Wilcoxon rank-sum
test.
B. Aggregate plots of mCA/CA (left), mCG/CG (center), and BS-sequencing coverage rates
and GC composition (right) phased on boundaries of TADs defined in Hi-C data from the
cerebral cortex at eight weeks of age. TADs containing MeCP2-repressed (red),
MeCP2-activated (blue), or all other genes (purple) are shown. “Inside” indicates TADs
containing genes of interest. Black line and ribbon for each plot indicates the mean and
standard deviation of 20 sets of resampled boundaries generated by shuffling TAD
locations in the genome (see methods).
C. A histogram of -log10 p-values for paired t-tests, comparing the difference in DNA
methylation on either side of the TAD boundaries or 1000 resampled TAD boundaries as
in B. Histogram shows the distribution of p-values for resampled TADs, red line
indicates p-value for true TADs.
D. Cross correlation analysis of mCG/CG signal within and across TAD boundaries for all
genes. mCG/CG values were calculated for 10 intra-domain regions and 10 equally-sized
regions up and downstream of each TAD. Correlation between these regions across all
TADs is shown (see methods).
E. Boxplots of mCA/CA and mCG/CG within contact domains that contain
MeCP2-repressed genes, MeCP2-activated genes, or no dysregulated genes. Contact
domains were defined by analysis of Hi-C data generated from cerebral cortex neurons
isolated from fetal brain (Bonev et al., 2017). **, p < 10^-3; ***, p < 10^-8 Wilcoxon
rank-sum test.
F. Aggregate plots of mCA/CA (left), mCG/CG (center), and BS-sequencing coverage rates
and GC composition (right) phased on boundaries of contact domains defined in Hi-C
data from fetal cortical neurons. Presented as in panel B.
G. A histogram of -log10 p-values for paired t-tests, comparing the difference in DNA
methylation on either side of contact domain boundaries or 100 resampled contact
domain boundaries as in panel F. Histogram shows the distribution of p-values for
resampled contact domains, red line indicates p-value for true contact domains.
H. Cross correlation analysis of mCA/CA and mCG/CG signal within and outside of contact
domains as in panel D. Resampling was performed by shuffling contact domain-sized
regions around the genome and repeating the analysis of all genes (see methods).
I. Boxplots of mCA/CA within TADs defined in cerebral cortex (top) and cerebellum
(bottom) that contain MeCP2-re- pressed genes, MeCP2-activated genes, or no
dysregulated genes. ***, p < 10^-8 Wilcoxon rank-sum test. Cerebral cortex TADs were
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compared to genes from this study. Cerebellum TADs were compared to genes
previously identified as misregulated in the cerebellum and multiple other brain regions
(Gabel et al., 2015).
J. Cross correlation analysis of mCA/CA signal within and outside of TADs defined in
cerebral cortex (top) and cerebellum (bottom), as performed in panel H.
K. Aggregate plots of mCA/CA from frontal cortex (top) and granule neurons (bottom)
phased on boundaries of MeCP2 repressed TADs defined in cerebral cortex (top) and
cerebellum (bottom). Analysis performed on TADs with highly differing mCA levels as
in Figure 2.1G.
A-D analysis of Hi-C interaction data (Dixon et al., 2012), and DNA methylation, n=2 (Stroud et
al., 2017) from the cerebral cortex at 8 weeks of age. E-H analysis of Hi-C interaction data from
neurons isolated from E14.5 cortex (Bonev et al., 2017), and DNA methylation, n=2 (Stroud et
al., 2017) from the cerebral cortex at 8 weeks of age. I-K analysis of bisulfite data from 6-week
frontal cortex and granule neurons isolated from 7-12 week old cerebellum (Lister et al., 2013;
Mellén et al., 2017)(Mellén et al., 2017). Hi-C data from 6-8 week old Cerebellum (Yamada et
al., 2019). Note that some panels from Figure 2.1 are repeated here to allow for comparisons.
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Figure 2.10. Binding of DNMT3A and recruitment of MeCP2 are shaped by
topologically-associating domains. Related to Figure 2.2.
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A. Density scatter plot of DNMT3A ChIP/Input signal at 2 weeks of age and mCA/CA
levels at 8 weeks of age for random 1kb regions of the genome. Spearman rho shown for
the correlation between DNMT3A signal and mCA/CA level. ***, p < 10^-8.
B. Aggregate plot of Input CPM at 2 weeks phased on boundaries of TADs that contain
MeCP2-repressed genes (TADS from cerebral cortex at eight weeks of age). Black line
and ribbon for each plot indicates the mean and standard deviation of 20 resampled
boundaries generated by shuffling contact domain locations in the genome (see methods).
C. Cross correlation analysis of DNMT3A ChIP-seq signal at 2 weeks of age for contact
domains defined in fetal cortical neurons. DNMT3A ChIP/Input values were calculated
for 10 intra-domain regions and 10 equally-sized regions up and downstream of each
domain. Correlation between these regions across all domains is shown (see methods).
D. Density scatter plot of DNMT3A ChIP/Input signal at 2 weeks of age and mCA/CA
levels at 8 weeks of age for contact domains defined in fetal cortical neurons. Spearman
rho shown for the correlation between DNMT3A signal and mCA/CA level. ***, p <
10^-8.
E. Cross correlation analysis (performed as in panel C) for DNMT3A ChIP-seq signal at 8
weeks of age in TADs defined in the cortex at 8 weeks of age.
F. Density scatter plot of DNMT3A ChIP/Input signal at 8 weeks of age and mCA/CA
levels at 8 weeks of age for TADs defined in the cortex at 8 weeks of age. Spearman rho
shown for the correlation between DNMT3A signal and mCA/CA level. ***, p < 10^-8.
G. Cross correlation analysis (performed as in panel C) for MeCP2 ChIP/Input signal at 8
weeks of age in TADs defined in the cortex at 8 weeks of age.
H. Barplots of genome-wide mC/C levels in a DNMT3A Nestin-cKO and control cerebral
cortex at 8 weeks of age. Data shown as means +\- SEM. *, p < 0.05 two-tailed t-test.
I. Boxplot of fold-changes in MeCP2 ChIP-seq signal within TADs upon ablation of mCA
in the DNMT3A Nestin-cKO. Change in signal is shown for TADs separated by quartiles
of mCA/CA (left) and mCG/CG (right) under wild-type conditions. Spearman rho shown
for the correlation between DNMT3A signal and mCA/CA level. *** p < 10^-8.
J. Heatmap of correlation between mCA/CA levels of gene body (top), enhancer (middle),
and TSS (bottom) regions found inside and outside of TADs and the average mCA/CA
level for each TAD. Distinct drop off in correlation coefficient for these elements when
they are found outside the TAD boundary illustrates influence of intra-TAD mCA/CA
consistency. Similar correlation level and drop-off in signal is not seen for resampled
TADs, placed in randomized positions in the genome (see methods).
K. Barplots of correlations of mCA/CA levels for gene bodies (left), enhancers (middle), and
TSSs (right), located in either the same TAD or separate TADs. To facilitate comparison,
distances between pairs of elements in different TADs was matched to distances between
pairs of elements in the same TAD (see methods).
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L. Density scatter plots of TAD methylation levels and methylation at kilobase-scale
genomic elements in the cerebral cortex at 8 weeks of age. Values for every TSS, gene
body, or enhancer in the genome are plotted against the TAD in which the element
resides. As in Figure 2E, data is subtracted from TADs such that element methylation
does not contribute to plotted TAD methylation. Spearman rho shown for the methylation
levels of each genomic element versus the methylation levels of the TAD that the element
is in. ***, p < 10^-8.
M. Density scatter plots of TAD methylation levels and methylation at resampled random
locations for regions size-matched to kilobase-scale genomic elements (as in panel L).
Values for every resampled TSS-, gene body-, or enhancer-sized region in the genome
are plotted against the TAD in which the element resides. Spearman rho shown for the
methylation levels of each randomized genomic element versus the methylation levels of
the TAD that the element is in. ***, p < 10^-8.
A,C,D Analysis of Hi-C interaction data from neurons isolated from E14.5 cortex (Bonev et al.,
2017), DNA methylation, n=2, from the cerebral cortex at 8 weeks of age, and DNMT3A
ChIP-seq data, n=3, from the cerebral cortex at 2 weeks of age (Stroud et al., 2017). B,E-G,I-M
Analysis of Hi-C interaction data (Dixon et al., 2012), DNA methylation (n=2 wild type),
DNMT3A ChIP-seq data, (n=2 wild type), (Stroud et al., 2017), and MeCP2 ChIP-seq data (n=2
per genotype) (Kinde et al., 2016) from the cerebral cortex at 8 weeks of age. H n=2 per
genotype for DNA methylation DNMT3A Nestin-cKO versus wild-type, 8 weeks of age. Note
that some panels from Figure 2.2 are repeated to allow for comparisons.

74

Figure 2.11. Changes in intronic RNA are consistent with promoter-associated
transcriptional upregulation of long, highly methylated, MeCP2-repressed genes in the
MeCP2 KO. Related to Figure 2.3.
A. Scatterplot of the log2 fold-changes in the MeCP2 KO versus wild type for exonic RNA
measured by total RNA sequenc- ing of cerebral cortex tissue compared to intronic RNA
measured by total RNA sequencing of isolated nuclei from this tissue. Genes identified as
MeCP2-repressed and MeCP2-activated in combined analysis of exonic RNA in MeCP2
KO and MeCP2 OE mice (Figure 1; S1) are indicated by red and blue dots respectively,
all other genes indicated as gray points.
B. Left, heatmap of changes in intronic RNA for genes detected as significantly
dysregulated (FDR <0.1) in nuclear RNA-seq from MeCP2 KO cerebral cortex (grey
indicates, no data for replicate). Right, venn diagram of the overlap between genes called
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as MeCP2-repressed or MeCP2-activated in analysis of nuclear intronic RNA expression
in the MeCP2 KO (pale colors) with genes called as dysregulated in combined analysis of
exonic RNA in the MeCP2 KO and MeCP2 OE mice (dark colors) (Figure 1; S1). ***, p
< 10^-8 hypergeometric test.
C. Aggregate plot of cerebral cortex mCA/CA levels for MeCP2-repressed,
MeCP2-activated, and all other genes defined by analysis of intronic RNA in the MeCP2
KO (see panel B). Mean mCA/CA for 1kb bins in the TSS and regions surrounding genes
is shown. For “Metagene” region, mean mCA/CA was calculated for 50 equal-sized bins
within the body of each gene.
D. Boxplot of gene lengths for MeCP2-repressed or MeCP2-activated, and all other genes
called by analysis of nuclear intronic RNA in the MeCP2 KO and wild type mice. *, p <
0.05; ***, p < 10^-8 Wilcoxon rank-sum test.
E. Running-average plot of fold-changes in intronic RNA expression in the MeCP2 KO and
wild type versus mean gene length (top) or mean gene body mCA/CA (bottom). Mean
fold-changes are plotted for bins of 201 genes sorted by length of mCA/CA per gene with
a 1-gene step (see methods).
F. Plot of spearman correlations between fold-changes in intronic RNA expression in the
MeCP2 KO and wild type versus mCA/CA or mCG/CG for regions in and around genes.
Analysis performed for 1kb bins across 200kb (top) and 2 Mb (bottom) regions.
G. Scheme to assess changes in pre-mature transcription termination in the MeCP2 KO
versus wild type. Similar to analysis carried out by Boswell et al., 2017, a “termination
ratio” for each gene above 50kb in each sample is defined as the ratio of read counts in
the first 25kb of each gene to the read counts in the last 25 kb of that gene. The mean
fold-change in the ratios between MeCP2 KO and wild type is calculated across all genes
in paired replicates.
H. Dotplot showing the change in termination ratio between the nuclear intronic RNA-seq
data in the MeCP2 KO and wild type for genes that are not significantly changed and
MeCP2-repressed genes. A prediction for the change in this ratio that would be expected
if the effects on mRNA in the MeCP2 KO were due entirely to changes in transcription
termina- tion rate was generated for comparison, “Predicted” (see methods).
I. Dotplot as in panel H, showing the change in termination ratio between the intronic
RNA-seq in the MeCP2 OE and wild type for genes that are not significantly changed
and MeCP2-repressed genes.
Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n= 6 per genotype for
RNA-seq; for MeCP2 OE: n=5 per genotype for RNA-seq; n=2 wild-type for DNA methylation
(Stroud et al., 2017).
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Figure 2.12. Analysis of enhancers dysregulated in MeCP2 mutants. Related to Figure 2.4
and Figure 2.6.
A. Boxplot of fold-changes in H3K27ac ChIP signal in MeCP2 KO and OE (left) and
MeCP2 ChIP/Input signal (right) for enhancers identified with combined ChIP-seq
analysis in KO and OE as MeCP2-repressed, MeCP2-repressed with high MeCP2/Input
(see methods), MeCP2-activated, or all other enhancers. Fold-changes were calculated by
edgeR analysis of H3K27ac ChIP-seq signal at enhancer regions (see methods).
Significantly dysregulated enhancers were defined as FDR < 0.1. *, p < 0.05, ***, p <
10^-8 Wilcoxon rank-sum test.
B. Left, boxplots of mC/C, mC/kb, and C sites/kb at MeCP2-repressed, MeCP2-repressed
with high MeCP2, MeCP2-activated, and all other enhancers, as displayed in panel A.
Right, heatmap of enrichments for median levels of mC/C, mC/kb, and C sites/kb for
MeCP2-repressed and MeCP2-activated enhancers compared to all other enhancers. *, p
< 0.05, **, p < 10^-3; ***, p < 10^-8 Wilcoxon rank-sum test.
C. Heatmap of enrichment significance for number of mC sites (mC/kb, left), methylation
level (mC/C, middle) and sequence occurrence (right) for trinucleotide sites in
MeCP2-repressed and MeCP2-activated enhancers. Signifi- cance of enrichment or
depletion was calculated by comparing occurrences of mC/kb, mC/C, or sequence alone
for each trinucleotide in the 2kb region surrounding enhancers to resampled sets of
enhancers that are not significantly changed and matched to changed enhancers for
H3K27ac signal (see methods).
D. Histograms of mCA/kb and mCG/kb in enhancers (black). Blue and red lines indicate the
distributions of methylation for MeCP2-activated and MeCP2-repressed enhancers
respectively.
E. Genome browser view of an example MeCP2-repressed gene, Zmat4 (as in Figure 4A),
showing overlaid wild-type and MeCP2 KO aggregate H3K27ac ChIP-seq signal,
H3K4me1 ChIP-seq peaks, H3K27ac peaks called as enhancers, and peaks from a
compendium of ATAC-seq peaks identified across 13 mouse tissues. Blue highlights
ATAC-seq peaks that correspond to sub-thresholded enrichment of H3K27ac, not
identified in peak calling analysis of H3K27ac ChIP-seq.
F. Boxplots of H3K27ac ChIP signal in MeCP2 KO versus wild type (left) and MeCP2 OE
vs wild type (right) for enhancers defined in this study, a compendium of detectable
ATAC-seq peaks, and non-peak regions that are size matched to ATAC-peaks but
selected to not overlap enhancers of ATAC-seq peaks. Values for the highest mCA/CA
decile are shown for each class, illustrating total levels of H3K27ac and mCA-dependent
dysregulation ***, p < 10^-8 Wilcoxon rank-sum test.
G. Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 KO versus wild type across
deciles of mCA/kb (left) and mCG/kb (right) for ATAC-peaks described in panel E.
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I.

J.

K.

L.

M.

Spearman rho shown for correlations of each methylation mark with change of H3K27ac
at enhancers. ***, p < 10^-8 Wilcoxon rank-sum test.
Boxplots of fold-changes of H3K27ac ChIP signal in MeCP2 OE versus wild type across
deciles of mCA/kb (left) and mCG/kb (right) for ATAC-peaks described in E. Spearman
rho shown for correlations of each methylation mark with change of H3K27ac at
enhancers. ***, p < 10^-8.
Quantitative 3C analysis of enhancers found in MeCP2 repressed genes, or control loci.
Data shown as means +\- SEM. No significant factors were detected in a 2-way ANOVA,
using enhancer locations and genotype.
Density scatter plot of log10 number of intragenic enhancers versus log10 gene length for
all genes in the genome. Spearman rho shown for the number of intragenic enhancers and
gene length for all genes with at least 1 enhancer. ***, p < 10^-8.
Running-average plot of fold-change in intronic RNA expression in the MeCP2 KO or
MeCP2 OE versus mCA/kb for genes containing enhancers (red line) and length-matched
sets of genes that do not contain enhancers (gray lines). Mean fold-changes are plotted
for bins of 201 genes sorted by mCA/kb with a 1-gene step (see methods).
Local correlation analysis correlating mCA/kb (left) and mCG/kb (right) for 1 kb
windows in and around genes to intronic RNA fold-changes for the gene in the MeCP2
KO (top) and OE (bottom). Genes at least 75kb in length are analyzed to allow
visualization of correlations in gene bodies. Genic windows of methylation go from the
TSS to 75kb downstream.
Heatmap of correlation between fold-change in H3K27ac at intragenic regions and gene
expression fold-change for MeCP2 KO and MeCP2 OE mice. Values are calculated as
partial correlation for enhancers or control non-enhancer regions of the same size,
removing the signal from the other class of element (see methods). Larger correlation for
enhancers over control regions illustrates the link between enhancer regulation and
transcriptional control.

Data from cerebral cortex of 7-10 week old animals. For MeCP2 KO: n=5 per genotype for
H3K27ac, n=6 per genotype for RNA-seq; for MeCP2 OE: n=3 per genotype for H3K27ac, n= 5
per genotype for RNA-seq; n=2 wild-type for DNA methylation (Stroud et al., 2017). ATAC-seq
peaks (Cusanovich et al., 2018). Note that some panels in C are repeated from Figure 2.4 to
allow for comparisons.
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Figure 2.13. Transcriptomic and epigenomic analysis of DNMT3A Baf53b-cKO. Related to
Figure 2.5.
A. Barplots of genome-wide methylation levels in the DNMT3A Baf53b-cKO at different
CN dinucleotides. Data shown as means +\- SEM. *, p < 0.05, **, p < 10^-3; ***, p <
10^-8 two-tailed t-test.
B. Barplots of mCG (left) and mCA (right) levels in the DNMT3A Baf53b-cKO at genes,
enhancers, and TSSs. Data shown as means +\- SEM. **, p < 10^-3; ***, p < 10^-8
two-tailed t-test.
C. Boxplots of mCG (left) and mCA (right) levels in the DNMT3A Baf53b-cKO within
TADs that contain MeCP2-re- pressed genes, MeCP2-activated genes, or no dysregulated
genes. ***, p < 10^-8 Wilcoxon rank-sum test.
D. Heatmap of H3K27ac fold-changes for enhancers detected as significantly dysregulated
in DNMT3A Baf53b-cKO mice by edgeR analysis (see methods).
E. Heatmap of enrichment significance for the number of mC sites (mC/kb) within
enhancers detected as significantly dysregulated in the DNMT3A Baf53b-cKO.
Significance of enrichment or depletion was calculated by comparing occurrences of
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mC/kb for each trinucleotide in the 2kb region surrounding enhancers to resampled sets
of enhancers that are not significantly changed but matched to changed enhancers for
H3K27ac signal (see methods).
F. Plot of spearman correlations between H3K27ac fold-change at enhancers in the
DNMT3A Baf53b-cKO and mC/kb levels in the wild-type brain for 500bp bins in and
around the enhancers. Plots are centered at the summit of enhancer H3K27ac ChIP peaks.
Data from cerebral cortex of 7-10 week old animals. n=6 per genotype for Bisulfite-seq analysis,
n=6 per genotype for H3K27ac.
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3.1

Abstract
Mutations in DNA methyltransferase 3A (DNMT3A) have been detected in autism and

related disorders, but how these mutations disrupt nervous system function is unknown. Here we
define the effects of DNMT3A mutations associated with neurodevelopmental disease. We show
that diverse mutations affect different aspects of protein activity yet lead to shared deficiencies in
neuronal DNA methylation. Heterozygous DNMT3A knockout mice mimicking DNMT3A
disruption in disease display growth and behavioral alterations consistent with human
phenotypes. Strikingly, in these mice we detect global disruption of neuron-enriched non-CG
DNA methylation, a binding site for the Rett syndrome protein MeCP2. Loss of this methylation
leads to enhancer and gene dysregulation that overlaps with models of Rett syndrome and
autism. These findings define effects of DNMT3A haploinsufficiency in the brain and uncover
disruption

of

the

non-CG

methylation

pathway

as

a

convergence

point

across

neurodevelopmental disorders.

3.2

Introduction
Precise regulation of transcription through epigenetic mechanisms is critical for nervous

system development (Cholewa-Waclaw et al., 2016). Exome sequencing studies have revealed
mutations in genes encoding epigenetic modifiers of chromatin structure as major underlying
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causes of neurodevelopmental diseases (NDD), including autism spectrum disorder (ASD)
(McRae et al., 2017; Sanders et al., 2015; Satterstrom et al., 2019). A challenge emerging from
these discoveries is to define the cellular functions of the disrupted proteins during normal
development and to search for shared pathways between these proteins that can potentially be
targeted for therapeutic development.
Gene regulation mediated by DNA methylation has emerged as an epigenetic mechanism
that plays a critical role in nervous system function (Kinde et al., 2015). In addition to the
classical methylation of cytosines found at CG dinucleotides (mCG), neurons contain uniquely
high levels of methyl-cytosine (mC) in a non-CG context, with this mark occurring primarily at
CA dinucleotides (mCA) (Guo et al., 2014; Lister et al., 2013; Xie et al., 2012). mCA is
deposited de novo through the activation of the DNA methyltransferase 3A (DNMT3A) enzyme
during the early postnatal period (1-6 weeks of age in mice). Levels of mCA increase specifically
in neurons until the number of methylation sites in the non-CG context is nearly equivalent to the
number of mCG sites (Guo et al., 2014; Lister et al., 2013; Xie et al., 2012). A critical function
for mCA is to serve as a binding site for a neuron-enriched chromatin protein, Methyl-CpG
binding Protein 2 (MeCP2) (Chen et al., 2015; Gabel et al., 2015; Guo et al., 2014). MeCP2 was
initially defined by its high affinity for mCG, but biochemical and genomic studies indicate that
it also tightly interacts with mCA to down-regulate transcription of genes with essential
functions in the brain (Boxer et al., 2019; Gabel et al., 2015; Kinde et al., 2016; Lagger et al.,
2017; Lyst and Bird, 2015). Loss of MeCP2 leads to the severe neurological disorder Rett
syndrome, while duplication causes MeCP2-duplication syndrome, an ASD, suggesting that
read-out of mCA is critical to nervous system function (Amir et al., 1999; Van Esch et al., 2005).
84

Human exome sequencing studies have recently identified de novo mutations in
DNMT3A in individuals with ASD (Feliciano et al., 2019; Iossifov et al., 2014; Sanders et al.,
2015; Satterstrom et al., 2019). Separate studies have also defined heterozygous disruption of
DNMT3A as the underlying cause of Tatton-Brown Rahman syndrome (TBRS), a heterogeneous
NDD characterized by intellectual disability, overgrowth, craniofacial abnormalities, anxiety,
and high penetrance of ASD (Tatton-Brown et al., 2014, 2018). While a small portion of the
mutations identified in affected individuals are truncations that are predicted to cause complete
inactivation of the enzyme, a majority of disease-associated alleles are missense mutations,
raising questions about whether loss-of-function effects are a primary mechanism of disruption
in DNMT3A disorders (Tatton-Brown et al., 2014, 2018). In addition, the large percentage of
missense mutations identified in affected individuals raises the need to establish deleterious
effects of these mutations, helping to definitively associate the mutations with NDD and end the
“diagnostic odyssey” for affected individuals and care-takers (Sawyer et al., 2016). Finally,
while heterozygous loss of DNMT3A has been studied in the context of oncogenesis in the
hematopoietic system (Cole et al., 2017), the effects of partial loss of DNMT3A on nervous
system function in vivo have not been examined and the consequences of possible methylation
changes on neuronal gene regulation and behavior are unknown.
Here we examine the molecular effects of neurodevelopmental disease-associated
DNMT3A mutations and explore the consequences of heterozygous DNMT3A mutation on the
neuronal epigenome. Our results indicate that missense mutations across canonical domains of
DNMT3A disrupt different aspects of protein function, yet mutations in all domains reduce the
enzyme’s capacity to deposit neuronal mCA. We then use DNMT3A heterozygous deletion mice
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as a model to assess the impact of shared DNMT3A loss-of-function effects that occur in
affected individuals with missense and deletion mutations. We detect altered growth and
behavior in these mice, supporting haploinsufficiency as a driver of pathology in DNMT3A
disorders. Through integrated epigenomic analysis, we reveal disruption of mCA throughout the
brain of DNMT3A mutant mice. We show that this loss of mCA leads to disruption of distal
regulatory enhancer activity and changes in gene expression that overlap with models of MeCP2
disorders and other ASDs. These findings define the effects of NDD-associated DNMT3A
mutations for the first time and implicate the disruption of mCA-mediated epigenomic regulation
as a convergence site across clinically distinct NDDs.

3.3

Results

Functional analysis of disease-associated DNMT3A mutations
Multiple DNMT3A mutations have been identified in individuals with ASD and TBRS.
However, the large number of missense mutations identified and the phenotypic heterogeneity of
individuals with these mutations suggests that alterations of amino acids within different protein
domains may have distinct consequences that dictate the nature and severity of disease.
Furthermore, it is not clear if missense mutations identified in patient populations are truly
disruptive, raising the need for direct assessment of molecular function to ascribe mutations as
potentially causative. We therefore sought to assess the effects of disease-associated DNMT3A
mutations on protein expression, cellular localization, and catalytic activity, looking for common
effects that may be core to the development of NDD.
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We engineered amino-acid alterations homologous to human disease mutations into a
FLAG-tagged DNMT3A protein expression vector and assessed multiple mutations found within
each functional domain of the protein (Figure 3.1A). These analyses included mutations in the
chromatin

interacting

proline-tryptophan-tryptophan-proline

(PWWP)

domain,

the

auto-inhibitory Histone H3 lysine 4 interacting ATRX-DNMT3-DNMT3L (ADD) domain, and
the well-defined methyltransferase catalytic domain (Gowher and Jeltsch, 2018). Transfection
into heterologous cells facilitated rapid assessment of protein expression by western blot, cellular
localization by immunocytochemistry, and catalytic activity by using an in vitro
methyltransferase assay. Mutations in the PWWP domain resulted in a reduction in DNMT3A
protein expression and loss of nuclear localization compared to wild-type controls (Figure
3.1B-D, Figure 3.8A-C). When expressed at equal levels to that of wild-type protein however,
these mutations exhibited normal catalytic activity in the in vitro methyltransferase analysis
(Figure 3.1E,F). In contrast, mutations found in the catalytic methyltransferase domain of
DNMT3A showed wild-type expression and localization but displayed deficits in catalytic
activity in vitro (Figure 3.1B-F, Figure 3.8A-C). Mutations in the ADD domain of DNMT3A
displayed normal protein localization and expression levels and exhibited equal or higher
methylation activity compared to wild-type protein in vitro (Figure 3.1B-F, Figure 3.8A-C).
To further evaluate the functional effects of disease-associated DNMT3A mutations in
the context of endogenous chromatin, we tested the capacity of DNMT3A mutants to establish
DNA methylation across the genome in mouse cortical neurons. For this analysis, we focused on
the DNMT3A-dependent global build-up of mCA in postmitotic neurons (Gabel et al., 2015;
Guo et al., 2014; Lister et al., 2013). Cultured neurons isolated from the cerebral cortex at
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embryonic day 14.5 accumulate mCA in vitro and this build-up can be blocked by
lentiviral-mediated delivery of Cre recombinase to DNMT3Aflx/flx cells at 3 days in vitro (DIV)
(Figure 3.2A, Figure 3.8D,E). We co-transduced Cre with wild-type or mutant DNMT3A
lentivirus at equal levels (Figure 3.8F) to test the capacity of each protein to rescue deposition of
DNA methylation. Testing of mutations across the major domains of DNMT3A detected deficits
in mCA accumulation for all disease-associated mutations tested (Figure 3.2B). In this analysis,
mutations in the ADD domain that exhibited robust catalytic activity in vitro displayed
moderate-to-severe deficits in mCA deposition in neurons. The ADD domain has been
implicated in both histone binding and auto-inhibition of the protein (Guo et al., 2015), thus
results in this neuronal assay may indicate that loss of ADD function blocks the capacity of the
enzyme to engage with chromatin and promote DNMT3A methylation activity in cells. Notably,
disease mutations that may be associated with more severe patient phenotypes (intellectual
disability) show a near-complete loss of mCA rescue, while mutations associated with ASD but
not ID (such as V665L) have a more moderate depletion of mCA. This suggests a possible
gradient of disease phenotypes that may be driven by differential mutation severity. Unlike
mCA, global mCG levels show no significant differences in this in vitro system, likely due to the
redundant function of the DNMT1 methyltransferase in maintaining methylation of CG sites
(Figure 3.8G,H). Together our results indicate that although NDD-associated mutations in
DNMT3A affect different protein domains and alter distinct aspects of protein function (e.g.
localization, chromatin interaction, catalysis), these mutations share a common outcome of
reduced enzymatic activity on neuronal DNA, with many mutations resulting in functionally null
proteins.
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In vivo growth and behavioral effects of heterozygous DNMT3A disruption
Our in vitro findings that multiple NDD-associated missense mutations in DNMT3A
result in complete or near-complete loss of function, coupled with the identification of deletion
and nonsense mutations in TBRS patients, suggest that 50% reduction of DNMT3A activity
occurs in a substantial fraction of affected individuals. Thus, studying the effects of heterozygous
inactivation of DNMT3A in vivo is an important first step in understanding the potential
epigenomic and systems level consequences of DNMT3A disruption in NDD. Previous studies
have demonstrated severe developmental deficits, disruptions in movement, and perinatal
lethality associated with constitutive complete loss of DNMT3A (homozygous null mutation)
(Okano et al., 1999) and with removal of DNMT3A from the brain (conditional DNMT3A
deletion) (Nguyen et al., 2007). However, the relevance of heterozygous mutation of DNMT3A
to neurodevelopmental disease has only recently been uncovered, and the growth and behavioral
effects of partial DNMT3A inactivation have not been systematically assessed. We therefore
carried out growth, behavioral, and molecular analyses of mice carrying a constitutive
heterozygous deletion of exon 19 of Dnmt3a (see methods) (Kaneda et al., 2004). We find that
this mutation leads to 50% reduction of RNA and protein expression, allowing us to study the in
vivo effects of heterozygous null mutation of DNMT3A (referred to as DNMT3AKO/+) (Figure
3.9A-C).
We first examined phenotypes relevant to overgrowth in individuals with heterozygous
DNMT3A mutations (Tatton-Brown et al., 2018), including enlarged body size and obesity
(body weight), tall stature (long-bone length), and macrocephaly (skull dimensions).
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DNMT3AKO/+ mice showed similar body weight to controls in the early postnatal period but were
significantly heavier than controls as mature adults (Figure 3.3A). This phenotype mimics a
maturity-associated trend toward increasing body weight observed in TBRS patients
(Tatton-Brown et al., 2018). Measurements of leg bone length, a major determinant of height in
humans (Duyar and Pelin, 2003), indicated a significant increase in total length of long leg
bones, with significantly increased tibia length in DNMT3AKO/+ mice and a trend towards longer
femur length (Figure 3.3B, Figure 3.10A-D). Morphometric analyses of the cranium and
mandible indicated very subtle differences between DNMT3AKO/+ mice and their wild-type
littermates (Figure 3.10E-G). One linear distance spanning the rostrocaudal length of the
interparietal bone is larger in DNMT3AKO/+ mice relative to wild-type littermates. Two linear
distances in the facial region were significantly larger in wild-type mice, while all other
comparisons were not significantly different (Figure 3.10E). This result suggests very slight
disruptions in growth of the facial region in DNMT3A KO/+ mice. Together these findings uncover
effects on long bone length that mirror aspects of the human disorder, while skull development in
DNMT3AKO/+ mice shows more limited effects. Additionally, enlarged body mass in these mice
appears to mimic overgrowth and obesity detected in individuals with TBRS (Tatton-Brown et
al., 2014, 2018).
To examine neurological and behavioral phenotypes in DNMT3AKO/+ mice, we first
assessed basic measures of sensation and motor performance such as balance (ledge test,
platform test), grip strength (inverted screen test), motor coordination (walking initiation,
rotarod), and sensorimotor gating (pre-pulse inhibition). DNMT3AKO/+ mice were not
significantly different in these assays (Figure 3.11A-G), indicating that heterozygous loss of
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DNMT3A does not grossly disrupt sensorimotor function. This allowed us to accurately assess
more complex aspects of behavior and cognition.
We next carried out a panel of assays with relevance to neuropathology observed in
humans with DNMT3A mutations, including anxiety, autism, and intellectual disability.
DNMT3AKO/+ mice displayed reduced exploratory behavior during open field testing, including
reduced distance traveled and rearing (Figure 3.3C,D). DNMT3AKO/+ mice also displayed
anxiety-like behavior in this assay, as they spent less time in the center of the open field arena
(Figure 3.3E). In tests of climbing behavior, DNMT3AKO/+ mice showed longer latency to climb
to the bottom of a pole and to the top of mesh screens (Figure 3.11H-J), suggesting that
DNMT3AKO/+ mice display differences in volitional movement. To further assess anxiety-like
behavior, we tested mice in the elevated plus maze and observed that DNMT3AKO/+ mice spent
less time exploring the open arms of the maze with no change in percent entries made into all
arms (Figure 3.3F, Figure 3.11K). Overall, these results demonstrate that the DNMT3AKO/+ mice
display changes in exploratory behavior, suggesting altered emotionality and increased
anxiety-like behaviors.
Intellectual disability is a highly penetrant phenotype observed in patients with DNMT3A
mutations, so we assessed learning and memory in the DNMT3AKO/+ mice using fear
conditioning and Morris water maze tests. In the foot-shock induced fear conditioning task,
DNMT3AKO/+ mutants showed heightened freezing response during training, as well as
contextual and auditory recall phases of conditioned fear testing (Figure 3.3G-I, Figure
3.11L,M). Mutant mice also showed delayed extinction of freezing behavior in response to the
auditory cue alone (Figure 3.11M). These alterations in responses do not arise from altered
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sensation of pain from the shock (Figure 3.11N), and therefore suggest altered emotionality or
cognition in the mutant mice. Assessment of spatial and contextual memory by Morris water
maze testing demonstrated that DNMT3AKO/+ mice were slower to learn to find a visible platform
and did not learn the location of the hidden platform over time to the level of wild-type controls
(Figure 3.11O,P), with no differences in swimming speed (Figure 3.11Q,R). There were no
significant effects on distance traveled in target zone or platform crossings in the probe trial,
though DNMT3AKO/+ mice trended towards fewer platform crossings (Figure 3.11S,T). These
findings suggest that DNMT3AKO/+ mutants do not show severe deficits in learning and memory
but do display differences in task performance that further suggest altered emotionality or
cognition in these mice.
DNMT3A has been identified as a high confidence autism gene (Sanders et al., 2015) and
there is a high rate of autism diagnoses in patients with TBRS (Tatton-Brown et al., 2018). We
therefore sought to characterize common phenotypes examined in mouse models of autism
(marble burying, three chamber social approach, ultrasonic vocalizations). We detected a
significant reduction in marble burying activity for DNMT3AKO/+ mice, indicating alterations in
repetitive digging behavior (Figure 3.3J, Figure 3.11U). Evaluation of social interaction
behaviors in the three-chamber social approach assay for adult mice (Yang et al., 2011) revealed
that DNMT3AKO/+ mice spend reduced time investigating both mice and objects. They also
display reduced overall activity, with no change in preference index for sociability or novelty
(Figure 3.12A-D) (Nygaard et al., 2019). Given that carrying out these tests under normal
lighting and experimental conditions may induce anxiety responses in addition to probing
sociability, we considered that the reduced exploration seen in DNMT3AKO/+ may reflect the
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anxiety-like phenotypes of these animals rather than changes in sociability. Indeed, when we
carried out three-chamber analysis under low lighting conditions to mitigate anxiety in the mice,
we detected similar exploratory behavior, as well as similar sociability and social novelty
seeking responses in wild-type and DNMT3AKO/+ mice (Figure 3.12E-H) (Manno et al., 2020).
To explore changes in pro-communication behaviors, we measured maternal-isolation induced
ultrasonic vocalizations (Barnes et al., 2017). We detected a reduction in the number of calls in
DNMT3AKO/+ mice at postnatal day five, suggesting deficits in early pro-social behaviors or
developmental delay in the normal acquisition of this behavior (Figure 3.3K). Together these
results indicate alterations in some behaviors commonly assessed in mouse models of autism
(Chang et al., 2017; Kazdoba et al., 2014; Mei et al., 2016; Simola and Granon, 2019; Takumi et
al., 2019), with our findings suggesting a reduction in activity and exploration, as well as
changes in communication behaviors.
Overall, our physiological and behavioral analyses demonstrate that heterozygous
deletion of DNMT3A results in growth and behavior changes in mice with relevance to the
overgrowth, anxiety, communication, and memory-associated phenotypes observed in patients
with DNMT3A mutations. These data support a model in which DNMT3A haploinsufficiency
contributes to altered growth and behavioral circuits to drive phenotypes in NDD.

Global disruption of DNA methylation in the DNMT3AKO/+ brain
We next investigated the epigenomic defects that may underlie the altered behaviors
observed in DNMT3AKO/+ mice. We first used sparse whole-genome bisulfite sequencing to
efficiently survey effects on global DNA methylation levels for multiple brain regions and liver
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tissue isolated from wild type and DNMT3AKO/+ mice. This analysis detected limited reductions
in genome-wide mCG levels in the DNMT3AKO/+ brain that were not apparent in non-neural
tissue (liver, Figure 3.4A). In contrast, mCA levels were reduced by 30-50% across all brain
regions examined in DNMT3AKO/+ mice (Figure 3.4B). Analysis of DNA methylation across
postnatal development in the cerebral cortex, a brain region with high levels of mCA at 8 weeks,
suggested that deficits in mCA appear during initial accumulation of this methyl mark at 1-6
weeks (Figure 3.4B). Thus, global mCA levels in the brain appear to be highly sensitive to
heterozygous DNMT3A disruption, while overall global mCG levels are largely maintained.
DNA methylation at specific genomic elements, including promoters, enhancers, and
gene bodies is thought to play an important role in regulating transcription. Alterations in
methylation at these regions can impact gene expression to affect the development and function
of the brain (Clemens et al., 2019; Nord and West, 2019; Stroud et al., 2017). We therefore
assessed changes in methylation at base-pair resolution by high-depth whole-genome bisulfite
sequencing to identify potential changes in mCA and mCG at these important regulatory sites.
For this analysis we focused on the cerebral cortex, as this region is enriched for mCA (Figure
3.4B) and disrupted in ASD and MeCP2 disorders (Clemens et al., 2019; Satterstrom et al., 2019;
Sceniak et al., 2016; de la Torre-Ubieta et al., 2016). High-resolution analysis of mCG confirmed
the extremely subtle reduction in mCG across all classes of genomic elements (Figure 3.5A-D).
We considered however, that CG dinucleotides in specific sites in the neuronal genome may be
more sensitive to a partial reduction in DNMT3A activity. For example, in the hematopoietic
system, heterozygous disruption of DNMT3A leads to reductions in DNA methylation in
genomic regions that can be identified as sensitive to complete loss of DNMT3A (Cole et al.,
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2017). We therefore evaluated CG-differentially methylated regions (CG-DMRs) previously
identified as becoming highly methylated in the adult cortex (Figure 3.13A) (Lister et al., 2013).
Because DNMT3A is the only de novo methyltransferase expressed in the postnatal brain, we
hypothesized that adult-specific CG-DMRs might be sensitive to a reduction in enzyme activity.
Indeed, we found that these sites build up mCG during postnatal development and do not become
methylated in a brain-specific DNMT3A conditional knockout mouse (DNMT3A Nestin- cKO)
(Stroud et al., 2017) (Figure 3.13B). Analysis of these adult-specific CG-DMRs in the
DNMT3AKO/+ model indicated that these sites are particularly sensitive to partial inactivation of
DNMT3A (Figure 3.5A,C,D).
Because a substantial percentage of mCG in neurons can occur in an oxidized,
hydroxymethyl form (hmCG), we performed oxidative bisulfite sequencing analysis of DNA
from the cortex. This analysis revealed no clear evidence of widespread differential effects on
the oxidized or unoxidized forms of mCG across classes of genomic regions in the DNMT3AKO/+
(Figure 3.13C), suggesting that hmCG is largely preserved in the DNMT3AKO/+ brain. However,
future experiments will be required to uncover if there are more subtle site-specific changes in
hmCG.
To further search for local sites of altered mCG in the DNMT3AKO/+, we performed de
novo calling of CG-differentially methylated regions using the BSmooth algorithm (Hansen et
al., 2012). We identified 6164 hypo- and 378 hyper-CG-DMRs across the genome that met high
stringency filters for size and reproducibility (Figure 3.5A-C,E, Figure 3.13D, see methods). The
hypo-DMRs significantly overlap with the previously identified adult-specific CG-DMRs (Lister
et al., 2013) (Figure 3.5F, Figure 3.13E), further supporting the idea that DNMT3A is
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haploinsufficient for postnatal mCG deposition at these sites. Examination of the genomic
distribution of all DNMT3AKO/+ CG-DMRs revealed significant overlap of hypo-DMRs with
putative enhancer regions, gene bodies, and promoters (Figure 3.5A-C,F, Figure 3.13E). DMRs
were also highly enriched for overlap with CpG island shores, regions disrupted in studies of
DNMT3A mutation outside of the nervous system (Cole et al., 2017; Spencer et al., 2017)
(Figure 3.5C, Figure 3.13E). Together these findings indicate that a small subset of mCG sites
are particularly sensitive to heterozygous loss of DNMT3A and that localization of these
CG-DMRs to regulatory elements suggests that these methylation changes could impact gene
expression.
We next examined the profile of mCA at genomic elements of different scales that have
relevance to gene regulation. In contrast to the limited mCG changes in the DNMT3AKO/+,
analysis of mCA levels detected consistent 30-50% reductions at nearly all genomic regions
examined (Figure 3.5G). This was true of gene bodies, promoters, and CpG island shores. CpG
islands show very low mCA levels in wild-type cortex and displayed less reduction of mCA,
possibly due to floor effects in bisulfite-sequencing (see methods). Comparing the mCA changes
within each class of genomic elements as a function of wild-type mCA levels suggested that
consistent reductions occurred across the genome, independent of the normal levels of mCA
(Figure 3.13F). This result suggests that changes in mCA levels in the DNMT3AKO/+ do not
preferentially impact specific classes of genomic elements, nor are they more severe in some
regions based on the level of mCA normally deposited.
Recent analysis has demonstrated that topologically-associating domains (TADs) of
chromatin folding can impact gene regulation by influencing DNMT3A binding and subsequent
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mCA deposition (Boxer et al., 2019; Clemens et al., 2019; Nothjunge et al., 2017). The average
level of mCA within TADs is associated with the level of mCA at enhancers within TADs, and
high-mCA enhancers found in high-mCA TADs are particularly robust targets of repression by
MeCP2 (Clemens et al., 2019). We therefore specifically assessed mCA levels at TADs and
enhancers genome-wide. This analysis detected reductions in TAD mCA levels that were similar
to global reductions in mCA at other genomic elements (Figure 3.5G). Enhancers also showed
this pervasive depletion of mCA (Figure 3.5G). Thus, widespread loss of mCA for TADs, and
the enhancer elements contained within them, occurs in DNMT3AKO/+ mice and has the potential
to impact epigenetic control of regulatory elements by MeCP2.

Enhancer dysregulation results from methylation deficits in DNMT3AKO/+ mice
We next examined how disruption of DNA methylation can affect epigenetic regulation
in DNMT3AKO/+ neurons to alter gene expression and disrupt nervous system function. Recent
analyses indicate that mCA serves as a binding site for MeCP2 to mediate neuron-specific gene
regulation, in part by controlling the activity of distal regulatory enhancer elements (Boxer et al.,
2019; Clemens et al., 2019). Loss of MeCP2 in mice leads to genome-wide upregulation of the
activating mark Histone H3 lysine 27 acetylation (H3K27ac) at enhancers that contain high
levels of mCA and mCG sites, while overexpression of MeCP2 leads to reciprocal
downregulation of highly methylated sites. Alterations in enhancer activity in MeCP2 mutants
are linked to dysregulation of genes that can then drive nervous system dysfunction (Clemens et
al., 2019). These findings suggest that reduced CA methylation in the DNMT3AKO/+ would
remove binding sites for MeCP2 within enhancers, which could then result in dysregulation of
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enhancer activity that partially phenocopies the effects we have observed in MeCP2 mutant
mice.
To investigate this possibility directly, we quantified the change in DNMT3AKO/+ mCA
binding sites for enhancers significantly repressed by MeCP2 (Clemens et al., 2019). These
enhancers contain a large number of mCA sites due to high mCA/CA levels and an enrichment
of CA dinucleotides within these sequences. As a result, we found that the global 30-50%
reduction of mCA in the DNMT3AKO/+ leads to a larger loss in the total number of mCA sites at
MeCP2-repressed enhancers than at other enhancers genome-wide (Figure 6A,B). Thus
MeCP2-repressed enhancers are particularly susceptible to mCA binding site loss from
heterozygous mutation of DNMT3A.
To determine if the reduction of mCA sites at MeCP2-repressed enhancers affects their
activity, we assessed changes in enhancer activation level by H3K27ac ChIP-seq analysis of the
DNMT3AKO/+ and wild-type cerebral cortex. This analysis revealed significant changes in
acetylation at MeCP2-repressed enhancers (Figure 3.6A,C). Consistent with these effects arising
from 30-50% loss of the mCA that normally builds up post-mitotically at enhancers, we detect
changes that are concordant with, but smaller than, effects on enhancers previously observed
upon complete loss of post-mitotic mCA in the neuron-specific DNMT3A conditional knockout
mouse (DNMT3A Baf53b-cKO) (Clemens et al., 2019) (Figure 3.6C). We also find that
enhancers within highly methylated TADs show significantly higher increases in acetylation
compared with enhancers in other TADs (Figure 3.13G). This finding further supports a model in
which high mCA levels in TADs leads to repression of enhancers within these TADs by mCA
and MeCP2.
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Although significantly dysregulated enhancers can be detected in MeCP2 mutants, broad
sub-significance-threshold effects also occur genome-wide upon MeCP2 mutation, with
enhancers across the genome undergoing dysregulation that is proportional to the number of mC
binding sites at these regions (Figure 3.6D) (Clemens et al., 2019). Analysis of H3K27ac
changes at enhancers based on the normal density of mCA sites in these sequences genome-wide
revealed broad mCA-associated derepression of enhancers in DNMT3AKO/+ mouse cortex that is
similar to, but smaller in magnitude than, the effects observed in DNMT3A Baf53b- cKO and
MeCP2 knockout mice (MeCP2 KO). These effects are also reciprocal to effects observed in
MeCP2 overexpression mice (MeCP2 OE). Consistent with the limited disruption of mCG
genome wide in the DNMT3AKO/+ mice, there was only a limited association between changes in
enhancer activity and the level of mCG. This limited association contrasts with MeCP2 mutants,
where loss of protein binding at both mCG and mCA sites leads to enhancer dysregulation that is
associated with both mCA and mCG (Clemens et al., 2019) (Figure 3.6D).
Though there is limited evidence that a global change in mCG impacts enhancer activity
in the DNMT3AKO/+ cortex, we considered the potential for site-specific changes in mCG
(DMRs) to have functional effects on enhancers. We therefore assessed changes in acetylation at
enhancers containing CG-DMRs in the DNMT3AKO/+ cortex. Indeed, enhancers containing
hypo-CG-DMRs display subtle, but significant increases in acetylation compared to enhancers
without a DMR (Figure 3.13H). The results thus provide evidence that site specific mCG
changes in the DNMT3AKO/+ may result in functional consequences.
Together, our epigenomic analyses demonstrate that loss of half of the normal mCA sites
in the DNMT3AKO/+ cortex results in enhancer dysregulation that overlaps with MeCP2 mutant
99

mice. On a more limited scale, loss of CG methylation at specific enhancers can also impact
enhancer activity. These findings therefore uncover a role for shared neuronal chromatin
pathology between DNMT3A and MeCP2 disorders.

Overlapping transcriptional pathology between DNMT3AKO/+, MeCP2 disorders, and ASD
The epigenetic alterations we observe in DNMT3AKO/+ cerebral cortex can have direct
consequences on gene expression to drive neurological dysfunction in mice. Furthermore, the
overlapping effects on enhancers that we observe between DNMT3AKO/+ and MeCP2 mutant
mice suggest that there may be shared transcriptional pathology occurring upon loss of mCA in
DNMT3A disorders, as well as through disruption of MeCP2 in Rett syndrome and
MeCP2-duplication syndrome. We therefore assessed changes in gene expression in
DNMT3AKO/+ mice, interrogating the extent to which these effects overlap with those observed
upon complete disruption of mCA in the DNMT3A Baf53b-cKO and those observed in MeCP2
mutant mice. RNA-seq of DNMT3AKO/+ cerebral cortex identified subtle changes in gene
expression that are consistent in magnitude with effects observed in other heterozygous NDD
models (Fazel Darbandi et al., 2018; Gompers et al., 2017; Katayama et al., 2016) (Figure
3.14A). Additional analysis of noncoding RNA showed no change across major classes of
noncoding RNAs in the DNMT3AKO/+ cortex (Figure 3.14B).
Gene Ontology analysis of gene expression changes detected terms associated with
neurodevelopment processes, such as axonal guidance and recognition, that occur just before or
during the period when DNMT3A deposits mCA in the brain (Figure 3.14C). This is consistent
with the proposed role of DNMT3A in regulating transcriptional programs as neurons mature.
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Additionally, we see significantly reduced expression of relevant ASD genes, Shank2 and
Shank3, that suggest dysfunction at the synaptic level (Supplementary Table 3) (Guilmatre,
Huguet, Delorme, and Bourgeron, 2014). Our transcriptomic results suggest that genes critical to
the formation of neuronal circuits during development are affected upon heterozygous disruption
of DNMT3A, with disrupted development resulting in behavioral alterations we observe.
To determine the extent to which transcriptional dysregulation upon disruption of
DNMT3A and MeCP2 result in shared effects, we examined the degree to which genes detected
as significantly dysregulated in each mutant line overlap with the changes in the DNMT3AKO/+
cortex. Indeed, the significantly dysregulated genes in the DNMT3AKO/+ overlapped extensively
with genes identified as significantly dysregulated in DNMT3A Baf53b-cKO and MeCP2 mutant
mice (Figure 3.6E) (Clemens et al., 2019). Notably, shared gene expression effects between these
mouse models may have important functional impacts. For example, all three deletion models
show upregulation of Shroom3, which is associated with developmental defects when mutated in
humans (Das et al., 2014; Deshwar et al., 2020), and latrophilin-2, a post-synaptic adhesion
molecule with roles in synapse targeting and assembly in multiple brain regions (Anderson et al.,
2017; Zhang et al., 2020). The shared dysregulation of genes like these in DNMT3A and MeCP2
disorders, may contribute to synaptic dysfunction and disease pathology.
While a limited gene set is detected as significantly dysregulated in the DNMT3AKO/+, we
considered if genome-wide alterations in enhancer activity could lead to widespread, subtle
dysregulation of gene expression that is below the significance threshold of detection for
individual genes. In this way, the transcriptional pathology in the DNMT3AKO/+ brain would
overlap with similar subthreshold genome-wide effects observed upon loss of neuronal mCA
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(DNMT3A Baf53b- cKO) and in models of Rett syndrome (MeCP2 KO) and ASD (MeCP2 OE)
(Clemens et al., 2019; Gabel et al., 2015). Importantly, evidence from MeCP2 mutants suggests
that disease pathology arises from thousands of small changes in gene expression rather than
drastic changes in a few significant genes (Chen et al., 2015; Ip et al., 2018; Kinde et al., 2016).
As such, we may expect that disruption of the neuronal methylome in DNMT3AKO/+ may also
lead to numerous changes in gene expression that escape statistical significance yet still
contribute to disease pathology. To more comprehensively assess the degree to which subtle,
transcriptome-wide changes in the DNMT3AKO/+ phenocopy these MeCP2 mutant and DNMT3A
Baf53b- cKO models, we performed Generally Applicable Gene-set Enrichment (GAGE)
analysis (Luo et al., 2009) of genes detected as dysregulated. GAGE analysis revealed highly
significant, concordant changes in gene expression in the DNMT3AKO/+ for genes identified as
dysregulated upon loss of mCA in the DNMT3A Baf53b-c KO and in MeCP2 mutants (Figure
3.6F).
To further explore a model in which loss of mCA and enhancer dysregulation drives gene
expression changes in the DNMT3AKO/+, we examined enhancers associated with significantly
upregulated genes. This analysis revealed that these enhancers are enriched for mCA, show a
pronounced loss of mCA sites in the DNMT3A mutant, and display significant increases in
enhancer acetylation compared to all other enhancers (Figure 3.14D,E). Analysis of genes
containing enhancers that harbor a hypo-CG-DMR also detected significant upregulation in gene
expression compared to all other genes (Figure 3.14F), suggesting that local changes in mCG
may also contribute to transcriptomic changes in DNMT3AKO/+ mice.
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Having detected overlap in transcriptomic pathology between models of DNMT3A and
MeCP2 disorders, we explored if shared gene expression signatures in the DNMT3AKO/+ mice
extend to models of disorders that do not have established mechanistic links to DNMT3A
disorders. We therefore tested if DNMT3AKO/+ mice show significant alterations in gene sets
identified as dysregulated in other mouse models of NDD and in human gene sets implicated as
altered in the autistic brain. GAGE analysis across multiple datasets detected highly significant
dysregulation of gene sets identified in CHD8 and PTEN mouse models of overgrowth and ASD
(Gompers et al., 2017; Katayama et al., 2016; Tilot et al., 2016) as well as the SETD5 model of
NDD (Sessa et al., 2019) (Figure 3.7A). These findings support a role for overlapping gene
dysregulation underlying common symptomology found in affected individuals carrying
mutations in distinct epigenomic regulatory genes. We further extended our analysis to human
gene sets dysregulated in ASD postmortem brains (Gandal et al., 2018; Voineagu et al., 2011).
This analysis detected significant changes in the DNMT3AKO/+ cortex (Figure 3.7B), and
indicated upregulation of candidate genes linked to ASD from human genetics studies
(Abrahams et al., 2013; Banerjee-Basu and Packer, 2010) (Figure 3.7B). In addition, analysis of
co-expression modules of human brain development (Parikshak et al., 2013) showed overlap
with several neurodevelopmental modules including those that increase during early cortical
development and are enriched for ASD risk genes (M13, M16, and M17) (Figure 3.14G).
Modules involved in regulation of nucleic acids and gene regulation that are expressed early in
development and decrease over time are also increased upon heterozygous loss of DNMT3A
(M2 and M3) (Figure 3.14G). These results indicate that important sets of genes with opposing
developmental trajectories and function are altered upon loss of DNMT3A regulation.
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Resampling analysis indicates that significant dysregulation of these mouse and human gene sets
is not driven by enriched expression of these genes in the cortex (Figure 3.14H). Together these
findings suggest that the DNMT3AKO/+ mouse shares overlapping transcriptional pathology with
gene expression changes underlying ASD.

3.4

Discussion
Our functional analysis of NDD-associated DNMT3A mutations together with our in vivo

studies provide an initial working model of molecular etiology in DNMT3A disorders. Diverse
de novo missense mutations that arise in affected individuals disrupt enzyme function by
disabling the capacity of the enzyme to localize to chromatin in the nucleus, altering the
ADD-regulatory domain, or disrupting the activity of the methyltransferase domain.
Loss-of-function effects resulting from these missense mutations, or early truncations and gene
deletions in other individuals, lead to insufficient DNMT3A activity. The limited DNMT3A
activity in turn causes deficits in the deposition of mCG at specific sites during development, as
well as a massive deficit in postnatal mCA accumulation throughout the brain. These changes in
DNA methylation lead to alterations in epigenomic regulation, including subtle but widespread
disruption of mCA-MeCP2-mediated enhancer regulation in adult neurons, resulting in gene
expression changes that can contribute to deficits in nervous system function.
Our studies of DNMT3A mutations not only provide insight into the molecular etiology
of DNMT3A disorders, but also serve as a model for understanding the functional effects of
diverse de novo mutations underlying neurodevelopmental disorders. Exome sequencing studies
have identified a large and growing list of mutations in genes encoding epigenetic regulators in
104

individuals with NDD. Many of these are missense mutations and occur as heterozygous
disruptions (McRae et al., 2017; Satterstrom et al., 2019), leaving it unclear if simple
loss-of-function effects are sufficient to drive pathology through haploinsufficiency, or if more
complex effects play a role when individual amino acids are altered. In addition, while
identification of multiple mutations in a gene can implicate disruption of the gene as causative
for NDD, it remains possible that a subset of the mutations identified in affected individuals,
particularly missense mutations, are not in fact deleterious or causative. Functional testing of
these variants is therefore necessary to determine whether they underlie disease. Here, our
analysis of DNMT3A mutations in multiple functional assays has uncovered diverse mechanisms
by which the protein can be disrupted while pointing to a shared loss of function in the
deposition of neuronal DNA methylation. Notably, it is only by assessing multiple aspects of
protein function (i.e. expression, localization, activity, and cellular mCA levels) that we can
detect deficits for each mutation tested. For example, mutation of the ADD domain only disrupts
deposition of mCA in cells, possibly due to loss of regulation that can only be assessed in the
endogenous chromatin context. Together our findings establish deleterious effects of diverse
DNMT3A mutations and underscore the importance of multidimensional analysis of de novo
mutations to fully assess their role in NDD.
Our in vivo analyses show that heterozygous deletion of DNMT3A mirrors multiple key
features of DNMT3A disorders, including tall stature (increased long bone length), increased
body weight, and behavioral alterations. Detection of robust anxiety-like phenotypes in multiple
assays, deficits in pro-social communication, and alterations in repetitive behaviors align with
observed human phenotypes. In contrast, lack of severe deficits in learning and memory assays
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in our mouse model may indicate that some regions and systems in humans are more susceptible
to DNMT3A disruption than in mice. However, we do detect subtle alterations in behavior in
these assays and the lack of strong deficits may also reflect insensitivity of the methods used in
mice to measure specific aspects of disrupted cognition.
In all, our in vivo analysis indicates that heterozygous deletion of DNMT3A results in
effects which can guide future studies of molecular, cellular, and organismal dysfunction caused
by mutation of DNMT3A. We employed the DNMT3AKO/+ mouse experimental system to assess
how heterozygous DNMT3A disruption impacts epigenetic regulation in the brain. Our analysis
of DNA methylation in tissues from DNMT3AKO/+ mice detected subtle changes in genome-wide
mCG levels across brain regions, with no global mCG effects in non-neural tissue. Analysis of
local changes in mCG in the brain detected evidence of disrupted CG methylation at sites
methylated during postnatal development (i.e. adult hyper CG-DMRs) and at regulatory elements
including enhancers. These effects have the potential to disrupt gene expression and contribute to
neurological alterations in these mice. The limited nature of mCG effects is likely due to the
redundant function of the other DNA methyltransferases. The maintenance methyltransferase
DNMT1 has the capacity to preserve existing mCG patterns during cell divisions (Jeltsch et al.,
2018). In addition, the de novo methyltransferase DNMT3B is expressed with DNMT3A in
many tissues during early development and could provide critical redundancy for mCG
patterning (Okano et al., 1999). Nonetheless, some site-specific changes in mCG are also likely
to occur in early development and in non-neural tissues. For example, constitutive heterozygous
deletion of DNMT3A has been shown to disrupt mCG patterns in the blood and alter
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hematopoietic lineages (Cole et al., 2017). These changes in mCG can contribute to changes in
growth and other phenotypes observed in mice and humans.
In contrast to mCG, we detect a global reduction in mCA to approximately 30-50% of
wild-type levels in DNMT3AKO/+ cortex, striatum, cerebellum, and hippocampus. These results
generalize and extend findings in the hypothalamus (Sendžikaitė et al., 2019), demonstrating the
susceptibility of broad neuronal types and circuits to heterozygous loss of DNMT3A. The
susceptibility of mCA to heterozygous loss of DNMT3A is likely due to several related factors.
For example, DNMT3B is not expressed in postnatal neurons (Lister et al., 2013), and DNMT1
is not capable of depositing mCA (Jeltsch et al., 2018), making all mCA build-up in neurons
dependent on DNMT3A. In addition, the enzyme has slow kinetics for activity on CA sites
(Zhang et al., 2018) and deposition of mCA genome-wide by DNMT3A must take place in a
restricted time window (1-6 weeks) when the enzyme is highly expressed and active in neurons
(Clemens et al., 2019; Lister et al., 2013; Stroud et al., 2017). These constraints may make
enzyme levels limiting for mCA accumulation in neurons, providing an explanation for why
global mCA in the brain is sensitive to DNMT3A gene dosage. Notably, our findings suggest
that manipulations that activate the remaining DNMT3A, or prolong its high early postnatal
expression, might rescue deficits in mCA deposition. Conversely, duplication of the DNMT3A
gene could result in too much deposition of mCA and possibly cause significant neural
dysfunction akin to those effects seen in MeCP2 duplication disorder. Future studies can assess
the feasibility of rescue approaches and explore if DNMT3A duplication alters brain function.
Our analysis of chromatin changes downstream of altered DNA methylation has
uncovered a striking point of shared molecular disruption across models of DNMT3A disorders,
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Rett syndrome, and MeCP2 duplication syndrome. While the clinical profile and
pathophysiology of DNMT3A disorders is clearly distinct from MeCP2 disorders, we have
shown here that loss of approximately a quarter of MeCP2 binding sites across the neuronal
genome in the DNMT3AKO/+ cortex results in subtle but widespread disruption of
mCA-associated enhancer regulation that partially phenocopies loss of MeCP2. This enhancer
dysregulation can be linked to shared alterations in gene expression across these models. Given
the critical roles of MeCP2-regulated genes for nervous system function (Gabel et al., 2015;
Lagger et al., 2017; Lyst and Bird, 2015), these overlapping epigenomic and transcriptomic
effects likely contribute to aspects of neurologic dysfunction observed in DNMT3A disorders.
Overall, we find that the behavioral effects observed in the DNMT3AKO/+ mice are less
severe than homozygous conditional DNMT3A knockout and MeCP2 knockout mice, which
present with decreases in motor coordination, severely reduced body size, and increased
mortality (Nguyen et al., 2007; Stroud et al., 2017; Tillotson et al., 2017). These behavioral
differences between models mirror the differences in effects on mCA deposition and readout in
these strains, where DNMT3A conditional knockout mice lose all neuronal mCA and MeCP2
KO mice lose a major reader of both mCA and mCG, while the DNMT3KO/+ mice lose only half
of the mCA sites and a limited set of localized mCG sites. The persistence of many mCA and
mCG binding sites for MeCP2 in the DNMT3AKO/+ may partially explain how DNMT3A
mutations in humans manifest with less severe symptomology than in Rett Syndrome.
Independently, absence of DNMT3A early in prenatal development can contribute to overgrowth
and other non-overlapping aspects of DNMT3A and MeCP2 disorders. Together, our findings
show that disruption of mCA-MeCP2 mediated enhancer regulation likely contributes to multiple
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disorders with distinct symptomology, defining a site of convergent molecular etiology
underlying heterogeneous clinical syndromes.
Our transcriptomic analysis of changes of ASD/NDD gene sets in DNMT3A mice has
further detected overlap with NDD beyond MeCP2 disorders, including both mouse models of
NDD/ASD (e.g. CHD8) and gene sets identified in human idiopathic ASD. As additional
transcriptomic studies of mouse models and human NDD brain emerge, systematic analyses of
gene expression effects can identify shared aspects of transcriptional pathology that can
contribute to cognitive and social deficits across diverse causes of NDD. Notably, the large
number of chromatin-modifying enzymes mutated in these disorders raises the possibility that
shared transcriptomic effects emerge from common chromatin pathology. Our study has
identified alterations in mCA and enhancer regulation as a potential site of convergent
dysfunction in MeCP2 and DNMT3A disorders. Future studies may identify additional gene
disruptions in which alterations in mCA and enhancer dysregulation contribute to molecular
pathology, expanding the role of “methylopathies” in neurodevelopmental disease.

3.5

Methods

Animal husbandry
All animal protocols were approved by the Institutional Animal Care and Use Committee and the
Animal Studies Committee of Washington University in St. Louis, and in accordance with
guidelines from the National Institutes of Health (NIH). Mice were housed in a room on a 12:12
hour light/dark cycle, with controlled room temperature (20-22°C) and relative humidity (50%).
Home cages measured 28.5 cm x 17.5 cm x 12 cm and were supplied with corncob bedding and
standard laboratory chow and water. All mice were group-housed and adequate measures were
taken to minimize animal pain or discomfort.
Transgenic animals
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Male and female homozygous Dnmt3aflx/flx mice (Kaneda et al., 2004) were bred together for
viral-mediated DNMT3A replacement assay culture experiments. To generate the DNMT3A
heterozygous
mouse
model, Dnmt3aflx/flx

mice were crossed to CMV:Cre
(B6.C-Tg(CMV-cre)1Cgn/J)
to
generate
Dnmt3aKO
 / +Cre:CMV+/offspring.
KO/+
+/Dnmt3a Cre:CMV progeny were bred to C57BL/6J to outcross the cre recombinase and
generate experimental genotype (DNMT3AKO/+). Mice were genotyped with ear-DNA by PCR
for Dnmt3a and Cre, and recombination was tested. Subsequent experimental animals were
generated from Dnmt3aKO/+

males mated to C57BL/6J females to generate Dnmt3aKO/+

and
+/+
KO/+
Dnmt3a experimental and control animals for experiments. Dnmt3a
females were not used
for breeding to avoid social differences in mothering from mutant dams. Mice were weighed at a
variety of timepoints to assess growth.
Method Details
Immunocytochemistry
Staining. N
 euro-2a cells (ATCC, CCL-131) were grown on coverslips and transfected with
FLAG-tagged WT or mutant mouse DNMT3A plasmids and GFP plasmid. This FLAG-tag
allows for quantification of transfected DNMT3A protein only instead of endogenous DNMT3A.
Coverslips were fixed with 4% paraformaldehyde in PBS for 20 minutes, permeabilized with
0.1% Triton X-100 in PBS for 10 minutes, and blocked with 1% BSA in PBS for 1 hour all at
room temperature. Coverslips were incubated overnight at 4˚C in anti-DDDDK tag (FLAG-tag)
primary antibody (Abcam, 1:5000, ab1162). Coverslips were then washed in PBS and incubated
for 1 hour at room temperature with fluorescent secondary antibody (ThermoFisher, 1:500,
A-11011) and counterstained with DAPI. Imaging. Images were captured using a Nikon A1Rsi
confocal microscope with a 20x air objective. Laser settings were kept constant for each image.
Analysis/Quantification. Cells were counted using an automatic threshold in FIJI and manually
classified as displaying nuclear or non-nuclear signal by a blinded observer. This was determined
by evaluating the overlap of FLAG signal (DNMT3A) with DAPI signal (nucleus). For mutants
that did not reach expression levels comparable to the WT or for images that had too few
positive cells, cell number was counted manually. 8 separate transfections were run, with each
mutant being counted over 3 or more independent experiments. Sample sizes are as follows: WT,
15 images, 880 cells; W297del, 8 images, 435 cells; I310N, 8 images, 492 cells; S312fs11x, 12
images, 321 cells; G532S, 9 images, 695 cells; M548K, 7 images, 333 cells; V665L, 6 images,
635 cells; Y735C, 16 images, 613 cells; R749C, 8 images, 667 cells; P904L, 7 images, 692 cells.
While some mutants showed reduced protein expression, all proteins tested showed adequate
signal assessed as nuclear or non-nuclear. Percent nuclear was assessed per image and a
generalized linear model was run comparing each mutant to WT. P values for each mutant were
then Bonferroni corrected. Localization to the nuclear periphery was evident for the WT
FLAG-tagged protein and all nuclear-localized mutants, but no consistent differences in this
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localization was observed between WT and any mutants. We chose to use a generalized linear
model with Bonferroni correction to allow for us to compare ratios of percent nuclear signal
while accounting for experimental and biological replicates.
Modeling of DNMT3A disease mutations
HEK293T (ATCC, ACS-4500) or Neuro-2a cells (ATCC, CCL-131) were transfected with GFP
and FLAG-tagged WT or mutant mouse DNMT3A plasmids. Collected cell lysates were
ruptured by 3 freeze/thaw cycles using liquid nitrogen, or sonication ~42 hours after transfection.
Samples were then either used for western blotting (Neuro-2a cells), the in vitro radioactive
methyltransferase assay (HEK293T cells).
qRT-PCR
RNA isolated from neuronal cortical culture or mouse brain tissue was reverse transcribed using
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Dnmt3a a nd Actb
were measured by qPCR using the Power SYBR™ Green PCR Master Mix and primers Actb
(F:AAGGCCAACCGTGAAAAGAT, R:GTGGTACGACCAGAGGCATAC) and Dnmt3a
(F:GGCCTTCTCGACTCCAGATG, R:TTCCTCTTCTCAGCTGGCAC). Relative quantity of
Actb and Dnmt3a cDNA was determined by comparing the Ct of each primer set in each sample
to a standard curve and then normalizing the DNMT3A signal by the ACTB signal. We chose to
compare experimental conditions to WT samples using Student’s T-Tests with Bonferroni
correction, as these are two normally distributed groups (visually checked) with similar
variability.
In vitro radioactive methyltransferase assay
30 µl of cell lysate from HEK293T cells was used in the methyltransferase reaction previously
described (Russler-Germain et al., 2014). Lysates were incubated at 37˚C for 20 hours in 5 µl
reaction buffer of 20 mM HEPES, 30 mM NaCl, 0.5 mM DTT, 1 mM EDTA, 0.2 mg/ml BSA, 5
mM 3 H-labeled SAM (PerkinElmer, NET155050UC) and 500 ng/µl Poly(dI-dC) substrate
(Sigma P4929). Substrate was purified (Macherey-Nagel NucleoSpin Gel and PCR Clean-up)
and radioactivity measured using a scintillation counter. In instances where DNMT3A mutant
showed altered protein expression, cell lysate was re-balanced to match protein expression of
WT DNMT3A. The activity of endogenous DNMT3A present in the cells was accounted for by
normalizing values to GFP alone. Only experimental replicates where WT DNMT3A showed a
1.5-fold increase compared to GFP alone were used for subsequent analysis. Outliers beyond 2
standard deviations above or below the mean were removed. Number of independent replicates
are as follows: W297del, 18; I310N, 19; S312fs11x, 4; G532S, 10; M548K, 15; V665L, 11;
Y375C, 13; R749C, 7; P904L, 14. Significance was assessed using a one-sample student’s t-test,
as we are comparing groups normalized to WT and GFP back to the normalized value of 1.
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Viral-mediated DNMT3A replacement assay
Functional activity of DNMT3A mutants in cortical neurons was determined by measuring
methylation build-up in vitro. Timed mating of DNMT3Aflx/flx females and DNMT3Aflx/flx males
was performed to collect embryonic cortical DNMT3Aflx/flx neurons at embryonic day 14.5. At
E14.5, DNMT3Aflx/flx cortical neurons were isolated and plated (DIV 0). On DIV 3, neurons were
either not perturbed or virally transduced with one of three conditions: 1) Cre only, 2) Cre and
WT DNMT3A, or 3) Cre and mutant DNMT3A. DNA and RNA were isolated on DIV 12.5
using the AllPrep DNA/RNA Kit (Qiagen, 80204). DNA was used for whole genome bisulfite
sequencing, and RNA was used for qRT-PCR for DNMT3A. Results of pilot experiments (not
shown) indicate that at this timepoint mCA is not saturated and sensitive to total levels of
DNMT3A activity. Number of independent replicates are as follows: W297del, 5; S312fs11x, 4;
G532S, 7; M548K, 6; V665L, 10; Y375C, 11; R749C, 6; P904L, 8. Buildup of methylation over
development was carried out without performing any viral transduction. Significance was
assessed using a one-sample student’s t-test or 1-way ANOVA.
Ultrasonic vocalization and analysis
A total of 76 DNMT3AKO/+ (n=30, 16 male and 14 female) and litter-matched WT (n=46, 25
male and 21 female) mice were used for ultrasonic pup vocalization (USV) recording and
analyzed as previously described (Barnes et al., 2017; Dougherty et al., 2013; Holy and Guo,
2005). Dams were removed from the nest for a 10-minute acclimation, and individual pups had
their body temperature measured using an infrared laser thermometer. Pups were then removed
from their nest and placed in a dark, enclosed chamber. Ultrasonic vocalizations were recorded
for 3 minutes with an Avisoft UltraSoundGate CM16 microphone and 416H amplifier using
Avisoft Recorder software (gain = 6 dB, 16 bits, sampling rate = 250 kHz). Pups were then
weighed and returned to their nest and littermates. All mice were recorded at postnatal days 5, 7,
and 9, and on either day 11 or 15. Frequency sonograms were prepared and analyzed in
MATLAB (frequency range = 40 kHz to 120 kHz, FFT size = 256, overlap = 50%) with
individual syllables identified and counted according to previously published methods
(Dougherty et al., 2013; Holy and Guo, 2005). Significance was assessed using a within-subjects
repeated measures ANOVA over timepoints 5-9, as these were when there was data from all
experimental subjects, and these are optimal testing times where number of calls was highest.
Marble burying
A total of 27 DNMT3AKO/+ (n=13, 8 male and 5 female) and litter-matched WT (n=14, 7 male
and 7 female) mice were used for marble burying. Marble burying is a natural murine behavior
and has been used to indicate repetitive digging as well as anxiety-related behaviors. Protocol
was adapted from previously published methods (Lazic, 2015; Maloney et al., 2019a). In brief,
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8-week old mice were placed in a transparent enclosure (28.5 cm x 17.5 cm x 12 cm) with clean
aspen bedding and 20 dark blue marbles evenly spaced in a 4 x 5 grid on top of the bedding.
Animals explored freely for 30 minutes. The number of buried marbles were counted every 5
minutes by two independent blinded observers. Marbles were considered “buried” if they were at
least two-thirds covered by bedding. Enclosure and marbles were cleaned thoroughly between
animals. Significance was assessed using a within-subjects repeated measures ANOVA to
determine if rate of burying marbles is different between genotypes. These statistical methods are
more appropriate than a simple t-test at 30 minutes, as mice may have buried all marbles before
this timepoint, and significant changes in marble burying behavior may have occurred at earlier
timepoints in the assay.
Adult behavioral battery
A total of 72 DNMT3AKO/+ (n=39, 18 male and 21 female) and litter-matched WT (n=33, 15
male and 18 female) mice were used for adult behavioral testing. Mice were housed in mixed
genotype home cages with 2-5 animals per cage, and all tests were performed during the light
cycle. All experimenters were blinded to genotype during testing. For increased experimental
rigor and reproducibility, we used three separate cohorts of mice to ensure quality and
consistency in any observed phenotypes.
Testing started when mice were 3-4 months of age. The sequence of behavioral testing
was designed to minimize carry-over effects across behavioral tests. Most assays were performed
on cohorts 1 and 2 with cohort 3 being performed to test for reproducibility in some assays.
Because of differences in testing sequences and exposure of mice to prior tests between cohorts,
we examined separate cohorts individually and looked at combined cohorts. Testing was
performed by the Washington University in St. Louis Animal Behavior Core.
One-hour locomotor activity
Locomotor activity was evaluated by computerized photobeam instrumentation in transparent
polystyrene enclosures (47.6 cm x 25.4 cm x 20.6 cm) as previously described (Wozniak et al.,
2004). Activity variables such as ambulations and vertical rearings were measured in addition to
time spent in a 33 cm x 11 cm central zone.
Sensorimotor battery
Mice were assayed in walking initiation, balance (ledge and platform tests), volitional movement
(pole and inclined screens), and strength (inverted screen) as previously described (Grady et al.,
2006; Wozniak et al., 2004). For the walking initiation test, mice were placed on the surface in
the center of a 21 cm x 21 cm square marked with tape and the time for the mouse to leave the
square was recorded. During the balance tests, the time the mouse remained on an elevated
plexiglass ledge (0.75 cm wide) or small circular wooden platform (3.0 cm in diameter) was
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recorded. During the Pole test, mice were placed at the top of a vertical pole with nose pointing
upwards. The time for the mouse to turn and climb down the pole was recorded. For the inclined
screen tests, a mouse was placed (oriented head-down) in the middle of an elevated mesh grid
measuring 16 squares per 10 cm angled at 60° or 90°. Time for the mouse to turn 180° and climb
to the top was recorded. For the inverted screen test, a mouse was placed on a similar screen and
when the mouse appeared to have a secure grasp of the screen, the screen was inverted 180° and
the latency for the mouse to fall was recorded. All tests had a duration of 60 seconds, except for
the pole test which was 120 seconds. Two separate trials were done on subsequent days and
averaged time of both trials was used for analysis. Data from the walking initiation, ledge, and
platform tests were not normally distributed and therefore analyzed using Mann-Whitney U tests.
Continuous and accelerating rotarod
Motor coordination and balance were assessed using the rotarod test (Rotamex-5, Columbus
Instruments, Columbus, OH) with three conditions: a stationary rod (60-second maximum), a
rotating rod at constant 5 rpm (60-second maximum), and a rod with accelerating rotational
speed (5 – 20 rpm, 180-second maximum) as previously described (Grady et al., 2006). This
protocol is designed to minimize learning and instead measure motor coordination, so testing
sessions were separated by 4 days to allow for extinction. Testing included one trial on stationary
rod, and two trials on both the constant-speed rotarod and accelerating rotarod. Later timepoints
in the constant speed rotarod test failed tests of normality, as the majority of mice stayed on the
rotating rod for all 60 seconds. However, data were analyzed with two-way repeated-measures
ANOVA.
Morris water maze
Spatial learning was assessed as previously described (Wozniak et al., 2004). Cued trials (visible
platform, variable location) and place trials (submerged, hidden platform, consistent location)
were conducted in which escape path latency, length, and swimming speeds were recorded.
Animal tracking was done using a computerized system (ANY-maze, Stoelting). During cued
trials, animals underwent 4 trials per day over 2 consecutive days with the platform being moved
to a different location for each trial with few distal spatial cues available. Each trial lasted no
longer than 60 seconds, with a 30-minute interval between each trial. Performance was analyzed
across four blocks of trials (2 trials/block). After a three-day rest period, animals were tested on
place trials, in which mice were required to learn the single location of a submerged platform
with several salient distal spatial cues. Place trials occurred over 5 consecutive days of training,
with 2 blocks of 2 consecutive trials (60-second trial maximum, 30-second inter-trial-interval
after the mouse has reached the platform) with each block separated by 2 hours. Mice were
released into different quadrants over different trials. Place trials were averaged over each of the
five consecutive days (4 trials/block). One hour after the final block, a probe trial occurred
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(60-second trial maximum) in which the platform is removed, and the mouse is released from the
quadrant opposite where the platform had been located. The time spent in pool quadrants, and
the number of crossings over the exact platform location were recorded. DNMT3AKO/+ mice
showed a small, but significant reduction in target zone time in cohort 2, though there was no
difference in cohort 1. Additionally, female mice had significantly faster swimming speeds than
male mice across both genotypes.
Elevated plus maze
Anxiety-like behaviors were examined using the elevated plus maze as previously described
(Boyle, 2006). The apparatus contains a central platform (5.5 cm x 5.5 cm) with two opposing
open arms and two opposing closed arms (each 36 cm x 6.1 cm x 15 cm) constructed of black
Plexiglas. Mouse position is measured using beam-breaks from pairs of photocells configured in
a 16 x 16 matrix and outputs are recorded using an interface assembly (Kinder Scientific) and
analyzed using software (MotoMonitor, Kinder Scientific) to determine time spent, distance
traveled, and entries made into open arms, closed arms, and the center area. Test sessions were
conducted in a dimly lit room with each session lasting 5 minutes and each mouse tested over 3
consecutive days. Data shown are from day 1. All mice showed a decrease in time, distance, and
entries into open arms on days 2 and 3. There was no significant difference between genotypes in
percent entries into open arms (Figure 3.11K; P=0.137; unpaired Student’s T-Test) or total
entries into arms (data not shown), indicating that both genotypes explored the maze. Percent
distance traveled in open arms showed similar effects to percent time in open arms (Percent
distance traveled: P=0.027; unpaired Student’s T-Test). Analysis of these data in individual
cohorts detected DNMT3AKO/+ significant effects for the percent of open arm time on the first
day in cohorts 1 and 3, with no evidence of an effect in cohort 2. Individual cohorts also showed
no significant difference between genotypes in percent open arm entries suggesting that mice
explored the elevated plus maze sufficiently to detect anxiety-like behaviors.
Acoustic startle/prepulse inhibition
Sensorimotor gating was evaluated as previously described (Dougherty et al., 2013;
Gallitano-Mendel et al., 2008; Hartman et al., 2001). In short, mice were presented with an
acoustic startle response (120 dB auditory stimulus pulse, 40 ms broadband burst) and a
pre-pulse (response to pre-pulse plus startle pulse). Stimulus onset began at 65 seconds, and 1ms
force readings were obtained and averaged to produce an animal’s startle amplitude. 20 startle
trials were presented in 20 minutes. The first 5 minutes were an acclimation period where no
stimuli above the 65 dB background were presented. The session started and finished with 5
consecutive startle (120 dB pulse) trials. The middle 10 trials were interspersed with pre-pulse
trials, consisting of an additional 30 presentations of 120 dB startle stimuli preceded by pre-pulse
stimuli of 4, 12, or 20 dB above background (10 trials for each PPI trial type). To calculate
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percent pre-pulse inhibition, we used %PPI = 100 × (ASRstartle
pulse)/ASRstartle pulse alone.

pulse alone

− ASRprepulse

+ startle

Conditioned fear
Fear conditioning was done as previously described (Maloney et al., 2019a, 2019b). Mice were
habituated to an acrylic chamber (26 cm x 18 cm x 18 cm) containing a metal grid floor and an
odorant and was illuminated by LED light which remained on for the duration of the trial. Day 1
testing lasted 5 minutes in which, after a brief baseline period with no tone, an 80 dB tone
sounded for 20 seconds at trial timepoints 100, 160, and 220 seconds. A 1.0 mA shock
(unconditioned stimulus) occurred within the last 2 seconds of the tone (conditioned stimulus).
Baseline freezing behavior during the first 2 minutes and the freezing behavior during the last 3
minutes was quantified using image analysis (Actimetrics, Evanston, Illinois). On Day 2, testing
lasted for 8 minutes in which the light was illuminated but no tones or shocks were presented. On
Day 3, testing lasted for 10 minutes in which the mouse was placed in an opaque chamber with a
different odorant than the original test chamber. After a brief baseline period with no tone, the 80
dB tone began at 120 seconds and lasted for the remainder of the trial and freezing behavior to
the conditioned auditory stimulus was quantified for the remaining 8 minutes. DNMT3AKO/+
mice show elevated freezing levels during training and testing, which may reflect a baseline
propensity to freeze, stronger fear conditioning, or an emotional hypersensitivity to the
foot-shock. Additionally, our data suggest that the increased freezing in the DNMT3AKO/+ mice
does not appear to be due to an increased pain response, as mutant mice showed similar levels of
shock sensitivity. Evaluation of baseline freezing levels in individual cohorts only showed
significance in one of the two cohorts tested.
3-Chamber social approach
Sociability was assayed as previously described (Moy et al., 2004; Silverman et al., 2011). Mice
were tested in a rectangular all-Plexiglas apparatus (each chamber measuring 19.5 cm x 39 cm x
22cm) divided into three chambers with walls containing rectangular openings (5 cm x 8 cm) and
sliding doors. The apparatus was in a room with indirect light and was cleaned between tests
with Nolvasan solution. Stimulus mice were contained within a small stainless-steel withholding
cage (10 cm height x 10 cm diameter; Galaxy Pencil/Utility Cup, Spectrum Diversified Designs),
allowing minimal contact between mice without allowing fighting. Between tests, withholding
cages were cleaned with 75% ethanol solution. A digital video camera recorded movement of the
mouse within the apparatus and allowed for tracking with ANY-maze (Stoelting). Distance and
time spent in each chamber and investigation zones surrounding the withholding cages were
recorded. Zones were defined as 12 cm in diameter from the center of withholding cages.
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The test sequence consisted of 4 consecutive 10-minute trials in which the test mouse is placed in
the middle chamber and allowed to freely explore the environment. In the first trial, the mouse is
placed in the middle chamber with the doors to other chambers shut. In the second trial, the
mouse is placed in the middle chamber and can explore all three chambers of the task, allowing it
to acclimate to the environment. Neither genotype tested showed a preference towards a side of
the chamber during this habituation. For the third trial, a sex-matched novel conspecific was
placed within a withholding cage with the other cage remaining empty. For the fourth trial, the
same sex-matched conspecific was in one withholding cage, while a new unfamiliar sex-matched
stimulus mouse was placed in the other withholding cage. The locations of stimuli mice were
counterbalanced across groups for the third trial and randomized novel or familiar for the fourth
trial.
Reduced anxiety 3-chamber social approach
An add-on cohort was used to investigate sociability in a low-light environment with minimal
distractions and stressors. A total of 37 DNMT3AKO/+ (n=18, 9 male and 9 female) and
litter-matched WT (n=19, 9 male and 10 female) mice 10-12 weeks of age were used. These
mice had not been used for previous behavioral analysis. Two additional DNMT3A mice were
removed from the cohort prior to analysis, as they appeared sickly and showed reduced
movement. Social approach was carried out as described previously (Manno et al., 2020). In
brief, mice were tested in a rectangular clear acrylic apparatus (60 cm x 40.5 cm) separated into
three equally sized chambers divided by walls with sliding doors (6 cm x 6 cm), and with one
cup placed in each of the edge chambers. The apparatus was in an isolated, quiet room with
minimal sound and low-light (270 lux). Three 10-minute phases were carried out. In the first
phase, the test mouse freely explored all chambers of the apparatus. In the second phase, a
sex-matched conspecific mouse was added to the one of the cups in the side chambers, and the
test mouse was allowed to freely explore. In the third phase, a sex-matched novel conspecific
was added to the remaining empty cup and the test mouse was allowed to explore. Between
experimental mice, the apparatus was cleaned with 70% ethanol. A digital video camera
recorded the sessions and mouse location was measured. For analysis, only the first 5 minutes of
each phase was used, as mice rapidly habituate to this task (Manno et al., 2020).
Statistical analysis for behavioral tests
Behavioral data were analyzed with R v3.3.2 (including the ANOVA function from the Car
package in R (Fox and Weisberg, 2011)) and plots were made using GraphPad Prism 7.03a.
Normality was assessed using the Shapiro-Wilkes test and visually confirmed. Data not normally
distributed were analyzed using non-parametric tests, with the exception of continuous rotarod
data. No consistent genotype by sex interaction effects were observed for any tests. As expected,
bodyweights were significantly different between males and females and we therefore presented
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this data separated by sex. Data were collapsed across sex for presentation across all other tests.
Statistical testing was performed using planned assay-specific methods, such as using Student’s
T-Tests for single parameter comparisons between genotypes, and within-subjects two-way
repeated-measures ANOVA for comparisons across timepoints. Individual timepoints within
repeated measures tests were evaluated using Sidak’s multiple comparisons test. Individual
cohorts were analyzed separately and in aggregate with similar trends seen across cohorts
(Supplementary Table 5), therefore data from all cohorts were included together.
Tissue collection
Brain tissue was dissected from DNMT3AKO/+ and WT littermate mice in ice-cold PBS,
flash-frozen in liquid nitrogen, and stored at -80°C.
Western blotting
Western blotting from cell culture. Neuro-2a cells were collected and combined with 2x laemmli
buffer with 5% β-mercaptoethanol. Samples were passed through a Wizard Column (Fisher,
Wizard Minipreps Mini Columns, PRA7211), boiled for 5 minutes, and run on a BioRad 4-12%
acrylamide gel at 125 V for 60 minutes. Samples were then transferred to a nitrocellulose
membrane, which was bisected between 37kDa and 50kDa bands. Membranes were blocked
with 3% bovine serum albumin in TBS-T for 1 hour at room temperature and then the lower
membrane was immunostained with anti-GFP (ThermoFisher, 1:2000, A-11122) while the upper
membrane was immunostained with anti-DDDDK (Abcam, 1:1000, ab1162) for 12-16 hours at
4°C. All primary and secondary antibodies were diluted in 3% Bovine Serum Albumin in
TBS-T. Membranes were next washed with TBS-T, and then incubated for 1 hour at room
temperature with IR-dye secondary antibody (IRDye 800CW Donkey anti-Rabbit, LI-COR
Biosciences, 1:15,000, product number: 926-32213). Blots were then washed with PBS, imaged
using the LiCOR Odyssey XCL system, and quantified using Image Studio Lite software
(LI-COR Biosciences). FLAG (DDDDK) and GFP levels were normalized to a standard curve,
and protein levels are expressed as normalized DDDDK values divided by normalized GFP
values to enable comparison of FLAG (DDDDK) levels between blots. Each blot included a
standard curve and WT samples. Outliers beyond 2 standard deviations above or below the mean
were removed. Number of independent replicates are as follows: WT, 29; W297del, 7; I310N, 7;
S312fs11x, 12; G532S, 7; M548K, 9; V665L, 7; Y375C, 8; R749C, 6; P904L, 7. Significance
was assessed using a one sample Student’s T-Test, as protein expression levels were normalized
to GFP and WT, and mutant protein expression was compared to the normalized WT value of 1.
Western blotting from tissue. Brain tissue samples were homogenized with a dounce
homogenizer in buffer with protease inhibitors (10mM HEPES pH 7.9, 10mM KCl, 1.5mM
MgCl2, 1mM DTT, 10mM EDTA). A portion of the lysate was removed and 1% SDS was
118

added. Samples were boiled for 10 minutes, followed by a 10-minute spin at 15,000g.
Supernatant was collected and run through a Wizard Column (Fisher, Wizard Minipreps Mini
Columns, PRA7211), then diluted in LDS sample buffer with 5% β-mercaptoethanol. Samples
were boiled for 5 minutes, run on an 8% acrylamide gel for 60 minutes at 125 V, and transferred
to a nitrocellulose membrane. Membrane was bisected between 75kDa and 100kDa. Membranes
were blocked with 3% bovine serum albumin in TBS-T for 1 hour at room temperature, and the
upper membrane was immunostained with anti-DNMT3A (Abcam, 1:1000, ab13888) while the
lower membrane was immunostained with anti-α-Tubulin (Abcam, 1:1000, ab52866) for 12-16
hours at 4°C. All primary and secondary antibodies were diluted in 3% Bovine Serum Albumin
in TBS-T. Membranes were next washed with TBS-T, and then incubated for 1 hour at room
temperature with IR-dye secondary antibody (IRDye 800CW Goat anti-Rabbit, or IRDye
800CW Goat anti-Mouse, LI-COR Biosciences, 1:15,000, product numbers: 926-32211 and
926-32210 respectively). Blots were then washed with PBS, imaged using the LiCOR Odyssey
XCL system, and quantified using Image Studio Lite software (LI-COR Biosciences). DNMT3A
and α-Tubulin levels were normalized to a standard curve, and protein levels are expressed as
normalized DNMT3A values divided by normalized α-Tubulin values to enable comparison of
DNMT3A levels between blots. For brain region analysis, sample sizes of n=4 per genotype (2
male and 2 female pairs) were used. For time course analysis, sample sizes of n=2 per genotype
(1 male and 1 female pairs) were used for all time points except the 2-week timepoint in which
n=6 (3 male and 3 female pairs) was used. Significance was assessed using a Student’s T-Test
for brain regions, and a two-way ANOVA considering genotype and time to determine if there
was a detectable difference in protein expression over development.
Bisulfite sequencing
Whole genome bisulfite sequencing from cortical cultures. Samples were chosen for whole
genome bisulfite sequencing if mutant and WT samples expressed equal amounts of Dnmt3a
mRNA as measured by qRT-PCR (Figure 3.8F). DNA from cortical cultures was bisulfite
converted and prepared for sequencing using the Tecan Ovation Ultralow Methyl-Seq Kit
(Tecan, 0335-32) and the Epitect Bisulfite Kit (Qiagen, 59824) was used for bisulfite conversion.
We used alternate bisulfite conversion cycling conditions ([95°C, 5 min; 60°C, 20 min] x 4
cycles, 20°C hold) to ensure lowest possible bisulfite non-conversion rate. Libraries were
PCR-amplified for 10-11 cycles. Libraries were then pooled and sequenced at a depth of
0.01-0.03x genomic coverage using an Illumina MiSeq 2x150 through the Spike-In Cooperative
at Washington University in St. Louis. Significance was assessed using a one-sample student’s
t-test, as we are comparing groups normalized to WT and GFP back to the normalized value of 1.
Whole genome bisulfite sequencing from tissue. DNA was isolated from tissue using the DNEasy
Kit (Qiagen). 300 ng of DNA was prepared for sequencing using the Ovation Ultralow
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Methyl-Seq Kit (Tecan, 0335-32) with and the Epitect Bisulfite Kit (Qiagen, 59824) was used
for bisulfite conversion. For these samples, 300 ng of DNA was fragmented for 45 seconds with
the Covaris E220 sonicator (10% Duty Factory, 175 Peak Incidence Power, 200 cycles per burst,
milliTUBE 200µL AFA Fiber). DNA was then purified using 0.7 volumes of Agencourt Beads
to select for long DNA inserts for sequencing. We used alternate bisulfite conversion cycling
conditions ([95°C, 5 min; 60°C, 20 min] x 4 cycles, 20°C hold) to ensure lowest possible
bisulfite non-conversion rate. Libraries were PCR-amplified for 12 cycles. Libraries were then
pooled and sequenced using an Illumina MiSeq 2x150 through the Spike-In Cooperative at
Washington University in St. Louis. Samples for shallow-depth sequencing (Figure 3.4A,B)
were sequenced at 0.01-0.03x genomic coverage. For brain region and liver methylation, n=2 per
genotype per region (one male pair, one female pair). For developmental time course
methylation, n=3-4 per genotype per timepoint, with at least one male and one female pair.
8-week cortex samples for deep sequencing (Figure 3.5, Figure 3.6A-D, Figure 3.13D-H) were
sequenced at 25-27x coverage per genotype using two male and two female WT-DNMT3AKO/+
pairs (n=4 per genotype). Samples were sequenced either using the HiSeq 3000 or NextSeq 500
at 2x150 or 1x150, respectively. For shallow sequencing experiments, significance was assessed
using either a two-sample Student’s T-Test to compare global methylation values of the cortex
between two genotypes or using a two-way ANOVA to compare broad methylation changes
across a variety of brain regions or timepoints. Genomic element comparisons were done using
two-sample Student’s T-Tests with Bonferroni correction.
Oxidative bisulfite sequencing from tissue. DNA was isolated from tissue using the DNEasy Kit
(Qiagen, 69504). 450 ng of DNA was prepared for sequencing using the Ovation Ultralow
Methyl-Seq Kit (Tecan, 0335-32) with TrueMethyl oxBS plugin (Tecan, 0414-32). For these
samples, 450 ng of DNA was fragmented for 45 seconds with the Covaris E220 sonicator (10%
Duty Factory, 175 Peak Incidence Power, 200 cycles per burst, milliTUBE 200µL AFA Fiber).
DNA was then purified using 0.7 volumes of Agencourt Beads to select for long DNA inserts for
sequencing. 2/3 of the sample (~300 ng of DNA) was used for OxBS libraries, whereas the
remaining 1/3 (~150 ng of DNA) was used for bisulfite libraries. We used alternate bisulfite
conversion cycling conditions ([95°C, 5 min; 60°C, 20 min] x 2 cycles; 95°C, 5 min; 60°C, 40
min; 95°C, 5 min; 60°C, 45 min; 20°C hold) to ensure lowest possible bisulfite non-conversion
rate. Bisulfite and oxidative bisulfite libraries were PCR-amplified for 11 and 13 cycles
respectively. Libraries were then pooled and sequenced using an Illumina MiSeq 2x150 through
the Spike-In Cooperative at Washington University in St. Louis. Samples were sequenced at
0.8-2.2x genomic coverage per replicate (two male replicates per genotype). Genomic element
comparisons were done using two-sample Student’s T-Tests with Bonferroni correction.
Whole-genome bisulfite analysis
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Bisulfite sequencing analysis was performed as previously described (Clemens et al., 2019).
Briefly, data were adapter-trimmed, mapped to mm9, then deduplicated and called for
methylation using BS-seeker2. Methylation levels across regions were assessed using bedtools
map -o sum, summing the number of reads mapping to Cs (supporting mC) and the amount of
coverage in the region, then dividing those two numbers (Quinlan and Hall, 2010).
Hydroxymethylation was calculated as the percent methylation found in the BS-seq minus the
percent methylation found in the matching oxBS-seq. Due to count noise, this occasionally
resulted in apparent negative hydroxymethylation. During bisulfite sequencing not all DNA can
be efficiently bisulfite converted. Though our methods should maximize the amount of converted
unmethylated C, there is still a small percentage of unmethylated cytosines that are called as
methylated due to non-conversion (0.2-0.3%). Due to this non-conversion, very lowly
methylated regions (e.g. mCA at CpG islands) may not show the same percent reduction in mCA
as highly methylated regions. Data were visualized using the UCSC genome browser
(http://genome.ucsc.edu) (Kent et al., 2002). CpG islands were obtained from the UCSC table
browser (Haeussler et al., 2019), and CpG Shores were defined as the 8kb surrounding them.
Average methylation per-sample is normally distributed in all regions examined, and variance
between genotypes is similar, fitting the assumptions of a 2-sample t-test. Methylation levels for
individual elements are not necessarily normally distributed, so non-parametric tests were used
instead. This approach to mirrors multiple other studies quantifying mCA levels across the
genome (Lister et al., 2013; Luo et al., 2017) where de novo calling of basepair resolution mCA
DMRs is avoided due to low statistical power because of low mCA/CA levels at any individual
site, and instead focuses on quantification of mCA/CA levels in populations of pre-defined
regions of known functional importance.
Differentially methylated region detection
BSmooth (Hansen et al., 2012) was used to call differentially CpG methylated regions between
DNMT3AKO/+ and WT mice, using four biological replicates. CG sites were filtered for requiring
at least 2x coverage in all replicates and differentially methylated regions were called with a
statistical threshold of t-stat >2.0. These regions were further filtered for a length >100 bp and a
requirement that the smoothed per-rep methylation values were consistent. For hypomethylated
regions all WT mCG/CG values needed to be greater than any KO mCG/CG value, and for
hypermethylated regions all KO methylation values needed to be higher than all WT methylation
values. Data fit the assumptions and requirements of BSmooth. Data were distributed evenly
between chromosomes, and the overlap between DMRs and regions of interest fit a
hypergeometric distribution, making a fisher's exact test appropriate. In order to calculate an
expected overlap of DMRs and genomic regions, for each chromosome, an equal number of
resampled DMRs were placed, at random throughout the chromosome, as true DMRs, ensuring
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that the two do not overlap. From this, the overlap of genomic regions with resampled DMRs
was compared to the same overlap with true DMRs.
RNA sequencing
Total RNA isolation was carried out as previously described (Clemens et al., 2019). In brief,
cerebral cortex was dissected in ice-cold PBS from DNMT3AKO/+ and WT littermates at 8 weeks
of age (n=7 pairs, 3 male, 4 female). Cortex was lysed in RLT buffer following the RNeasy Mini
Kit (Qiagen, 74104). RNA libraries were generated from 250 ng of RNA with NEBNext Ultra
Directional RNA Library Prep Kit for Illumina (NEB) using a modified amplification protocol
(37°C, 15 minutes; 98°C, 30 seconds; [98°C, 10 seconds; 65°C, 30 seconds; 72°C, 30
seconds]x13; 72°C, 5 minutes; 4°C hold). RNA libraries were sequenced using Illumina
HiSeq3000 1x50bp with the Genome Technology Access Center at Washington University in St.
Louis, typically yielding 15-30 million single-end reads per sample.
RNA sequencing analysis
RNA sequencing analysis was performed as previously described (Clemens et al., 2019). Briefly,
raw FASTQ files were trimmed with Trim Galore and rRNA sequences were filtered out with
Bowtie. Remaining reads were aligned to mm9 using STAR (Dobin et al., 2013) with the default
parameters. Reads mapping to multiple regions in the genome were then filtered out, and
uniquely mapping reads were converted to BED files and separated into intronic and exonic
reads. Finally, reads were assigned to genes using bedtools coverage -counts (Quinlan and Hall,
2010).
For gene annotation we defined a "flattened" list of longest transcript forms for each gene,
generated on Ensgene annotations and obtained from the UCSC table browser. For each gene,
Ensembl IDs were matched up to MGI gene names. Then, for each unique MGI gene name, the
most upstream Ensgene TSS and the most downstream TES were taken as that gene's start and
stop. Based on these Ensembl gene models, we defined TSS regions and gene bodies.
Differentially expressed genes were identified using a Wald test through DESeq2, running using
default parameters on exonic reads from the DNMT3AKO/+ and WT.
To assess effects on other noncoding RNAs in the DNMT3AKO/+ strain, we realigned our
RNA-seq data to all mouse noncoding RNAs from RNAcentral (The RNAcentral Consortium
2019, Nucleic Acids Res.) , then ran DESeq2 on the counts from each noncoding transcript.
Chromatin immunoprecipitation protocol
Chromatin immunoprecipitation was performed as previously described (Clemens et al., 2019;
Cohen et al., 2011). Cerebral cortex was dissected on ice in PBS from DNMT3AKO/+ and WT
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littermates at 8-weeks old (n=5 pairs, 3 male, 2 female). The tissue was flash-frozen in liquid
nitrogen and stored at -80°C. Chromatin was fragmented with the Covaris E220 sonicator (5%
Duty Factory, 140 Peak Incidence Power, 200 cycles per burst, milliTUBE 1mL AFA Fiber).
ChIP was performed with H3K27ac antibody (0.025-0.1µg; Abcam, ab4729) and libraries were
generated using Ovation Ultralow Library System V2 (Tecan, 0344NB-32). Libraries were
sequenced using Illumina HiSeq 3000 with the Genome Technology Access Center at
Washington University in St. Louis, typically yielding 15-40 million single-end reads per
sample.
Chromatin immunoprecipitation analysis
ChIP sequencing analysis was performed as previously described (Clemens et al., 2019). Briefly,
reads were mapped to mm9 using bowtie2 and reads were extended based on library sizes and
deduplicated. Bedtools coverage –counts was used to quantify ChIP signal at the transcriptional
start site (TSS), gene body (GB), and transcriptional end site (TES) (Quinlan and Hall, 2010).
edgeR was then used to determine differential ChIP-signal across genotypes. Data were
visualized using the UCSC genome browser (http://genome.ucsc.edu) (Kent et al., 2002).
Controlled resampling
A similar resampling approach was used as previously described (Clemens et al., 2019). Briefly,
for every entry in a sample set (e.g. DNMT3A-dysregulated genes), an entry in the control set
(e.g. all other genes) with a similar desired characteristic (e.g. expression) was selected,
generating a control set of the same size and variable distribution as the sample set.
Identification of dysregulated enhancers
Enhancer regions from Clemens et al. 2019 were used, and enhancers dysregulated in the
DNMT3AKO/+ were called using the same method. Briefly, H3K27ac ChIP-seq reads were
quantified in all acetyl peak regions, and edgeR was used to identify peaks with significantly
different amounts of H3K27ac signal. Peak regions were then divided into promoters, enhancers,
and non-identified peaks. Data fits the assumptions of BSmooth. Overlap between misregulated
enhancers in different genotypes fit a hypergeometric distribution.
GAGE
Gene set enrichment analysis for the gene sets described was performed using the Generally
Applicable Gene-set Enrichment (GAGE) program (Luo et al., 2009). The NDD models for
comparison were chosen by searching for gene expression datasets meeting the following
criteria: 1) NDD/ASD models that have at least some similar features to DNMT3A disorders
(e.g. ID, ASD) 2) generated with the RNA-seq approach 3) analyzed brain tissue with enough
similarity to our cortical analysis to justify a reasonable comparison. Analysis was performed
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directionally on the shrunken, log-normalized exonic fold changes from DESeq2 analysis of
DNMT3AKO/+ versus WT RNA-seq data. For each gene set, fold changes of genes in that set
were compared to a background of all expressed genes. Gene sets with an FDR q-value below
0.1 and an adjusted p-value below 0.5 following expression matched resampling repeated 1,000
times were considered statistically significant. Gene sets were selected for analysis from both
human and mouse studies of autism associated genes. SFARI genes (Abrahams et al., 2013) with
scores of equal to or less than 3 were considered. Date accessed: 6/20/2019.
GSEA
Gene Set Enrichment Analysis (GSEA) (version 7.0, the Broad Institute of MIT and
Harvard, http://software.broadinstitute.org/gsea/downloads.jsp) was performed on shrunken,
log-normalized exonic fold changes from DESeq2 between DNMT3AKO+ and WT RNA-seq
data. GSEA calculated a gene set Enrichment Score (ES) that analyzed genes were enriched in
the
biological
signal
conduction
on
the
MsigDB
(Molecular
Signatures
Database, http://software.broadinstitute.org/gsea/msigdb). Background was set to all expressed
genes in this study and 1,000 permutations were set to generate a null distribution for enrichment
score in the hallmark gene sets and functional annotation gene sets. The gene sets database used
for enrichment analysis were ‘c5.all.v7.0.symbols.gmt’, ‘c5.bp.v7.0.symbols.gmt’,
‘c5.cc.v7.0.symbols.gmt’and ‘c5.mf.v7.0.symbols.gmt’ and FDR <0.1 was defined as the cut-off
criteria for significance.
Craniofacial morphological analyses
A total of 24 sex-matched littermate paired mice (DNMT3AKO/+ n=12, 7 male, 5 female; WT
n=12, 7 male, 5 female) across 3 time-points (8 weeks DNMT3AKO/+ n=4, WT n=4; 20 weeks
DNMT3AKO/+ n=4, WT n=4; 25 weeks DNMT3AKO/+ n=4, WT n=4) were fixed in 4%
paraformaldehyde through intracardiac perfusion. Whole mouse heads were scanned at the
Musculoskeletal Research Center at Washington University in St. Louis using a Scanco µCT40
machine. CT images had voxel dimensions of 0.018 millimeters and were reconstructed on a
2048x2048 pixel grid. The CT images were converted to 8bit images using ImageJ
(https://imagej.nih.gov/ij/) and surface reconstructions were acquired in Avizo
(http://www.vsg3d.com/). Thirty-five three-dimensional landmarks were collected from surface
reconstructions of
the cranium
and mandible using Stratovan Checkpoint
(https://www.stratovan.com/products/checkpoint).
Generalized Procrustes Analysis in MorphoJ software was used to explore the differences and
similarities of shape between the DNMT3AKO/+ mice and their WT littermates as previously
described (Hill et al., 2013). To control for possible differences in size, the landmark coordinate
data were natural log-transformed and analyzed with a linear regression model. Additionally, to
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localize differences in form to specific linear distances, landmark data were analyzed using
Euclidean Distance Matrix Analysis (EDMA).
Bone length measurements
We chose to quantify long bones that may directly relate to the height phenotype seen in patients.
A total of 24 sex-matched littermate paired mice (DNMT3AKO/+ n=12, 7 male, 5 female; WT
n=12, 7 male, 5 female) across 3 time-points (8 weeks DNMT3AKO/+ n=4, WT n=4; 20 weeks
DNMT3AKO/+ n=4, WT n=4; 25 weeks DNMT3AKO/+ n=4, WT n=4) were fixed in 4%
paraformaldehyde through intracardiac perfusion. Decapitated mouse bodies were scanned at the
Musculoskeletal Research Center at Washington University in St. Louis using a Faxitron Model
UltraFocus100 Dual X-Ray machine. Bone lengths were measured using ImageJ. Data were
taken over three age time-points: 8 weeks, 20 weeks, and 25 weeks of age for male and female
mice. There was no significant difference in bone lengths based upon sex, but there was a
difference based by age. To normalize for this age effect, data were expressed as DNMT3AKO/+
bone lengths normalized to the WT lengths within groups. This also mirrors how human data are
presented. Left and right bones were measured and the larger was used for analysis.
Experimental design
Authenticated cell lines from ATCC (HEK293T, NEURO-2A) were used, and no mycoplasma
contamination testing was needed. Sample sizes were chosen based upon previously published
studies using similar techniques. Statistical tests and exclusion criteria (values beyond 2 standard
deviations of the group mean) were similar to that of previously published studies and indicated
in the appropriate methods. For all animal experiments, experimenters were blinded to genotype
during data collection. No treatment conditions were used, so no samples or animals were
allocated to experimental groups and no randomization was needed. Tests that assume equal
variance were only run if group variances were similar, otherwise alternative tests were used.
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3.8

Figures

Figure 3.1. Disease-associated DNMT3A mutations disrupt distinct aspects of protein
function.
A. Schematic of human DNMT3A protein showing canonical domains and
disease-associated mutations (Sanders et al., 2015; Tatton-Brown et al., 2018) that were
tested in this study.
B. Example immunoblot of DNMT3A mutant protein expression in Neuro-2a cells.
C. Example images of DNMT3A protein immunocytochemistry from wild type and PWWP
domain mutant in Neuro-2a cells. Scale bar = 20μm.
D. Quantification of DNMT3A mutant protein localization (n=6-16 images; Generalized
Linear Model test of percent nuclear expression per image for mutants compared to WT
with Bonferroni correction).
E. Schematic of in vitro methylation assay for DNMT3A mutant proteins isolated from
HEK293T cells.
F. Activity of DNMT3A mutant proteins in the in vitro methylation assay normalized to WT
DNMT3A (set equal to 1) and GFP-only (set equal to 0) controls. (n=4-19; one-sample
Student’s T-Test with Bonferroni correction).
*, P<0.05; **, P<
 0.01; ***, P<
 0.001; #, P<0.0001. Bar graphs indicate mean and SEM.
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Figure 3.2. Disease-associated DNMT3A mutations prevent buildup of neuronal CA
methylation.
A. Schematic of DNMT3A functional analysis in primary culture neurons. Cortical neurons
are harvested from DNMT3Aflx/flx mice at E14.5 and cultured. After 3 days in vitro (DIV),
neurons are virally transduced with Cre recombinase and WT or mutant FLAG-tagged
DNMT3A. On DIV 12.5, DNA and RNA are collected. Equal DNMT3A mRNA
expression is verified by qRT-PCR (Figure S1F) and DNA is used for whole genome
bisulfite sequencing analysis.
B. Relative mCA amount compared to Cre only (set equal to 0) and Cre+WT DNMT3A (set
equal to 1) controls (n=4-11; one-sample Student’s T-Test with Bonferroni correction).
*, P<0.05; **, P<
 0.01; ***, P<
 0.001; #, P<0.0001. Bar graphs indicate mean and SEM.
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Figure 3.3. Heterozygous disruption of DNMT3A in vivo leads to growth and behavioral
alterations.
A. Body weight of DNMT3AKO/+ and WT mice at three developmental timepoints (Male
P=0.038 genotype by age interaction effect, F(2,50)=3.494, n=6-18; Female P=
 0.0032
genotype by age interaction effect, F(2,48)=6.498; Female P=
 0.0016 genotype effect,
F(1,48)=11.18, n=5-17; two-way ANOVA).
B. Lengths of femur and tibia bones measured by dual X-ray imaging shown as standard
deviations from the WT mean for the DNMT3AKO/+ mice (n=12; paired Student’s
T-Test).
C. Total ambulations during 1-hour open-field testing, split into 10-minute bins (P=
 0.0008
effect by genotype, F(1,46)=13.02, n=21,27; two-way repeated-measures ANOVA with
Sidak’s multiple comparison test).
D. Number of rearing events during 1-hour open-field testing, split into 10-minute bins
(P=
 0.0103 effect by genotype, F(1,46)=7.161, n=21,27; two-way repeated-measures
ANOVA with Sidak’s multiple comparison test).
E. Total time spent in the center zone of field during open-field testing (P=
 0.0075, n=21,27;
unpaired Student’s T-Test).
F. Percent of time mice spent in the open arms compared to all arms during first day of
elevated-plus maze testing (P=0.0069; n=33,39; unpaired Student’s T-Test).
G-I. Percent time spent freezing in
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G. Conditioned fear training (Baseline: P=0.0071 effect by genotype, F(1,50)=7.897; Cue:
P=0.0013 effect by genotype, F(1,50)=11.7; n=26; two-way repeated-measures ANOVA
with Sidak’s multiple comparisons test),
H. contextual fear trials (P=
 0.0215, n=26; unpaired Student’s T-Test), and
I. cued fear trials (Before Cue: P=0.0606; After Cue: P=0 .00014; n=26; unpaired Student’s
T-Test).
J. Quantification of marbles buried during 30 minutes of testing split into 5-minute bins
(P=
 0.0374 effect by genotype, F(1,25)=4.834, n=14,13; two-way repeated-measures
ANOVA with Sidak’s multiple comparison test).
K. Number of ultrasonic calls from pup isolated from the nest for 3-minute testing at
indicated developmental time points; P=
 0.0378 effect by genotype, F(1,285)=4.355, n=9-46;
two-way ANOVA with Sidak’s multiple comparisons test.
*, P<0.05; **, P<
 0.01; ***, P<
 0.001; ****, P<0.0001. Box plots contain 10th-90th percentiles of
data, with remaining data represented as individual points. Line graphs and bar graphs indicate
mean and SEM.

137

Figure 3.4. Global DNA methylation levels upon heterozygous loss of DNMT3A.
A. Global mCG levels in DNA isolated from brain regions of 8-week old mice (left)
(unpaired Student’s T-Test with Bonferroni correction), and developmental time course
of global mCG in the cerebral cortex (right), as measured by sparse whole genome
bisulfite sequencing (WGBS).
B. Global mCA levels in DNA isolated from brain regions of 8-week old mice (left)
(unpaired Student’s T-Test with Bonferroni correction), and developmental time course
of global mCA in the cerebral cortex (right), as measured by sparse WGBS (P<0.0001
effect by genotype, F(1,27)=1024; P<
 0.0001 effect by age F(5,27)=884.6; n=3-4; two-way
ANOVA).
Bonferroni corrected P-values indicated along the X-axis. *, P<
 0.05; ***, P<
 0.001. Line graphs
indicate mean and SEM.
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Figure 3.5. High-resolution analysis of DNA methylation changes in the DNMT3AKO/+
cerebral cortex.
A. Genome browser views of mCA and mCG in WT and DNMT3AKO/+ cerebral cortex as
measured by high-depth WGBS. Broad view showing global reduction in mCA (left).
Grey dashed line in mCA plots to facilitate visual comparison of global mCA levels
between genotypes. Zoomed-in view of a DNMT3AKO/+ CG-hypo-DMR that overlaps an
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enhancer (center) and a DNMT3AKO/+ CG-hypo-DMR at a CpG-island shore that overlaps
with an adult-specific DMR (right). WT H3K27ac ChIP-seq signal (Clemens et al.,
2019), peaks of enhancer-associated H3K4me1 (Stamatoyannopoulos et al., 2012), peaks
of promoter-associated H3K4me3 (Stamatoyannopoulos et al., 2012), CpG islands, and
gene annotations (Haeussler et al., 2019) are shown below to illustrate overlap between
DMRs and functional elements in the genome.
B,C.Overlay of mCG signal for DMR regions shown in A.
D. Violin plot of mCG/CG level (top) and percent reduction, (DNMT3AKO/+-WT)/WT,
(bottom) in WT and DNMT3AKO/+ cerebral cortex across indicated classes of genomic
regions. Mean mCG/CG levels per-replicate are overlaid as dots on the violin plot. (n=4
per genotype; paired Student’s T-Test with Bonferroni correction).
E.

Heat map of CG DMRs called in the DNMT3AKO/+ cortex. Biological replicates (B1-B4)
are indicated.

F.

Observed and background (from resampled DMRs, see methods) overlap between
DNMT3AKO/+ cortex CG-DMRs and various genomic regions (Fisher’s Exact Test).

G. Violin plot of mCA/CA level (top) and percent reduction, (DNMT3AKO/+-WT)/WT,
(bottom) in WT and DNMT3AKO/+ cerebral cortex across indicated classes of genomic
regions. Mean mCA/CA levels per-replicate are overlaid as dots on the violin plot. (n=4;
paired Student’s T-Test with Bonferroni correction).
*, P<0.05; **, P<
 0.01; ***, P<
 0.001; ****, P<0.0001. Bar graphs indicate mean and SEM
across biological replicates.
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Figure 3.6. DNMT3AKO/+ enhancer dysregulation and transcriptomic pathology overlaps
with MeCP2 mutants.
A. Genome browser view of DNA methylation and H3K27ac ChIP-seq data from WT and
DNMT3AKO/+ cerebral cortex (top). Overlaid H3K27ac signal and mCA/CA levels at
enhancer regions highlighted in blue that were identified as dysregulated enhancers upon
disruption of mCA or MeCP2 (Clemens et al., 2019) (bottom).
B. Mean mCA sites/kb in WT and DNMT3AKO/+ cortex (top) and number of mCA sites/kb
lost in the DNMT3AKO/+ cortex (bottom) for enhancers significantly dysregulated in
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MeCP2 mutants (**, P<0.01; ***, P<0.001; n=4; paired Student’s T-Test with
Bonferroni correction).
C. Boxplot of fold-change in H3K27ac signal in DNMT3A Baf53b- cKO and the
DNMT3AKO/+ cortex for enhancers defined as significantly dysregulated in MeCP2
mutants (***, P<
 10-8; **** P<
 10-12; n=5 biological replicates of DNMT3AKO/+ and WT;
Wilcoxon test).
D. Heatmap of changes in H3K27ac signal for indicated mutants across deciles of enhancers
sorted by wild-type mCA or mCG sites/kb (P<
 2.2e-16, DNMT3AKO/+ mCA/kb; P<
 2.2e-16,
DNMT3AKO/+ mCG/kb; Spearman Rho correlation).
E. Observed versus background (estimated by resampling, see methods) overlap of
significantly dysregulated genes (padj. < 0.1) in the DNMT3AKO/+ and genes dysregulated
in DNMT3A Baf53b-cKO or MeCP2 mutant mice (***, P<
 e-5; ****, P<
 e-10;
hypergeometric test).
F. Significance of gene set expression changes in the indicated direction in the
DNMT3AKO/+ cortex for GAGE analysis of gene sets identified as dysregulated in
DNMT3A Baf53b- cKO or MeCP2 mutant mice (Clemens et al., 2019).
Note: legend is shared in B and C. Box plots indicate median and quartiles. Bar graphs indicate
mean and SEM.
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Figure 3.7. Gene dysregulation in the DNMT3AKO/+ overlaps with other ASD/NDD
disorders.
A. GAGE analysis of expression changes in DNMT3AKO/+ for dysregulated gene sets
identified in studies of NDD mouse models (Gompers et al., 2017; Katayama et al., 2016;
Sessa et al., 2019; Tilot et al., 2016) (n=7 biological replicates of DNMT3AKO/+ and WT).
B. GAGE analysis of expression changes in DNMT3AKO/+ for gene sets identified in studies

of human ASD. ASD module 12 (synaptic) and 16 (immune) were previously identified
in weighted-gene coexpression analysis of human ASD brain (Voineagu et al., 2011), and
ASD-dysregulated genes were previously identified (Abrahams et al., 2013; Gandal et al.,
2018).
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Figure 3.8 Related to Figures 3.1 and 3.2.
A. Example images of DNMT3A mutant protein immunocytochemistry in Neuro-2a cells.
Scale bar = 20μm.
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B. Full example immunoblot from Figure 1B with the truncated S312fs11x DNMT3A
mutant protein indicated with an asterisk.
C. Quantification of immunoblot signal of DNMT3A (α-FLAG) from mutant proteins
(n=6-30; unpaired Student’s T-Test with Bonferroni correction). Though PWWP mutants
show reduced protein expression, the remaining protein expression was adequate to
assess cellular localization.
D. Genome wide mCA levels over time in WT neuronal cortical cultures, as measured by
sparse WGBS (P=
 0.0035 effect by time, F(3,4)=29.45, n=2; one-way ANOVA).
E. Genome-wide mCA levels in DNMT3A mutant add-back cortical cultures at DIV 12.5
(n=7-11; unpaired Student’s T-Tests with Bonferroni correction).
F. qRT-PCR of Dnmt3a normalized to Actb for samples analyzed by WGBS. (n=4-11;
one-sample Student’s T-Test with Bonferroni correction).
G. Genome wide mCG levels over time in neuronal cortical cultures, as measured by sparse
WGBS (P>0.05 effect by time, F(3,4)=2.722, n=2; one-way ANOVA).
H. Genome-wide mCG levels in DNMT3A mutant add-back cortical cultures at DIV 12.5
(P>
 0.05; n=7-11; planned unpaired Student’s T-Tests with Bonferroni correction).
***, P<0.001; ****, P<
 0.0001. Bar graphs indicate mean and SEM. Box plots contain 10th-90th
percentiles of data, with remaining data represented as individual points.
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Figure 3.9 Related to Figures 3.3,3.4,3.5,3.6 and 3.7.
A. Normalized Dnmt3a mRNA and protein expression from 2-week cortices of
DNMT3AKO/+ and wild-type littermates (mRNA n=5, protein n=4, unpaired Student’s
T-Test).
B. Protein expression of DNMT3A normalized to α-Tubulin measured by western blotting
for cerebral cortex of DNMT3AKO/+ and wild-type littermates over developmental time
(P=
 0.0157 effect by genotype, F(1,16)=7.303, n=2-5; two-way ANOVA).
C. Protein expression of DNMT3A normalized to α-Tubulin measured by western blotting
for hippocampus, striatum, and cerebellum (P=
 0.0010 effect by genotype, F(1,18)=15.48,
n=4; two-way ANOVA).
*, P<0.05; ****, P<
 0.0001. Line plots indicate mean and SEM. Box plots contain 10th-90th
percentiles of data, with remaining data represented as individual points.

146

Figure 3.10 Related to Figure 3.3.
A,B Measurements of A femur and B tibia by dual x-ray imaging in WT and DNMT3AKO/+
mice at 8, 20, and 25 weeks of age. Lines indicate mean and SEM, with points indicating
individual animals.
C
Standard deviations from WT mean for DNMT3AKO/+ sum of femur and tibia. (n=12;
paired Student’s T-Test). Bar plot indicates mean and SEM.
D
Example dual x-ray image of mouse body with femur and tibia indicated.
E
Example of reconstructed skull from µCT imaging with landmarks used for craniofacial
analysis shown. Red line indicates distances that are significantly larger in the WT
compared to the DNMT3AKO/+, while blue line indicates distance that is significantly
smaller in the WT compared to the DNMT3AKO/+ (P<
 0.05).
F,G Principal component analysis of F cranial and G mandibular shape shows no clear
separation between groups along PC1 or PC2.
**, P<0.01. Bar graph indicates mean and SEM.
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Figure 3.11 Related to Figure 3.3.
(A-J) Comparison of DNMT3AKO/+ and WT mice across a battery of sensorimotor assays.
DNMT3AKO/+ mice show no significant difference in (A) walking initiation, or latency to fall off
(B) ledge or (C) platform. (D-E) DNMT3AKO/+ mice show no difference compared to WT
littermates in motor coordination as evidenced by time on a continuous (D) and accelerating (E)
rotarod. (F) DNMT3AKO/+ mice show no difference in grip strength compared to WT littermates
evidenced by no change in time on an inverted screen. (G) Mean % pre-pulse inhibition shows
no significant difference between genotypes. DNMT3AKO/+ mice show a significant increase in
time to (H) climb down a pole (P=
 0.016, n=21,27; unpaired Student’s T-Test), and to the top of
a (I) 60° inclined screen (P=
 0.039, n=21,27; unpaired Student’s T-Test) and a (J) 90° inclined
screen (P=
 0.045, n=21,27; unpaired Student’s T-Test). (K) DNMT3AKO/+ mice show no deficit
in elevated plus maze exploration as measured by percent entries into open arms. (L) Percent
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time spent freezing in contextual fear trials (P=0.0215 effect by genotype, F(1,50)=5.633, n=26;
two-way repeated-measures ANOVA), and (M) cued fear trials (Baseline: P=
 0.0606 effect by
genotype, F(1,50)=3.685; Cue: P<
 0.0001 effect by genotype, F(1,50)=17.03; n=26; two-way
repeated-measures ANOVA with Sidak’s multiple comparisons test). (N) Shock sensitivity
during conditioned fear test as indicated by the minimum shock needed to exhibit a behavioral
response in mice shows no significant difference between genotypes. (O-R) Path distance to
escape platform and swim speeds in the Morris water maze task. DNMT3AKO/+ mice show
increased path distance to escape platform in both (O) cued trials (P=
 0.0012 effect by genotype,
F(1,46)=11.93; P=
 0.0433 interaction effect of genotype and trial block, F(3,138)=2.784; n=21,27;
two-way repeated-measures ANOVA) and (P) place trials (P=0.0408 interaction effect of
genotype and trial block, F(4,184)=2.55 n=21,27; two-way repeated-measures ANOVA). No
significant difference is seen in swimming speed during (Q) cued trials (P=0 .0634 effect by
genotype, F(1,46)=3.619 n=21,27; two-way repeated-measures ANOVA) and (R) place trials
(P=0.098 effect by genotype, F(1,46)=2.845, n=21,27; two-way repeated-measures ANOVA). (S)
DNMT3AKO/+ mice show no significant difference in time spent in the target quadrant of a
Morris water maze compared to WT littermates. (T) DNMT3AKO/+ mice show a trend towards a
reduction in platform crossings in the probe trial (P=
 0.0609; n=21,27; unpaired Student’s
KO/+
T-Test). (U) After 30 minutes, DNMT3A
mice have significantly fewer total marbles buried
(P=
 0.0438; n=13,14; unpaired Student’s T-Test).
*, P<0.05; **, P<
 0.01; ****, P<
 0.0001. Bar graphs and line plots indicate mean and SEM. Box
th
th
plots contain 10 -90 percentiles of data, with remaining data represented as individual points.
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Figure 3.12 Related to Figure 3.3.
A-D Social approach results from moderate-light apparatus show reduced activity in
DNMT3AKO/+ mice.
A Quantification of time spent in zones closest to each cup during phase with empty cup
and novel conspecific (Empty, P=
 0.0026; Novel, P=0.0095; n=33,39; unpaired Student’s
T-Test).
B Time spent in zones closest to novel mouse and familiar mouse (Familiar, P=
 0.29; Novel,
P=0.24; n=33,39; unpaired Student’s T-Test).
C Preference Index for novel conspecific in the 3-chambered social approach task for WT
and DNMT3AKO/+ mice using time spent in zones as calculated:
Mouse/(Mouse+Object)x100 or Novel/(Novel+Familiar)x100 within each animal.
D Total distance traveled during the 3-chambered social approach task for WT and
DNMT3AKO/+ mice shows a broad reduction of distance traveled across all trials by
DNMT3AKO/+ mice (P=
 0.018 effect by genotype, F(1,70)=5.862, n=33,39; two-way
ANOVA).
E-H Social approach results from low-light apparatus with minimal experimenter presence
show no differences between wild-type and DNMT3AKO/+ mice.
E Quantification of time spent in zones closest to each cup during phase with empty cup
and novel conspecific (Empty, P=
 0.85 Novel, P=0.49; n=19,18; unpaired Student’s
T-Test).
F Time spent in zones closest to novel mouse and familiar mouse (Familiar, P=
 0.75; Novel,
P=0.86; n=19,18; unpaired Student’s T-Test).
G Preference Index for novel conspecific in the 3-chambered social approach task shows no
change for WT and DNMT3AKO/+ mice calculated using the same approach as C.
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H

Total distance traveled during the 3-chambered social approach task for WT and
DNMT3AKO/+ mice shows no reduction of distance traveled across trials by DNMT3AKO/+
mice (P=0.77 effect by genotype, F(1,105)=0.08, n=19,18; two-way ANOVA).
**, P<0.01. Box plots contain 10th-90th percentiles of data, with remaining data represented as
individual points.
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Figure 3.13 Related to Figures 3.4,3.5, and 3.6.
A. Boxplots of CG methylation over postnatal development for regions called as having
higher methylation in the frontal cortex of fetal versus adult tissue (Fetal-Specific DMR),
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or called as having higher methylation in the frontal cortex of the adult versus fetal tissue
(Adult-specific DMR). DMRs from Lister et al. 2013, methylation data from Stroud et al.
2017. (Wilcoxon rank sum test with Bonferroni correction)
B. Boxplots of cortical methylation of WT and DNMT3A Nestin-cKO (Stroud et al. 2017) at
8 weeks postnatal within developmental DMRs shown in A (Wilcoxon rank sum test with
Bonferroni correction).
C. CG/CG (left) and hmCG/CG (right) from WT and DNMT3AKO/+ cortices in various
genomic contexts as measured by oxidative bisulfite sequencing (paired Student’s T-Test
with Bonferroni correction).
D. Boxplots of cortical methylation of WT and DNMT3AKO/+ at 8 weeks postnatally within
DMRs defined in the DNMT3AKO/+ model. DMRs are called on this data set, so no
additional statistics were run on genotype differences.
E. Heatmap of log2 odds-ratios of observed and background (derived from resampling, see
methods) overlap between DNMT3AKO/+ cortex CG-DMRs and various genomic regions.
Color indicates magnitude of enrichment (Observed/resampled), number indicates -log10
p-value for Fisher-exact tests between observed and resampled values.
F. Smooth scatter plots of WT and DNMT3AKO/+ mCA/CA for classes of genomic regions.
G. Boxplot of fold-changes in H3K27ac signal in the DNMT3AKO/+ and WT cortex for
enhancers found within TADs with high (top 10%) and low (bottom 10%) average levels
of mCA/CA.
H. Boxplot of fold-changes in H3K27ac signal in the DNMT3AKO/+ and WT cortices from
enhancers containing hypo/hyper CG-DMRs, and from enhancers containing no DMRs.
***, P<0.001; ****, P<
 0.0001; #, P<
 2.2e-16. Box plots indicate median and quartiles.

153

Figure 3.14 Related to Figures 6 and 7.
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A. Volcano plot of DESeq log2 fold changes of the DNMT3AKO/+ versus WT. Genes
reaching a significance of padj.
 <0.1 are colored in red.
B. Boxplot of DESeq log2 fold changes from noncoding RNAs from RNAcentral, organized
by RNA type.
C. Top ten up- and down-regulated Gene Ontology terms from Broad GSEA Molecular
Signatures Database version 7.0 (Subramanian et al., 2005). All terms are significant at
an FDR<0.1.
D. Mean mCA sites/kb in WT and DNMT3AKO/+ cortex (top) and number of mCA sites/kb
lost in the DNMT3AKO/+ cortex (bottom) for enhancers found within genes called as
significantly dysregulated in the DNMT3AKO/+ (n=4; paired Student’s T-Test with
Bonferroni correction).
E. Boxplot of fold-change in H3K27ac signal in enhancers found within genes called as
significantly dysregulated in the DNMT3AKO/+ (n=5 biological replicates of DNMT3AKO/+
and WT; Wilcoxon test)
F. Boxplot of DESeq log2 fold changes of in gene expression in the DNMT3AKO/+ versus
WT, for genes containing enhancers with hypo-CG-DMRs, genes containing enhancers
with hyper-CG-DMRs, and all other genes containing enhancers.
G. GAGE analysis of developmental expression modules (Parikshak et al., 2013).
Significant modules (q-value<0.1) are colored in red (left). Expression matched
resampling of each gene set was performed 1,000 times and analyzed using GAGE for
enrichment in DNMT3AKO/+ fold-change data (gray violin). This was compared with the
true gene set p-value (red point) to test for significance (right). Only the direction of
dysregulation in which the gene sets showed the highest significance (i.e. DNMT3AKO/+
greater or less) is shown.
H. Expression matched resampling of GAGE analysis for gene sets displayed in Figures 6
and 7. Only the direction of dysregulation in which the gene set showed significance (i.e.
DNMT3AKO/+ greater or less) is shown.
Note: legend is shared in D and E. *, P<
 0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
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Chapter 4: Conclusions and future directions
This dissertation begins to interrogate the influences on mCA deposition genome-wide,
and how the megabase scale of topologically associating domains enables MeCP2 to repress
many enhancers within highly methylated domains. As these enhancers preferentially contact the
genes they are in, repression of these enhancers represses long, highly methylated genes that are
likely to contain multiple enhancers (Clemens et al. 2020). This method of neural regulation may
apply to multiple disease models, as we find that a mouse heterozygous knockout of DNMT3A
(modeling TBRS) exhibits a 50% decrease in mCA with minor effects on mCG (Christian et al.
2020). These methylation reductions contribute to overlapping gene expression and enhancer
activity changes with the MeCP2 knockout, as MeCP2 is likely less able to bind to what were
previously highly methylated enhancers.

In preliminary research I have leveraged a library of existing ChIP-seq and bisulfite-seq
data (Stroud et al., 2017) in order to interrogate the exact factors that affect mCA deposition in
the genome. My work first verified that the observed pattern of a negative correlation between
gene expression and that gene’s mCA levels. However, this relationship is known to be weak,
with many highly expressed yet highly methylated genes, and lowly expressed, lowly methylated
genes throughout the genome. Correlations between genic mCA and expression are also
relatively low, with a Pearson r value of -0.18. Previous work noted that the methylation of the
surrounding TAD can have large impacts on gene methylation (Clemens et al., 2020), so I used
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both factors to build a linear model on both expression and TAD methylation (Figure 4.1). This
model showed significant improvement over using either TAD methylation or expression alone
(Pearson r2 = 0.33809). In addition, the model demonstrated a lowly significant interaction term
between TAD methylation and gene expression, indicating that the expression-associated
demethylation effect occurs independently from the amount of TAD methylation around the
gene.

While the expression-mCA inverse relationship has been noted in the literature (Stroud et
al. 2017), less is known regarding the specific factors that might be associated with gene
expression or TAD methylation that might impact genic mCA. For example, H3K36me3 within
gene bodies is associated with expression (Kolasinska-Zwierz et al., 2009), but the presence of
phosphoserine-5 polymerase II is the most direct indication of active transcription through the
region (Komarnitsky et al. 2000; Ahn et al. 2004; Phatnani and Greenleaf 2006). Thus, it is
important to determine exactly which ChIP-seq signals and histone marks may have a direct
effect on DNMT3A binding and mCA deposition within the gene body. To this end, I analyzed a
variety of ChIP-seq signals generated in 2-week postnatal mouse cortex (Stroud et al., 2017) and
tested the performance of linear models on all pairwise comparisons of each of the ChIP marks
(Figure 4.2). This analysis found that the predictive power of each variable was relatively
dispersed, but several factor-pairs consistently resulted in better models than other signals.
Phosphoserine Pol II generated well-performing models with a variety of paired signals, for
instance, but H3K36me3 did not add much accuracy to many variables, suggesting that the
relationship between expression and mCA is not mediated by H3K36me3 presence.
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Interestingly, H3K9me2, while not generally well-predicting, makes the most predictive model
of the set specifically when combined with H3K27me2, suggesting that the H3K9me2
relationship to mCA is dependent on the amounts of H3K27me2 within the region.

The analysis of these ChIP signals indicated that DNMT3A binding could not be
predicted solely by a few biological signals, and that the relationship between these factors and
mCA deposition may be more complicated than can be modeled linearly. To circumvent these
limitations, I trained a random forest (RF) model with 5-fold cross-validation (Liaw et al. 2002;
Stone 1974; Dietterich 1998) on all ChIP-seq marks previously used in my model. This approach
successfully predicted mCA patterns with high accuracy (Pearson r2 = 0.685911), and feature
importances roughly matched with the performance of each factor in linear modeling, with the
most important factors being phosphoserine Pol II, and H3K27me2. Because it had been
previously noted that the methylation of extragenic regions depended on different factors than
the methylation of intragenic regions (Stroud et al., 2017), I also trained and tested a random
forest model on extragenic data, as well as both extragenic and intragenic data. Many features
between intragenic and extragenic data shared similar amounts of importance, but the most
important factors between extragenic and intragenic regions were generally not shared.
H3K27me2 and phosphoserine Pol II had minimal importance in the extragenic data, which had
H3.3 as the best predicting mark directing methylation. This result may be driven by a bimodal
relationship of mCA and H3.3, as there is a high correlation of H3.3 to mCA within the low
levels of H3.3 in extragenic regions, but a negative correlation when H3.3 reaches higher levels
within gene bodies (figure 4.3).
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While the predictive power of the random forest model is higher than what could be
achieved from a linear model or from any single factor individually, there still remains a large
amount of variance unexplained (~30%). This gap could be due to noise in the measurement of
mCA or ChIP signal, but it could also be due to a lack of relevant biological information, such as
a chromatin mark or protein that recruits DNMT3A that wasn’t assessed in the original set of
factors used. A particularly relevant factor to assess and test is H3K36me2, which has recently
been suggested to bind DNMT3A in non-neural cells (Weinberg et al., 2019). In addition to the
recent work linking DNMT3A and H3K36me2, mutations in NSD1, a histone methyltransferase
responsible for depositing H3K36me2, cause Sotos syndrome, a disease with overlapping
features with TBRS (Kurotaki et al., 2002). Further linking Sotos syndrome to mCA is evidence
that methylation in general is disrupted in Sotos syndrome patient blood (Choufani et al., 2015).
To examine if H3K36me2 occupancy could be used to predict mCA levels, we generated
H3K36me2 ChIP-seq data from 2-week cortex, and I used this data to predict mCA, along with
the other data generated previously. The results were somewhat surprising, as although
H3K36me2 was the most important variable reported in a random forest model, its addition did
not give the model any noticeable improvement in accuracy. This may be an effect of the high
amount of noise in this additional assay, or an indication that the information that would be
added by H3K36me2 could be interpolated from the many other factors used in the model.

In order to define a minimal set of factors that could accurately predict mCA, and to see
if H3K36me2 would be included in this minimal set, I implemented a recursive feature addition
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approach that assessed the performances of models given different numbers of features. This
approach found that 6-8 factors were required to predict mCA with 96-99% of the power of the
full model, highlighting their importance to DNMT3A and mCA deposition. Further research
focused on these factors has the potential to uncover critical regulators of mCA patterning across
the genome.

Given the known links between H3K36me2 and DNMT3A, the overlapping phenotypes
exhibited in disruptions of H3K36me2 and mCA establishers, and the degree to which mCA
patterns rely on this histone mark, there is a pressing need to verify the link between H3K36me2
and mCA. Research into the relationship between NSD1 and the neuronal epigenome could also
shed light into the mechanisms of Sotos syndrome and whether it is affected by alterations in
mCA. To assess the effects of H3K36me2 loss on mCA, we are planning to generate a knockout
of NSD1 within neurons and assess the transcriptomic and epigenomic effects this has within the
brain. We predict that, unlike mutations of DNMT3A, that global mCA levels in the brain will be
largely unchanged. However, it is likely that the patterns and distribution of mCA throughout the
genome will be altered, and regions rich in H3K36me2 in wildtype conditions will have
substantially lower methylation levels in the NSD1 knockout. Enhancers and genes within these
newly demethylated regions would then be expected to increase in activity and expression,
overlapping with effects observed in the DNMT3A and MeCP2 mutants. If we observe these
effects, it will establish a previously unrecognized function for H3K36me2 in guiding mCA
deposition, and provide direct evidence that mCA may be disrupted in another
neurodevelopmental disorder, Sotos syndrome.
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To further test the biological significance of the minimal set of mCA-predicting factors
identified by machine learning approaches, we are also planning on assessing these marks in a
separate region of the brain, the cerebellum, and applying a random forest model, previously
trained on these marks within the cortex. The accuracy of these predictions, versus the accuracy
of predictions made on a model trained on cerebellar data, will then tell us if the relationships
between mCA and these different biological variables are consistent between brain regions. This
approach would enable us to computationally verify the biological importance of these factors
without requiring a lengthy biochemical assay or generating numerous knockout animals.

In conclusion, my dissertation work finds that a small number of factors are predictive of
neuronal mCA deposition, and are likely influenced by TADs, which are known to be regions of
consistency of many histone modifications. This TAD-level of variance then establishes
~100-kilobase sized regions of enriched mCA, which have the potential to contain tens or
hundreds of enhancers and other regulatory elements. MeCP2 can bind and repress these
enhancers en-masse in order to repress long, highly-methylated genes, which are preferentially
linked to and activated by the many highly-methylated enhancers that they contain. This
mechanism of repression by MeCP2 may apply to multiple neurodevelopmental disorders, each
of which may alter different steps in the mCA establishment-readout pathway, generating
different, but overlapping transcriptomic, epigenomic, and phenotypic features. More research
into the proteins that surround and interact with this pathway has the potential to shed insight
into a variety of neurodevelopmental disorders, as they may be linked to mCA-based regulation.
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4.1

Figures
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Figure 4.1. Machine learning approaches find a minimal set of mCA predictive factors
A. Conceptual illustration of linear model combining expression and TAD mCA levels
(mC/CA) to predict genic mCA levels. Lines linking components of the linear model are
labeled with their weighted coefficients. Accuracy of final model fit is Pearson r2 =
0.33809
B. Heatmap of r2 values for linear models using ChIP-seq signals to fit mCA levels at genic
regions, given combinations of 2 factors. Diagonal of matrix is the r2 value of a linear
model given only that single factor. Models built with 5kb intragenic bins of the genome,
placed at least 3kb away from transcriptional start sites.
C. Density scatter plots of input-normalized H3.3 ChIP-seq signal and mCA levels at 5kb
regions across the genome, either within or outside of genes.
D. Line plot, plus bar plots, of the mean accuracy and feature importances of random forest
prediction models, for increasing numbers of variables. Only the 10 best performing
combinations of variables are plotted. Mean feature importances are calculated from their
feature importances in each of the 10 best performing combinations of variables - a
model that does not use that feature is considered to be an importance of 0. Mean feature
importances are scaled to the performance of the models used, for readability, and all
have total sums of importances of 1, prior to scaling.
All analysis shown was carried out for mouse cerebral cortex. ChIP-seq data were generated
from 2-week postnatal mice, and bisulfite-seq data is from 8-week postnatal cortex. H3K36me2
ChIP-seq data was generated for this study, and the rest of the dataset was generated by (Stroud
et al. 2017)
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